,ID,lineage,string
0,doi:10.4269/ajtmh.21-0542,B.1.1.7,"Among the sequences were three novel viral variants: BV-1 with a B.1.1.7/20I genetic background and an additional spike mutation Q493R, associated with a mild but longer-than-usual COVID-19 case in a college-age person, BV-2 with a T478K mutation on a 20B genetic background, and BV-3, an apparent recombinant lineage."
1,doi:10.4269/ajtmh.21-0542,B.1.617,"Mutations of Q493 resulting in an amino acid change to either arginine (R) or lysine (K) have been reported as an adaptation associated with resistance to monoclonal neutralizing antibodies in laboratory tests1 and Q493K confers resistance to the Regeneron antibody cocktail2 and bamlanivimab.3 It was recently reported that there are four major epitope classes on the SARS-CoV-2 spike protein receptor-binding domain where neutralizing antibodies bind, and that Q493R (BV-1) and E484K (not found in BV-1, but important in B.1.351 and B.1.617 variants) mediate roughly equivalent levels of resistance to only class-2 neutralizing antibodies, as defined in that study.4 Based on this, it is inferred that the Q493R mutation of BV-1 may confer resistance to some neutralizing antibodies, though we have not directly tested the neutralizing activity."
2,doi:10.4269/ajtmh.21-0542,B.1.351,"Mutations of Q493 resulting in an amino acid change to either arginine (R) or lysine (K) have been reported as an adaptation associated with resistance to monoclonal neutralizing antibodies in laboratory tests1 and Q493K confers resistance to the Regeneron antibody cocktail2 and bamlanivimab.3 It was recently reported that there are four major epitope classes on the SARS-CoV-2 spike protein receptor-binding domain where neutralizing antibodies bind, and that Q493R (BV-1) and E484K (not found in BV-1, but important in B.1.351 and B.1.617 variants) mediate roughly equivalent levels of resistance to only class-2 neutralizing antibodies, as defined in that study.4 Based on this, it is inferred that the Q493R mutation of BV-1 may confer resistance to some neutralizing antibodies, though we have not directly tested the neutralizing activity."
3,doi:10.4269/ajtmh.21-0542,B.1.243,"Of these, 56 (60%) sequences were of B.1.1.7/20I/501Y.V1 lineage; four isolated from early February through mid-March were of a B.1.1.519/20B lineage including three sequences with the T478K mutation that has been reported from the designated BV-2 (hCoV-19/USA/GHRC-BV2-EQ04518823/2021, hCOV-19/USA/GHRC-BV2-EQ04526485/2021 and hCoV-19/USA/GHRC-BV2-EQ04531246/2021), a lineage was first detected in the United States, but subsequently became common in Canada and Mexico with a peak near the end of March 2021; 22 were B.1.2/20G including BV-3, a genome very similar to other local 20G lineage sequences, except for the addition of a cluster of four spike mutations (P681H, T716I, S982A, and D1118H) that were not present in any local 20G lineage genomes, but were all present on all local 20I/501Y.V1 lineages, suggesting BV-3 arose from a recombination of a partial spike gene from a 20I/501Y.V1 strain on a 20G background (hCoV-19/USA/GHRC-BV3-EQ04527243/2021); five were B.1.596/20G; two were B.1.234/20A; two were B.1.243/20A; and one was B.1/20A (Figure 1)..

Phylogenetic placement of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequences within existing lineages."
4,doi:10.4269/ajtmh.21-0542,B.1.234,"Of these, 56 (60%) sequences were of B.1.1.7/20I/501Y.V1 lineage; four isolated from early February through mid-March were of a B.1.1.519/20B lineage including three sequences with the T478K mutation that has been reported from the designated BV-2 (hCoV-19/USA/GHRC-BV2-EQ04518823/2021, hCOV-19/USA/GHRC-BV2-EQ04526485/2021 and hCoV-19/USA/GHRC-BV2-EQ04531246/2021), a lineage was first detected in the United States, but subsequently became common in Canada and Mexico with a peak near the end of March 2021; 22 were B.1.2/20G including BV-3, a genome very similar to other local 20G lineage sequences, except for the addition of a cluster of four spike mutations (P681H, T716I, S982A, and D1118H) that were not present in any local 20G lineage genomes, but were all present on all local 20I/501Y.V1 lineages, suggesting BV-3 arose from a recombination of a partial spike gene from a 20I/501Y.V1 strain on a 20G background (hCoV-19/USA/GHRC-BV3-EQ04527243/2021); five were B.1.596/20G; two were B.1.234/20A; two were B.1.243/20A; and one was B.1/20A (Figure 1)..

Phylogenetic placement of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequences within existing lineages."
5,doi:10.4269/ajtmh.21-0542,B.1.2,"Of these, 56 (60%) sequences were of B.1.1.7/20I/501Y.V1 lineage; four isolated from early February through mid-March were of a B.1.1.519/20B lineage including three sequences with the T478K mutation that has been reported from the designated BV-2 (hCoV-19/USA/GHRC-BV2-EQ04518823/2021, hCOV-19/USA/GHRC-BV2-EQ04526485/2021 and hCoV-19/USA/GHRC-BV2-EQ04531246/2021), a lineage was first detected in the United States, but subsequently became common in Canada and Mexico with a peak near the end of March 2021; 22 were B.1.2/20G including BV-3, a genome very similar to other local 20G lineage sequences, except for the addition of a cluster of four spike mutations (P681H, T716I, S982A, and D1118H) that were not present in any local 20G lineage genomes, but were all present on all local 20I/501Y.V1 lineages, suggesting BV-3 arose from a recombination of a partial spike gene from a 20I/501Y.V1 strain on a 20G background (hCoV-19/USA/GHRC-BV3-EQ04527243/2021); five were B.1.596/20G; two were B.1.234/20A; two were B.1.243/20A; and one was B.1/20A (Figure 1)..

Phylogenetic placement of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequences within existing lineages."
6,doi:10.4269/ajtmh.21-0542,B.1.1.519,"Of these, 56 (60%) sequences were of B.1.1.7/20I/501Y.V1 lineage; four isolated from early February through mid-March were of a B.1.1.519/20B lineage including three sequences with the T478K mutation that has been reported from the designated BV-2 (hCoV-19/USA/GHRC-BV2-EQ04518823/2021, hCOV-19/USA/GHRC-BV2-EQ04526485/2021 and hCoV-19/USA/GHRC-BV2-EQ04531246/2021), a lineage was first detected in the United States, but subsequently became common in Canada and Mexico with a peak near the end of March 2021; 22 were B.1.2/20G including BV-3, a genome very similar to other local 20G lineage sequences, except for the addition of a cluster of four spike mutations (P681H, T716I, S982A, and D1118H) that were not present in any local 20G lineage genomes, but were all present on all local 20I/501Y.V1 lineages, suggesting BV-3 arose from a recombination of a partial spike gene from a 20I/501Y.V1 strain on a 20G background (hCoV-19/USA/GHRC-BV3-EQ04527243/2021); five were B.1.596/20G; two were B.1.234/20A; two were B.1.243/20A; and one was B.1/20A (Figure 1)..

Phylogenetic placement of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequences within existing lineages."
7,doi:10.4269/ajtmh.21-0542,B.1,"Of these, 56 (60%) sequences were of B.1.1.7/20I/501Y.V1 lineage; four isolated from early February through mid-March were of a B.1.1.519/20B lineage including three sequences with the T478K mutation that has been reported from the designated BV-2 (hCoV-19/USA/GHRC-BV2-EQ04518823/2021, hCOV-19/USA/GHRC-BV2-EQ04526485/2021 and hCoV-19/USA/GHRC-BV2-EQ04531246/2021), a lineage was first detected in the United States, but subsequently became common in Canada and Mexico with a peak near the end of March 2021; 22 were B.1.2/20G including BV-3, a genome very similar to other local 20G lineage sequences, except for the addition of a cluster of four spike mutations (P681H, T716I, S982A, and D1118H) that were not present in any local 20G lineage genomes, but were all present on all local 20I/501Y.V1 lineages, suggesting BV-3 arose from a recombination of a partial spike gene from a 20I/501Y.V1 strain on a 20G background (hCoV-19/USA/GHRC-BV3-EQ04527243/2021); five were B.1.596/20G; two were B.1.234/20A; two were B.1.243/20A; and one was B.1/20A (Figure 1)..

Phylogenetic placement of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequences within existing lineages."
8,doi:10.4269/ajtmh.21-0542,B.1.596,"Of these, 56 (60%) sequences were of B.1.1.7/20I/501Y.V1 lineage; four isolated from early February through mid-March were of a B.1.1.519/20B lineage including three sequences with the T478K mutation that has been reported from the designated BV-2 (hCoV-19/USA/GHRC-BV2-EQ04518823/2021, hCOV-19/USA/GHRC-BV2-EQ04526485/2021 and hCoV-19/USA/GHRC-BV2-EQ04531246/2021), a lineage was first detected in the United States, but subsequently became common in Canada and Mexico with a peak near the end of March 2021; 22 were B.1.2/20G including BV-3, a genome very similar to other local 20G lineage sequences, except for the addition of a cluster of four spike mutations (P681H, T716I, S982A, and D1118H) that were not present in any local 20G lineage genomes, but were all present on all local 20I/501Y.V1 lineages, suggesting BV-3 arose from a recombination of a partial spike gene from a 20I/501Y.V1 strain on a 20G background (hCoV-19/USA/GHRC-BV3-EQ04527243/2021); five were B.1.596/20G; two were B.1.234/20A; two were B.1.243/20A; and one was B.1/20A (Figure 1)..

Phylogenetic placement of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequences within existing lineages."
0,doi:10.3390/ijerph19031573,B.1.617.2,The Delta variant (B.1.617.2) has dominated in many countries over the world.
0,doi:10.1128/mra.00721-21,B.1.480,"Two genomes belonged to genetic group 20A/B.1/GH, and the other belonged to genetic group 20A/B.1.480/GH."
1,doi:10.1128/mra.00721-21,B.1,"Two genomes belonged to genetic group 20A/B.1/GH, and the other belonged to genetic group 20A/B.1.480/GH."
0,doi:10.3390/v13112295,B.1.617,"The novel variants harbored by the B.1.617 lineage (kappa and delta) carry mutations within the receptor-binding domain of spike (S) protein (L452R + E484Q and L452R + T478K), the region binding to the host receptor."
1,doi:10.3390/v13112295,B.1.617.3,"B.1.617.1, B.1.617.2, and B.1.617.3 [34]."
2,doi:10.3390/v13112295,B.1.617.2,"B.1.617.1, B.1.617.2, and B.1.617.3 [34]."
3,doi:10.3390/v13112295,B.1.617.1,The SARS-CoV-2 S protein of the B.1.617.1 (kappa) variant harbors a total of eight mutations [37].
0,doi:10.2807/1560-7917.es.2021.26.49.2101059,B.1.617,"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant of concern (VOC) (Phylogenetic Assignment of Named Global Outbreak Lineages (Pangolin) designation B.1.617) sub-lineage AY.4.2 recently accounted for an increased proportion of coronavirus disease (COVID-19) cases caused by the Delta variant in the United Kingdom (UK), increasing from 3.8% to 20.3% in the weeks of 19 September 2021 and 15 November 2021, respectively [1,2]."
1,doi:10.2807/1560-7917.es.2021.26.49.2101059,B.1.617.2,The titres for AY.4.2 did not differ significantly from those measured for the parental Delta lineage B.1.617.2 (median titre: 87 vs 118; p > 0.050) or Delta sub-lineage AY.4 (median titre: 87 vs 118; p > 0.050).
2,doi:10.2807/1560-7917.es.2021.26.49.2101059,P.1,"Virus neutralisation titres for other VOC, Alpha (Pango lineage designation B.1.1.7), Beta (Pango lineage designation B.1.351) and Gamma (Pango lineage designation P.1) were available for 24 of the 30 serum samples (Figure 3)."
3,doi:10.2807/1560-7917.es.2021.26.49.2101059,B.1.1.7,"Virus neutralisation titres for other VOC, Alpha (Pango lineage designation B.1.1.7), Beta (Pango lineage designation B.1.351) and Gamma (Pango lineage designation P.1) were available for 24 of the 30 serum samples (Figure 3)."
4,doi:10.2807/1560-7917.es.2021.26.49.2101059,B.1.351,"Virus neutralisation titres for other VOC, Alpha (Pango lineage designation B.1.1.7), Beta (Pango lineage designation B.1.351) and Gamma (Pango lineage designation P.1) were available for 24 of the 30 serum samples (Figure 3)."
5,doi:10.2807/1560-7917.es.2021.26.49.2101059,B.1.1.529,"In addition, similar studies are urgently needed for the recently identified Omicron VOC (Pango lineage designation B.1.1.529) and its sub-lineages [18], which bear different spike mutations..

We would like to thank Birgit Knudsen, Louise Borup, and Dennis Jelsbak Schmidt for technical assistance."
0,doi:10.1101/2020.06.11.20128330,B.1,"The variant HEE-01 was imported from the Netherlands and was assigned to B lineage, HGSQ-USFQ-018, belongs to the B.1 lineage showing nine nucleotide differences with the reference strain and grouped with sequences from the United Kingdom, and HGSQ-USFQ-007 and HGSQ-USFQ-010 belong to the B lineage and grouped with sequences from Scotland."
0,doi:10.1016/j.ebiom.2021.103675,B.1.1.7,"We performed intranasal inoculation of SARS-CoV-2 into hamsters with the ancestral virus (nCoV-WA1-2020) or VOC first identified in the United Kingdom (B.1.1.7, alpha) and South Africa (B.1.351, beta) and analyzed viral loads and host responses.."
1,doi:10.1016/j.ebiom.2021.103675,B.1.351,"We performed intranasal inoculation of SARS-CoV-2 into hamsters with the ancestral virus (nCoV-WA1-2020) or VOC first identified in the United Kingdom (B.1.1.7, alpha) and South Africa (B.1.351, beta) and analyzed viral loads and host responses.."
2,doi:10.1016/j.ebiom.2021.103675,B.1.427,"Other variants more recently reported in the United States (B.1.427, B1.429) also harbor mutations in S (e.g., N501Y) that have been associated with reductions in neutralizing antibody titers [12].."
3,doi:10.1016/j.ebiom.2021.103675,V.2,"Graphs were generated using GraphPad Prism software (version 8)..

Enrichment of SARS-CoV-2 was performed using the Qiagen QIASeq SARS-CoV-2 Primer Panel (V.2)."
0,doi:10.1101/2021.02.05.21251182,B.1.351,"We examined whether sera from recovered and naive donors collected prior to, and following immunizations with existing mRNA vaccines, could neutralize the Wuhan-Hu-1 and B.1.351 variants."
1,doi:10.1101/2021.02.05.21251182,P.1,"Recently, viral variants of concern have emerged in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) that harbor specific mutations in their S proteins that may be associated with increased transmissibility (50–55)..

Of particular concern are mutations found in the B.1.351 lineage, which is defined by the D80A and D215G in the N-terminal domain (NTD), and the K417N, E484K, N501Y mutations in the RBD and the D614G mutation in S2 (52, 56)."
2,doi:10.1101/2021.02.05.21251182,B.1.1.7,"Recently, viral variants of concern have emerged in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) that harbor specific mutations in their S proteins that may be associated with increased transmissibility (50–55)..

Of particular concern are mutations found in the B.1.351 lineage, which is defined by the D80A and D215G in the N-terminal domain (NTD), and the K417N, E484K, N501Y mutations in the RBD and the D614G mutation in S2 (52, 56)."
0,doi:10.7759/cureus.16905,B.1.617,"The variants Delta and Kappa are now of most recent concern because of their well-increased infectivity, both a spin-off of the B.1.617 lineage, which was first identified in India in October 2020."
0,doi:10.1080/22221751.2021.1945423,B.1.1.7,"We assessed the neutralizing capacity of antibodies to prevent cell infection, using a live virus neutralization test with different strains [19A (initial one), 20B (B.1.1.241 lineage), 20I/501Y.V1 (B.1.1.7 lineage), and 20H/501Y.V2 (B.1.351 lineage)] in serum samples collected from different populations: two-dose vaccinated COVID-19-naive healthcare workers (HCWs; Pfizer-BioNTech BNT161b2), 6-months post mild COVID-19 HCWs, and critical COVID-19 patients."
1,doi:10.1080/22221751.2021.1945423,B.1.351,"We assessed the neutralizing capacity of antibodies to prevent cell infection, using a live virus neutralization test with different strains [19A (initial one), 20B (B.1.1.241 lineage), 20I/501Y.V1 (B.1.1.7 lineage), and 20H/501Y.V2 (B.1.351 lineage)] in serum samples collected from different populations: two-dose vaccinated COVID-19-naive healthcare workers (HCWs; Pfizer-BioNTech BNT161b2), 6-months post mild COVID-19 HCWs, and critical COVID-19 patients."
2,doi:10.1080/22221751.2021.1945423,B.1.1.241,"We assessed the neutralizing capacity of antibodies to prevent cell infection, using a live virus neutralization test with different strains [19A (initial one), 20B (B.1.1.241 lineage), 20I/501Y.V1 (B.1.1.7 lineage), and 20H/501Y.V2 (B.1.351 lineage)] in serum samples collected from different populations: two-dose vaccinated COVID-19-naive healthcare workers (HCWs; Pfizer-BioNTech BNT161b2), 6-months post mild COVID-19 HCWs, and critical COVID-19 patients."
0,doi:10.1016/j.bbrc.2021.05.058,B.1.1.248,New SARS-CoV-2 variants emerged in the United Kingdom and South Africa in December 2020 in concomitant with the Brazillian variant in February 2021 (B.1.1.248 lineage) and currently sparking worldwide during the last few months.
0,doi:10.1016/j.ebiom.2022.103926,P.1,"CRISPR-SPADE was then applied for discriminating SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) and validated in 208 clinical samples."
1,doi:10.1016/j.ebiom.2022.103926,B.1.1.7,"CRISPR-SPADE was then applied for discriminating SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) and validated in 208 clinical samples."
2,doi:10.1016/j.ebiom.2022.103926,B.1.1.529,"CRISPR-SPADE was then applied for discriminating SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) and validated in 208 clinical samples."
3,doi:10.1016/j.ebiom.2022.103926,B.1.617.2,"CRISPR-SPADE was then applied for discriminating SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) and validated in 208 clinical samples."
4,doi:10.1016/j.ebiom.2022.103926,B.1.351,"CRISPR-SPADE was then applied for discriminating SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) and validated in 208 clinical samples."
5,doi:10.1016/j.ebiom.2022.103926,B.1.352,"The broad versatility along with the high specificity of BrCas12b enables us to detect SARS-CoV-2 and distinguish its variants of concerns Alpha (B.1.1.7), Beta (B.1.352), Gamma (P1), Delta (B.1.617.2), and Omicron (B.1.1.529)."
0,doi:10.3390/v14030510,B.1,Sera from SARS-CoV2-naïve individuals had no detectable neutralizing activity against lineage B.1 SARS-CoV-2 or Gamma variant five months after the second vaccine dose.
0,doi:10.3390/diagnostics11071241,P.1,"Since January 2021, the diffusion of the most propagated SARS-CoV-2 variants in France (UK variant 20I/501Y.V1 (lineage B.1.1.7), 20H/H501Y.V2 (lineage B.1.351) and 20J/H501Y.V3 (lineage P.1)) were urgently screened, needing a surveillance with an RT-PCR screening assay."
1,doi:10.3390/diagnostics11071241,B.1.1.7,"Since January 2021, the diffusion of the most propagated SARS-CoV-2 variants in France (UK variant 20I/501Y.V1 (lineage B.1.1.7), 20H/H501Y.V2 (lineage B.1.351) and 20J/H501Y.V3 (lineage P.1)) were urgently screened, needing a surveillance with an RT-PCR screening assay."
2,doi:10.3390/diagnostics11071241,B.1.351,"Since January 2021, the diffusion of the most propagated SARS-CoV-2 variants in France (UK variant 20I/501Y.V1 (lineage B.1.1.7), 20H/H501Y.V2 (lineage B.1.351) and 20J/H501Y.V3 (lineage P.1)) were urgently screened, needing a surveillance with an RT-PCR screening assay."
3,doi:10.3390/diagnostics11071241,A.27,"Thirteen samples belonged to the UK variant (B.1.1.7), and two to A.27 with N501Y mutation."
0,doi:10.1080/20016689.2021.2002008,B.1.1.7,"The average proportion of B.1.1.7 variant was found to be a significant predictor of cumulative COVID-19 deaths within two months before the peak and between 1 January–25 February 2021, as well as of the deaths peak height considering proportions during the second wave and the pre-peak period."
0,doi:10.1080/19420862.2021.1953683,P.1,"MW06 alone and the cocktail show good effects in preventing escape mutations, including a series of variants of concern, B.1.1.7, P.1, B.1.351, and B.1.617.1."
1,doi:10.1080/19420862.2021.1953683,B.1.1.7,"MW06 alone and the cocktail show good effects in preventing escape mutations, including a series of variants of concern, B.1.1.7, P.1, B.1.351, and B.1.617.1."
2,doi:10.1080/19420862.2021.1953683,B.1.351,"MW06 alone and the cocktail show good effects in preventing escape mutations, including a series of variants of concern, B.1.1.7, P.1, B.1.351, and B.1.617.1."
3,doi:10.1080/19420862.2021.1953683,B.1.617.1,"Furthermore, the binding and blocking activities against a newly emerged variant, B.1.617.1, have been tested."
0,doi:10.3390/v13112183,B.1.617.2,"Here, we examined the sensitivity of RATs available in Japan in September 2021 for the detection of the delta variant (lineage B.1.617.2) of SARS-CoV-2..

All experiments with SARS-CoV-2 were performed in biosafety level 3 (BSL3) laboratories at the University of Tokyo, which were approved for such use by the Ministry of Health, Labour and Welfare, Japan..

Vero E6 cells expressing human serine protease TMPRSS2 (VeroE6-TMPRSS2) [18] were maintained in DMEM containing 10% fetal calf serum (FCS), 1 mg/mL G418, 100 units/mL penicillin, 100 µg/mL streptomycin, and 5 μg/mL Plasmocin prophylactic (InvivoGen, San Diego, CA, USA) and incubated at 37 °C under 5% CO2."
0,doi:10.2147/idr.s319439,B.1.1.7,"On January 5 2021, Ecuadorian COVID-19 genomic surveillance program detected a suspicious case of the B.1.1.7 lineage (alpha variant) of SARS-CoV-2 in Los Rios province, later confirmed by genome sequencing."
1,doi:10.2147/idr.s319439,P.1,"Up to date, four VOCs have been named by the World Health Organization as follows: lineage B.1.1.7 or alpha, first identified in the United Kingdom; lineage B.135 or beta, first identified in South Africa; lineage B.1.617.2 or delta, first identified in India; and lineage P.1 or gamma, first identified in Brazil and Japan."
2,doi:10.2147/idr.s319439,B.1.617.2,"Up to date, four VOCs have been named by the World Health Organization as follows: lineage B.1.1.7 or alpha, first identified in the United Kingdom; lineage B.135 or beta, first identified in South Africa; lineage B.1.617.2 or delta, first identified in India; and lineage P.1 or gamma, first identified in Brazil and Japan."
0,doi:10.1002/jmv.26393,B.1.5,"Pangolin lineages B.1 and B.1.5 were the most frequent, with B.1 being associated with prior travel to high‐risk areas.."
1,doi:10.1002/jmv.26393,B.1,"Pangolin lineages B.1 and B.1.5 were the most frequent, with B.1 being associated with prior travel to high‐risk areas.."
2,doi:10.1002/jmv.26393,B.1.3,"That is the case of lineages A.5, B.1.3, B.1.11, B.1.5.1, and B.1.25."
3,doi:10.1002/jmv.26393,A.5,"That is the case of lineages A.5, B.1.3, B.1.11, B.1.5.1, and B.1.25."
4,doi:10.1002/jmv.26393,B.1.11,"That is the case of lineages A.5, B.1.3, B.1.11, B.1.5.1, and B.1.25."
0,doi:10.1056/nejmoa2116185,B.1.1.7,"Most sequenced viral genomes (48 of 61, 79%) were variants of concern or interest — largely B.1.1.7 (alpha) (31 of the 35 genomes for variants of concern, 89%)."
1,doi:10.1056/nejmoa2116185,P.1,"NVX-CoV2373 was found to be safe and immunogenic in adults10,11 and provided high vaccine efficacy against severe disease caused by the B.1.351 (beta) variant of concern in a phase 2b trial in South Africa12 and against Covid-19 of any severity caused by the B.1.1.7 (alpha) variant of concern in a phase 3 trial in the United Kingdom.13 We describe the results of PREVENT-19 (Prefusion Protein Subunit Vaccine Efficacy Novavax Trial–COVID-19), a phase 3 trial of NVX-CoV2373 involving adults 18 years of age or older in the United States and Mexico conducted during a period in which the circulating variants were predominantly alpha, beta, P.1 (gamma), B.1.427 and B.1.429 (epsilon), and B.1.526 (iota).14."
2,doi:10.1056/nejmoa2116185,B.1.526,"NVX-CoV2373 was found to be safe and immunogenic in adults10,11 and provided high vaccine efficacy against severe disease caused by the B.1.351 (beta) variant of concern in a phase 2b trial in South Africa12 and against Covid-19 of any severity caused by the B.1.1.7 (alpha) variant of concern in a phase 3 trial in the United Kingdom.13 We describe the results of PREVENT-19 (Prefusion Protein Subunit Vaccine Efficacy Novavax Trial–COVID-19), a phase 3 trial of NVX-CoV2373 involving adults 18 years of age or older in the United States and Mexico conducted during a period in which the circulating variants were predominantly alpha, beta, P.1 (gamma), B.1.427 and B.1.429 (epsilon), and B.1.526 (iota).14."
3,doi:10.1056/nejmoa2116185,B.1.429,"NVX-CoV2373 was found to be safe and immunogenic in adults10,11 and provided high vaccine efficacy against severe disease caused by the B.1.351 (beta) variant of concern in a phase 2b trial in South Africa12 and against Covid-19 of any severity caused by the B.1.1.7 (alpha) variant of concern in a phase 3 trial in the United Kingdom.13 We describe the results of PREVENT-19 (Prefusion Protein Subunit Vaccine Efficacy Novavax Trial–COVID-19), a phase 3 trial of NVX-CoV2373 involving adults 18 years of age or older in the United States and Mexico conducted during a period in which the circulating variants were predominantly alpha, beta, P.1 (gamma), B.1.427 and B.1.429 (epsilon), and B.1.526 (iota).14."
4,doi:10.1056/nejmoa2116185,B.1.427,"NVX-CoV2373 was found to be safe and immunogenic in adults10,11 and provided high vaccine efficacy against severe disease caused by the B.1.351 (beta) variant of concern in a phase 2b trial in South Africa12 and against Covid-19 of any severity caused by the B.1.1.7 (alpha) variant of concern in a phase 3 trial in the United Kingdom.13 We describe the results of PREVENT-19 (Prefusion Protein Subunit Vaccine Efficacy Novavax Trial–COVID-19), a phase 3 trial of NVX-CoV2373 involving adults 18 years of age or older in the United States and Mexico conducted during a period in which the circulating variants were predominantly alpha, beta, P.1 (gamma), B.1.427 and B.1.429 (epsilon), and B.1.526 (iota).14."
5,doi:10.1056/nejmoa2116185,B.1.351,"NVX-CoV2373 was found to be safe and immunogenic in adults10,11 and provided high vaccine efficacy against severe disease caused by the B.1.351 (beta) variant of concern in a phase 2b trial in South Africa12 and against Covid-19 of any severity caused by the B.1.1.7 (alpha) variant of concern in a phase 3 trial in the United Kingdom.13 We describe the results of PREVENT-19 (Prefusion Protein Subunit Vaccine Efficacy Novavax Trial–COVID-19), a phase 3 trial of NVX-CoV2373 involving adults 18 years of age or older in the United States and Mexico conducted during a period in which the circulating variants were predominantly alpha, beta, P.1 (gamma), B.1.427 and B.1.429 (epsilon), and B.1.526 (iota).14."
0,doi:10.1016/j.ijid.2022.03.008,B.1.1.529,"We read with interest the recent article of Abdullah et al., who concluded that a significantly lower severity of illness associated with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron B.1.1.529 variant-driven epidemic wave had been observed in Tshwane, South Africa (Abdullah et al., 2021)."
1,doi:10.1016/j.ijid.2022.03.008,B.1.1.7,"This research was based on publicly available data thus Ethical Committee approval was unnecessary..

As listed in Table 1
, the total number of Italian citizens who tested positive for SARS-CoV-2 infection on January 12, 2021 (estimated prevalence of SARS-CoV-2 Alpha B.1.1.7 variant: 92%; vaccination rate: <0.1%) and January 12, 2022 (estimated prevalence of SARS-CoV-2 Omicron B.1.1.529 variant: >80%; vaccination rate: 86.6%) was 570,040 and 2,222,060, respectively."
0,doi:10.1016/j.jare.2021.07.008,B.1.617,"Worryingly, more and more variants are now being identified, such as 501Y.V1 (B.1.1.7) in the UK, 501Y.V2 (B.1.351) in South Africa, 501Y.V3 in Manaus, Brazil, and B.1.617/B.1.618 in India, which could lead to a severe epidemic rebound."
1,doi:10.1016/j.jare.2021.07.008,B.1.1.7,"Worryingly, more and more variants are now being identified, such as 501Y.V1 (B.1.1.7) in the UK, 501Y.V2 (B.1.351) in South Africa, 501Y.V3 in Manaus, Brazil, and B.1.617/B.1.618 in India, which could lead to a severe epidemic rebound."
2,doi:10.1016/j.jare.2021.07.008,B.1.351,"Worryingly, more and more variants are now being identified, such as 501Y.V1 (B.1.1.7) in the UK, 501Y.V2 (B.1.351) in South Africa, 501Y.V3 in Manaus, Brazil, and B.1.617/B.1.618 in India, which could lead to a severe epidemic rebound."
3,doi:10.1016/j.jare.2021.07.008,P.1,"Worryingly, more and more variants are now being identified, such as 501Y.V3/P.1 in Brazil and B.1.617/B.1.618 in India [9], [10], which also could reduce the effectiveness of neutralizing antibodies generated by the vaccine [11], [12]."
4,doi:10.1016/j.jare.2021.07.008,B.1.617.2,"To assess the effectiveness of antibodies elicited by S-15 or S-82 in controlling SARS-CoV-2 variants, we compared and analyzed amino acid sequences of the S-15 and S-18 of five “Variants of Concern” (including B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) and B.1.617.1 (Kappa))."
5,doi:10.1016/j.jare.2021.07.008,B.1.617.1,"To assess the effectiveness of antibodies elicited by S-15 or S-82 in controlling SARS-CoV-2 variants, we compared and analyzed amino acid sequences of the S-15 and S-18 of five “Variants of Concern” (including B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) and B.1.617.1 (Kappa))."
0,doi:10.1016/j.chom.2021.03.009,B.1.351,We compared antibody binding and live virus neutralization of sera from naturally infected and Moderna-vaccinated individuals against two SARS-CoV-2 variants: B.1 containing the spike mutation D614G and the emerging B.1.351 variant containing additional spike mutations and deletions.
1,doi:10.1016/j.chom.2021.03.009,B.1,We compared antibody binding and live virus neutralization of sera from naturally infected and Moderna-vaccinated individuals against two SARS-CoV-2 variants: B.1 containing the spike mutation D614G and the emerging B.1.351 variant containing additional spike mutations and deletions.
0,doi:10.1038/s42003-021-02858-9,B.1.617.2,"Some of these variants, such as B.1.617.2, B.1.1.7, and B.1.351, manifest higher infectivity and virulence than the earlier SARS-CoV-2 variants, with potential dramatic effects on the course of the pandemic."
1,doi:10.1038/s42003-021-02858-9,B.1.351,"Some of these variants, such as B.1.617.2, B.1.1.7, and B.1.351, manifest higher infectivity and virulence than the earlier SARS-CoV-2 variants, with potential dramatic effects on the course of the pandemic."
2,doi:10.1038/s42003-021-02858-9,B.1.1.7,"Some of these variants, such as B.1.617.2, B.1.1.7, and B.1.351, manifest higher infectivity and virulence than the earlier SARS-CoV-2 variants, with potential dramatic effects on the course of the pandemic."
0,doi:10.1101/2021.04.05.21254952,P.1,Viral variants of concern from B.1.1.7 to P.1 to B.1.351 form a remarkably consistent hierarchy of progressively decreasing antibody recognition by both vaccinees and infected patients exposed to Wuhan-Hu-1 antigens..
1,doi:10.1101/2021.04.05.21254952,B.1.1.7,Viral variants of concern from B.1.1.7 to P.1 to B.1.351 form a remarkably consistent hierarchy of progressively decreasing antibody recognition by both vaccinees and infected patients exposed to Wuhan-Hu-1 antigens..
2,doi:10.1101/2021.04.05.21254952,B.1.351,Viral variants of concern from B.1.1.7 to P.1 to B.1.351 form a remarkably consistent hierarchy of progressively decreasing antibody recognition by both vaccinees and infected patients exposed to Wuhan-Hu-1 antigens..
0,doi:10.2807/1560-7917.es.2022.27.4.2101196,B.1.1.529,"This suggests vaccine- or infection-induced immunity against SARS-CoV-2 infections is less effective against the Omicron than the Delta variant..

On 26 November 2021, the World Health Organization (WHO) declared the Omicron variant (Phylogenetic Assignment of Named Global Outbreak Lineages (Pangolin) designation B.1.1.529) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) a variant of concern [1]."
1,doi:10.2807/1560-7917.es.2022.27.4.2101196,B.1.617.2,"These alterations raise concerns about the protection evoked by current SARS-CoV-2 vaccines against the Omicron variant..

To explore possible escape from vaccine- or infection-induced immunity by Omicron compared with Delta, we here investigate the distribution of the Delta (B.1.617.2) and Omicron variants among SARS-CoV-2-positive individuals who had been naïve, had received the complete primary vaccination series or had a previous infection."
2,doi:10.2807/1560-7917.es.2022.27.4.2101196,B.1.1.7,This failure of detection of the S gene target in an otherwise positive PCR test has proven to be a highly specific proxy for the presence of the Alpha variant (B.1.1.7) in the past and also identifies Omicron [9-12].
3,doi:10.2807/1560-7917.es.2022.27.4.2101196,P.1,"This contrasts with what we observed in a previous analysis, where we did not find an increased risk of infection with the Delta, Beta (B.1.351) and Gamma (P.1) variants vs the Alpha variant in previously infected individuals [21]."
4,doi:10.2807/1560-7917.es.2022.27.4.2101196,B.1.351,"This contrasts with what we observed in a previous analysis, where we did not find an increased risk of infection with the Delta, Beta (B.1.351) and Gamma (P.1) variants vs the Alpha variant in previously infected individuals [21]."
0,doi:10.1101/2022.01.31.478506,B.1.351,"For example, the beta (B.1.351) variant infects deer mice (Peromyscus spp.)"
1,doi:10.1101/2022.01.31.478506,B.1.617.2,"The delta variant encompasses lineages such as B.1.617.2 and AY.3 that share common defining mutations like spike L452R, P681R, and D950N [12, 13].."
2,doi:10.1101/2022.01.31.478506,B.1.575,"Recently, identical sequences of lineage B.1.575 were discovered in a pet dog and cat and their owner [31], demonstrating that minimal viral evolution is required to overcome species barriers in at least one variant."
0,doi:10.1101/2021.10.27.465996,B.1.617.2,"7A3 at a dose of ≥5 mg/kg efficiently protects K18-hACE2 transgenic mice from the lethal challenge of B.1.351 or B.1.617.2, suggesting that the nanobody has promising therapeutic potentials to curb the COVID-19 surge with emerging SARS-CoV-2 variants..

Dromedary camel (Camelus dromedarius) VHH phage libraries were built for isolation of the nanobodies that broadly neutralize SARS-CoV-2 variants.."
1,doi:10.1101/2021.10.27.465996,B.1.351,"7A3 at a dose of ≥5 mg/kg efficiently protects K18-hACE2 transgenic mice from the lethal challenge of B.1.351 or B.1.617.2, suggesting that the nanobody has promising therapeutic potentials to curb the COVID-19 surge with emerging SARS-CoV-2 variants..

Dromedary camel (Camelus dromedarius) VHH phage libraries were built for isolation of the nanobodies that broadly neutralize SARS-CoV-2 variants.."
2,doi:10.1101/2021.10.27.465996,P.1,"However, emerging SARS-CoV-2 variants such as B.1.1.7 (Alpha, UK), B.1.351 (Beta, South Africa), and P.1 (Gamma, Brazil) have exhibited increased resistance to neutralization by monoclonal antibodies or post-vaccination sera elicited by the COVID-19 vaccines (15, 16)."
3,doi:10.1101/2021.10.27.465996,B.1.1.7,"However, emerging SARS-CoV-2 variants such as B.1.1.7 (Alpha, UK), B.1.351 (Beta, South Africa), and P.1 (Gamma, Brazil) have exhibited increased resistance to neutralization by monoclonal antibodies or post-vaccination sera elicited by the COVID-19 vaccines (15, 16)."
0,doi:10.1016/j.mran.2022.100202,P.1,"Gibbs energies of binding were calculated for several SARS-SoV-2 strains, including Hu-1 (wild type), B.1.1.7 (alpha), B.1.351 (beta), P.1 (Gamma), B.1.36 and B.1.617 (Delta)."
1,doi:10.1016/j.mran.2022.100202,B.1.36,"Gibbs energies of binding were calculated for several SARS-SoV-2 strains, including Hu-1 (wild type), B.1.1.7 (alpha), B.1.351 (beta), P.1 (Gamma), B.1.36 and B.1.617 (Delta)."
2,doi:10.1016/j.mran.2022.100202,B.1.1.7,"Gibbs energies of binding were calculated for several SARS-SoV-2 strains, including Hu-1 (wild type), B.1.1.7 (alpha), B.1.351 (beta), P.1 (Gamma), B.1.36 and B.1.617 (Delta)."
3,doi:10.1016/j.mran.2022.100202,B.1.617,"Gibbs energies of binding were calculated for several SARS-SoV-2 strains, including Hu-1 (wild type), B.1.1.7 (alpha), B.1.351 (beta), P.1 (Gamma), B.1.36 and B.1.617 (Delta)."
4,doi:10.1016/j.mran.2022.100202,B.1.351,"Gibbs energies of binding were calculated for several SARS-SoV-2 strains, including Hu-1 (wild type), B.1.1.7 (alpha), B.1.351 (beta), P.1 (Gamma), B.1.36 and B.1.617 (Delta)."
5,doi:10.1016/j.mran.2022.100202,B.1.526,"Huge numbers of global SARS-CoV-2 infections and insufficient discipline in conducting anti-epidemic measures have resulted in the emergence of new virus variants, starting from original Wuhan, through the Alpha (B.1.1.7 UK), Beta (B.1.351 S. Africa), Gamma (P.1 Brazil), Epsilon (B.1.429 California), Iota (B.1.526 New York), and more recently, Delta and Kappa (B.1.617.2 and B.1.617.1 India) (Farinholt et al., 2021)."
6,doi:10.1016/j.mran.2022.100202,B.1.617.2,"Huge numbers of global SARS-CoV-2 infections and insufficient discipline in conducting anti-epidemic measures have resulted in the emergence of new virus variants, starting from original Wuhan, through the Alpha (B.1.1.7 UK), Beta (B.1.351 S. Africa), Gamma (P.1 Brazil), Epsilon (B.1.429 California), Iota (B.1.526 New York), and more recently, Delta and Kappa (B.1.617.2 and B.1.617.1 India) (Farinholt et al., 2021)."
7,doi:10.1016/j.mran.2022.100202,B.1.617.1,"Huge numbers of global SARS-CoV-2 infections and insufficient discipline in conducting anti-epidemic measures have resulted in the emergence of new virus variants, starting from original Wuhan, through the Alpha (B.1.1.7 UK), Beta (B.1.351 S. Africa), Gamma (P.1 Brazil), Epsilon (B.1.429 California), Iota (B.1.526 New York), and more recently, Delta and Kappa (B.1.617.2 and B.1.617.1 India) (Farinholt et al., 2021)."
8,doi:10.1016/j.mran.2022.100202,B.1.429,"Huge numbers of global SARS-CoV-2 infections and insufficient discipline in conducting anti-epidemic measures have resulted in the emergence of new virus variants, starting from original Wuhan, through the Alpha (B.1.1.7 UK), Beta (B.1.351 S. Africa), Gamma (P.1 Brazil), Epsilon (B.1.429 California), Iota (B.1.526 New York), and more recently, Delta and Kappa (B.1.617.2 and B.1.617.1 India) (Farinholt et al., 2021)."
0,doi:10.3390/v14010027,B.1.351,"Six-week-old mice were inoculated intranasally with a representative virus from the original B.1 lineage, or the emerging B.1.1.7 and B.1.351 lineages."
1,doi:10.3390/v14010027,B.1.1.7,"Six-week-old mice were inoculated intranasally with a representative virus from the original B.1 lineage, or the emerging B.1.1.7 and B.1.351 lineages."
2,doi:10.3390/v14010027,B.1,"Six-week-old mice were inoculated intranasally with a representative virus from the original B.1 lineage, or the emerging B.1.1.7 and B.1.351 lineages."
0,doi:10.1016/j.antiviral.2021.105206,P.1,"Functional assays confirmed that three mAbs, F461G11, F461G15, and F461G16 neutralized four variants of concern (VOC): B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta) These mAbs are promising candidates for COVID-19 therapy, and understanding their interactions with virus spike protein should support further vaccine and antibody development.."
1,doi:10.1016/j.antiviral.2021.105206,B.1.1.7,"Functional assays confirmed that three mAbs, F461G11, F461G15, and F461G16 neutralized four variants of concern (VOC): B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta) These mAbs are promising candidates for COVID-19 therapy, and understanding their interactions with virus spike protein should support further vaccine and antibody development.."
2,doi:10.1016/j.antiviral.2021.105206,B.1.617.2,"Functional assays confirmed that three mAbs, F461G11, F461G15, and F461G16 neutralized four variants of concern (VOC): B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta) These mAbs are promising candidates for COVID-19 therapy, and understanding their interactions with virus spike protein should support further vaccine and antibody development.."
3,doi:10.1016/j.antiviral.2021.105206,B.1.351,"Functional assays confirmed that three mAbs, F461G11, F461G15, and F461G16 neutralized four variants of concern (VOC): B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta) These mAbs are promising candidates for COVID-19 therapy, and understanding their interactions with virus spike protein should support further vaccine and antibody development.."
4,doi:10.1016/j.antiviral.2021.105206,B.1.525,"Moreover, three of them demonstrated robust neutralization of a broad-spectrum of SARS-CoV-2 variants, including B.1.1.7, B.1.351, P.1, B.1.617.2 and B.1.525, indicating their potential as therapeutic agents..

VeroE6 cells were infected at low moi (<0.01) with SARS-CoV-2 (hCoV-19/Canada/ON_ON-VIDO-01-2/2020, GISAID accession# EPI_ISL_425177) in neat DMEM."
0,doi:10.3389/fimmu.2021.752003,B.1.1.7,"The variants, including B.1.1.7 (Alpha), B.1.351 (Beta), P1 (Gamma) and B.1.617.2 (Delta) have shown reduced sensitivity to monoclonal antibodies, plasma and/or sera obtained from convalescent patients and vaccinated individuals."
1,doi:10.3389/fimmu.2021.752003,B.1.617.2,"The variants, including B.1.1.7 (Alpha), B.1.351 (Beta), P1 (Gamma) and B.1.617.2 (Delta) have shown reduced sensitivity to monoclonal antibodies, plasma and/or sera obtained from convalescent patients and vaccinated individuals."
2,doi:10.3389/fimmu.2021.752003,B.1.351,"The variants, including B.1.1.7 (Alpha), B.1.351 (Beta), P1 (Gamma) and B.1.617.2 (Delta) have shown reduced sensitivity to monoclonal antibodies, plasma and/or sera obtained from convalescent patients and vaccinated individuals."
3,doi:10.3389/fimmu.2021.752003,P.1,"The other concerning immune escape substitution in the RBD is E484K, which is also present in the B.1.351 and P.1 variants."
4,doi:10.3389/fimmu.2021.752003,B.1.429,"The other significant RBD substitutions are Y453F in the B.1.1.298 variant (37), L452 in the B.1.429 (25) and B.1.617 variants (38)."
5,doi:10.3389/fimmu.2021.752003,B.1.1.298,"The other significant RBD substitutions are Y453F in the B.1.1.298 variant (37), L452 in the B.1.429 (25) and B.1.617 variants (38)."
6,doi:10.3389/fimmu.2021.752003,B.1.617,"The other significant RBD substitutions are Y453F in the B.1.1.298 variant (37), L452 in the B.1.429 (25) and B.1.617 variants (38)."
7,doi:10.3389/fimmu.2021.752003,A.1,"The FRNT50 titers for mAbs 55, 165, 253, and 318 are also relatively equal between Victoria strain (A.1) (67) and B.1.351, indicating that their epitopes are not impacted by the K417N, E484K and N501Y mutations (9, 11)."
8,doi:10.3389/fimmu.2021.752003,B.1.258,"They concluded that antibody 54042-4 bound to these RBD variants (B.1.17, B.1.351, P1, B.1.141, B.1.258) at a level comparable to the binding to the RBD of Wuhan-1 isolate."
9,doi:10.3389/fimmu.2021.752003,B.1.141,"They concluded that antibody 54042-4 bound to these RBD variants (B.1.17, B.1.351, P1, B.1.141, B.1.258) at a level comparable to the binding to the RBD of Wuhan-1 isolate."
10,doi:10.3389/fimmu.2021.752003,B.1.427,"Using authentic and pseudoviruses neutralization assays, researchers showed that LY-CoV1404 maintains potent neutralizing activity against multiple variants including B.1.1.7, B.1.351, B.1.427, P.1 and B.1.526."
11,doi:10.3389/fimmu.2021.752003,B.1.526,"They found that C118 and C022 Abs neutralized four SARS-CoV-2 variants (B.1.17, B.1.351, B.1.429, B.1.526)."
0,doi:10.1128/jvi.00685-21,P.1,"Here, we report the biophysical properties of the SARS-CoV-2 spike variants D614G, B.1.1.7, B.1.351, and P.1 with affinities to the ACE2 receptor and infectivity capacity, revealing weaknesses in the developed neutralizing antibody approaches."
1,doi:10.1128/jvi.00685-21,B.1.1.7,"Here, we report the biophysical properties of the SARS-CoV-2 spike variants D614G, B.1.1.7, B.1.351, and P.1 with affinities to the ACE2 receptor and infectivity capacity, revealing weaknesses in the developed neutralizing antibody approaches."
2,doi:10.1128/jvi.00685-21,B.1.351,"Here, we report the biophysical properties of the SARS-CoV-2 spike variants D614G, B.1.1.7, B.1.351, and P.1 with affinities to the ACE2 receptor and infectivity capacity, revealing weaknesses in the developed neutralizing antibody approaches."
3,doi:10.1128/jvi.00685-21,B.1.1.28,"Finally, two variants that emerged in Brazil (B.1.1.28 and P.1) contained mutational hallmarks of both the UK and South Africa variants, suggesting convergent evolution in SARS-CoV-2 due to similar selective pressures (16, 17)."
0,doi:10.3389/fimmu.2021.782506,B.1.617.2,"In this study, using an in silico approach, we have examined the binding abilities of eight mAbs against several SARS-CoV-2 variants of Alpha (B.1.1.7) and Delta (B.1.617.2) lineages."
1,doi:10.3389/fimmu.2021.782506,B.1.1.7,"In this study, using an in silico approach, we have examined the binding abilities of eight mAbs against several SARS-CoV-2 variants of Alpha (B.1.1.7) and Delta (B.1.617.2) lineages."
2,doi:10.3389/fimmu.2021.782506,B.1.617,"Strains reported from India, namely, B.1.617 (Kappa), B.1.617.2 (Delta), and B.1.618, have been characterized as exceedingly transmissible SARS-CoV-2 variants (14)."
3,doi:10.3389/fimmu.2021.782506,B.1.618,"Strains reported from India, namely, B.1.617 (Kappa), B.1.617.2 (Delta), and B.1.618, have been characterized as exceedingly transmissible SARS-CoV-2 variants (14)."
4,doi:10.3389/fimmu.2021.782506,B.1.351,"When we compared the efficacy of this mAb against the newly found Delta plus strain (B.1.617.2.1) and Beta strain (B.1.351), a very satisfactory binding interaction was observed as compared to the eight therapeutic mAbs (
Figure 1C
 and 
Table S7
)."
5,doi:10.3389/fimmu.2021.782506,P.1,"However, binding efficacy of the chimeric antibody against Gamma strain (P.1) was comparatively lower than that of the Delta, Delta plus, and Beta strain (
Figure 1C
, 
Tables S5
 and 
S7
).."
6,doi:10.3389/fimmu.2021.782506,B.1.617.3,"The B.1.617 lineage was first detected in India in March 2021, and this lineage constitutes three subtypes, viz., B.1.617.1, B.1.617.2, and B.1.617.3 (46)."
7,doi:10.3389/fimmu.2021.782506,B.1.617.1,"The B.1.617 lineage was first detected in India in March 2021, and this lineage constitutes three subtypes, viz., B.1.617.1, B.1.617.2, and B.1.617.3 (46)."
0,doi:10.1016/j.cell.2021.03.061,B.1.1.7,"The emergence and spread of SARS-CoV-2 lineage B.1.1.7, first detected in the United Kingdom, has become a global public health concern because of its increased transmissibility."
1,doi:10.1016/j.cell.2021.03.061,P.1,"Of particular note is the N501Y mutation in the receptor-binding domain of the spike protein, which is predicted to increase binding to human angiotensin-converting enzyme 2 (ACE2) receptors (Starr et al., 2020) and is also a defining feature of other variants of concern, such as B.1.351 and P.1 (Faria et al., 2021; Lauring and Hodcroft, 2021; Tegally et al., 2020)."
2,doi:10.1016/j.cell.2021.03.061,B.1.351,"Of particular note is the N501Y mutation in the receptor-binding domain of the spike protein, which is predicted to increase binding to human angiotensin-converting enzyme 2 (ACE2) receptors (Starr et al., 2020) and is also a defining feature of other variants of concern, such as B.1.351 and P.1 (Faria et al., 2021; Lauring and Hodcroft, 2021; Tegally et al., 2020)."
3,doi:10.1016/j.cell.2021.03.061,B.1.375,"During January 2021, only 47% (54/116) of the SGTF samples presented in Figure 4B that we sequenced were identified as B.1.1.7, while the majority were SARS-CoV-2 lineage B.1.375, which also has the spike gene Δ69/70 HV deletion that causes SGTF (Larsen and Worobey, 2020; Moreno et al., 2021)."
0,doi:10.1016/j.virusres.2022.198702,B.1.617.2,"Therefore, quick spread, genetic viral evolution, and incomplete vaccination schedules in many countries have been driving the emergence of SARS-CoV-2 variants that may interfere in the vaccine-derived immune response protective effectiveness (Kuzmina et al., 2021)..

SARS-CoV-2 variant B.1.617.2, also known as the Delta variant, has been quickly spread and detected in many countries (Bolze et al., 2021; Li et al., 2021; Public Health England, 2021)."
1,doi:10.1016/j.virusres.2022.198702,P.1,"Hatched squares correspond to at least one sequence with the given mutation although it has never been found with 100% frequency..

COVID-19 epidemic in Brazil, during 2021, was driven by the spread and predominance of the VOC Gamma (lineage P.1) which caused the highest wave of SARS-CoV-2, considering the number of cases, deaths, and hospitalization per day (Demoliner et al., 2021)."
2,doi:10.1016/j.virusres.2022.198702,B.1.1.28,"Despite this, in contrast to the huge COVID-19 epidemic wave associated with the substitution of B.1.1.28 by the VOC Gamma (Demoliner et al., 2021; Faria et al., 2021), Delta viral lineage replacement occurred without the SARS-CoV-2 cases increase, probably due to the high immunity levels (natural and/or vaccinated) in the RS State population (Secretaria da Saúde do Rio Grande do Sul, 2021b)."
0,doi:10.3390/microorganisms9081696,B.1.1.7,"Various lineages were identified in environmental samples; nevertheless, the highest percentages (49.4%) of the alpha variant (B.1.1.7) were detected in Austria, Liechtenstein, Slovenia, Czech Republic, Switzerland, Germany, and Italy."
1,doi:10.3390/microorganisms9081696,B.1.1,"Other prevalent lineages were B.1 (18.2%), B.1.1 (9.2%), and B.1.160 (3.9%)."
2,doi:10.3390/microorganisms9081696,B.1,"Other prevalent lineages were B.1 (18.2%), B.1.1 (9.2%), and B.1.160 (3.9%)."
3,doi:10.3390/microorganisms9081696,B.1.160,"Other prevalent lineages were B.1 (18.2%), B.1.1 (9.2%), and B.1.160 (3.9%)."
0,doi:10.1128/mbio.01140-21,P.1,"The VOCs include lineages such as B.1.1.7 (20I/501Y.V1 variant), P.1 (20J/501Y.V3 variant), B.1.351 (20H/501Y.V2 variant), and B.1.617.2."
1,doi:10.1128/mbio.01140-21,B.1.1.7,"The VOCs include lineages such as B.1.1.7 (20I/501Y.V1 variant), P.1 (20J/501Y.V3 variant), B.1.351 (20H/501Y.V2 variant), and B.1.617.2."
2,doi:10.1128/mbio.01140-21,B.1.351,"The VOCs include lineages such as B.1.1.7 (20I/501Y.V1 variant), P.1 (20J/501Y.V3 variant), B.1.351 (20H/501Y.V2 variant), and B.1.617.2."
3,doi:10.1128/mbio.01140-21,B.1.427,"In contrast, the VOI category includes B.1.525, B.1.526, P.2, and B.1.427/B.1.429."
4,doi:10.1128/mbio.01140-21,B.1.525,"In contrast, the VOI category includes B.1.525, B.1.526, P.2, and B.1.427/B.1.429."
5,doi:10.1128/mbio.01140-21,B.1.526,"In contrast, the VOI category includes B.1.525, B.1.526, P.2, and B.1.427/B.1.429."
6,doi:10.1128/mbio.01140-21,P.2,"In contrast, the VOI category includes B.1.525, B.1.526, P.2, and B.1.427/B.1.429."
7,doi:10.1128/mbio.01140-21,B.1.617.2,"Consequently, a new VOC has been identified from India, which is B.1.617.2 (Delta), and this variant is now spreading worldwide."
8,doi:10.1128/mbio.01140-21,B.1.425,The B.1.425 lineage was found in the USA.
9,doi:10.1128/mbio.01140-21,B.1.426,Lineage B.1.426 was also found in the USA.
10,doi:10.1128/mbio.01140-21,B.1.429,"We also searched for the new variants with keywords such as “B.1.1.7 lineage,” “P.1 lineage,” and “B.1.351 lineage.” A search for two other variant names with the keywords “B.1.427/B.1.429 variant” and “B.1.617.2 variant” was also performed."
0,doi:10.3389/fmicb.2020.615280,B.1.1,"We recovered 190 whole viral genomes collected from 13 Brazilian states from February 29 to April 31, 2020 and combined them with other B.1.1 genomes collected globally."
1,doi:10.3389/fmicb.2020.615280,B.1.1.33,"Our genomic survey confirms that lineage B.1.1.33 is responsible for a variable fraction of the community viral transmissions in Brazilian states, ranging from 2% of all SARS-CoV-2 genomes from Pernambuco to 80% of those from Rio de Janeiro."
2,doi:10.3389/fmicb.2020.615280,B.1,"The SARS-CoV-2 lineage B.1 was initially identified as the most common variant in Europe and is currently also the predominant viral lineage in the Americas (Candido et al., 2020; Deng et al., 2020; Fauver et al., 2020; Franco et al., 2020; Gonzalez-Reiche et al., 2020; Laiton-Donato et al., 2020; Paiva et al., 2020; Paniz-Mondolfi et al., 2020; Ramirez et al., 2020; Salazar et al., 2020; Taboada et al., 2020; Xavier et al., 2020)..

Genomic epidemiology has been a useful tool to track the community transmission of SARS-CoV-2, revealing that its epidemics in Oceania (Rockett et al., 2020; Seemann et al., 2020), Europe (Bluhm et al., 2020; Dellicour et al., 2020; Díez-Fuertes et al., 2020; Gambaro et al., 2020; Gudbjartsson et al., 2020; Miller et al., 2020; Oude Munnink et al., 2020), and the Americas (Deng et al., 2020; Gonzalez-Reiche et al., 2020; Worobey et al., 2020) resulted from multiple independent introductions followed by local dissemination of some viral strains."
3,doi:10.3389/fmicb.2020.615280,B.1.1.28,"The clade 1, characterized by one non-synonymous mutation in the spike protein (G25088T), was subsequently classified by the Pangolin nomenclature as lineage B.1.1.28, and the clade 2, defined by two non-synonymous synapomorphies in ORF6 (T27299C/I33T) and the nucleocapsid protein (T29148C/I292T), was classified as lineage B.1.1.33."
0,doi:10.1093/jtm/taab033,B.1.1.251,"The B.1.1.251 lineage was identified in a 32-old-man with headache, sore throat and coryza."
1,doi:10.1093/jtm/taab033,B.1.1.7,"Recently, new lineages defined by multiple S protein mutations associated with increased transmissibility of SARS-CoV-2 have been identified in the UK (B.1.1.7 lineage) and South Africa (B.1.351 lineage)."
2,doi:10.1093/jtm/taab033,B.1.351,"Recently, new lineages defined by multiple S protein mutations associated with increased transmissibility of SARS-CoV-2 have been identified in the UK (B.1.1.7 lineage) and South Africa (B.1.351 lineage)."
3,doi:10.1093/jtm/taab033,P.1,"In Brazil, two new variants from the B.1.1.28 lineage, namely P.1 and P.2, which present an E484K mutation in the S protein RBD, have been associated with increase in transmissibility, changes in antigenic profile and reinfection.2."
4,doi:10.1093/jtm/taab033,B.1.1.28,"In Brazil, two new variants from the B.1.1.28 lineage, namely P.1 and P.2, which present an E484K mutation in the S protein RBD, have been associated with increase in transmissibility, changes in antigenic profile and reinfection.2."
5,doi:10.1093/jtm/taab033,P.2,"In Brazil, two new variants from the B.1.1.28 lineage, namely P.1 and P.2, which present an E484K mutation in the S protein RBD, have been associated with increase in transmissibility, changes in antigenic profile and reinfection.2."
6,doi:10.1093/jtm/taab033,B.1,"The first case of COVID-19 in Sergipe was confirmed on 14 March 2020 in a female patient with recent travel to Spain infected with SARS-CoV-2 lineage B.1, which is the predominant known global lineage and is subdivided into > 70 variants."
7,doi:10.1093/jtm/taab033,B.1.212,"Until 29 January 2021, other six SARS-CoV-2 lineages have been reported in Sergipe including B.1.1.28 and B.1.1.33, as well as B.1.1.119, B.1.212, P.2 and the emergent B.1.1.251 lineage.."
8,doi:10.1093/jtm/taab033,B.1.1.33,"Until 29 January 2021, other six SARS-CoV-2 lineages have been reported in Sergipe including B.1.1.28 and B.1.1.33, as well as B.1.1.119, B.1.212, P.2 and the emergent B.1.1.251 lineage.."
9,doi:10.1093/jtm/taab033,B.1.1.119,"Until 29 January 2021, other six SARS-CoV-2 lineages have been reported in Sergipe including B.1.1.28 and B.1.1.33, as well as B.1.1.119, B.1.212, P.2 and the emergent B.1.1.251 lineage.."
0,doi:10.3390/v13091773,B.1.617.2,"B.1.617 is becoming a dominant Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) lineage worldwide with many sublineages, of which B.1.617.2 is designated as a variant of concern."
1,doi:10.3390/v13091773,B.1.617.3,"The pathogenicity of B.1.617.2 (Delta) and B.1.617.3 lineage of SARS-CoV-2 was evaluated and compared with that of B.1, an early virus isolate with D614G mutation in a Syrian hamster model."
2,doi:10.3390/v13091773,B.1,"The pathogenicity of B.1.617.2 (Delta) and B.1.617.3 lineage of SARS-CoV-2 was evaluated and compared with that of B.1, an early virus isolate with D614G mutation in a Syrian hamster model."
3,doi:10.3390/v13091773,B.1.351,"Cross neutralizing antibodies were detected in animals infected with B.1, Delta, and B.1.617.3 variant, but neutralizing capacity was significantly lower with B.1.351 (Beta variant)."
4,doi:10.3390/v13091773,B.1.617,Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) B.1.617 lineage variants were first reported in India in October 2020.
5,doi:10.3390/v13091773,B.1.617.1,"Among the reported sublineages, B.1.617.1 is designated as a variant of interest and B.1.617.2 as a variant of concern (VOC) by the World Health Organization [1]."
0,doi:10.1101/2021.07.03.450938,P.1,"The assay also detected SARS-CoV-2 South African (Beta, β), Brazilian/Japanese variant P.1 (Gamma, γ), and Californian (Epsilon, ε), variants of concern or interest (VoC)."
1,doi:10.1101/2021.07.03.450938,B.1.1.7,"Although the rate of mutation in the viral genome is believed to be slower than other viral pathogens, several variants of concern (VoC) have become dominant strains in different locations around the world such as the U.K. variant B.1.1.7 (Alpha, α), the South African variant B.1.135 (Beta, β), the Brazilian/Japanese variant P.1 (Gamma, γ), the Indian variant B.1.617.2 (Delta, δ), and the Californian variant B.1.427/B.1.429 (Epsilon, ε)4 {WHO EPI-WIN, Update 60 https://www.who.int/teams/risk-communication/epi-win-updates}."
2,doi:10.1101/2021.07.03.450938,B.1.617.2,"Although the rate of mutation in the viral genome is believed to be slower than other viral pathogens, several variants of concern (VoC) have become dominant strains in different locations around the world such as the U.K. variant B.1.1.7 (Alpha, α), the South African variant B.1.135 (Beta, β), the Brazilian/Japanese variant P.1 (Gamma, γ), the Indian variant B.1.617.2 (Delta, δ), and the Californian variant B.1.427/B.1.429 (Epsilon, ε)4 {WHO EPI-WIN, Update 60 https://www.who.int/teams/risk-communication/epi-win-updates}."
3,doi:10.1101/2021.07.03.450938,B.1.135,"Although the rate of mutation in the viral genome is believed to be slower than other viral pathogens, several variants of concern (VoC) have become dominant strains in different locations around the world such as the U.K. variant B.1.1.7 (Alpha, α), the South African variant B.1.135 (Beta, β), the Brazilian/Japanese variant P.1 (Gamma, γ), the Indian variant B.1.617.2 (Delta, δ), and the Californian variant B.1.427/B.1.429 (Epsilon, ε)4 {WHO EPI-WIN, Update 60 https://www.who.int/teams/risk-communication/epi-win-updates}."
4,doi:10.1101/2021.07.03.450938,B.1.427,"Although the rate of mutation in the viral genome is believed to be slower than other viral pathogens, several variants of concern (VoC) have become dominant strains in different locations around the world such as the U.K. variant B.1.1.7 (Alpha, α), the South African variant B.1.135 (Beta, β), the Brazilian/Japanese variant P.1 (Gamma, γ), the Indian variant B.1.617.2 (Delta, δ), and the Californian variant B.1.427/B.1.429 (Epsilon, ε)4 {WHO EPI-WIN, Update 60 https://www.who.int/teams/risk-communication/epi-win-updates}."
0,doi:10.3390/v14030454,B.1,H1 (B.1) with the highest substitution rate has become the most dominant haplotype subtype since March 2020 and has evolved into multiple haplotype subtypes with smaller substitution rates.
1,doi:10.3390/v14030454,B.1.1,"Many evolutionary characteristics of early SARS-CoV-2, such as H3 being the only early haplotype subtype that existed for the shortest time, the global prevalence of H1 and H1-5 (B.1.1) within a month after being detected, and many high divergent genome sequences early in February 2020, indicate the missing of early SARS-CoV-2 genomic data."
2,doi:10.3390/v14030454,A.1,"Through molecular epidemiological analysis of 16,373 SARS-CoV-2 genomes at the early stage (from December 2019 to 10 May 2020), we identified nine specific mutation sites of high linkage and four major haplotype subtypes, including H1 (Pango lineage B.1), H2 (identical to the reference sequence at the 9 sites, Pango lineage B), H3 (Pango lineage A.1) and H4 (Pango lineage A) [4]."
3,doi:10.3390/v14030454,B.1.1.7,"Since the epidemic variants, such as H1 and B.1.1.7, often occurred with multiple linked mutation sites, we have proposed an efficient method of analyses of key mutations, linkage, and haplotype subtypes epidemic trend, and developed them into two automated tools, AutoVEM and AutoVEM2 [5,6]."
4,doi:10.3390/v14030454,B.1.177,"Through these tools, we further found that there were more distinctive and highly linked mutation sites in H1-2 (Pango lineage B.1.177) and H1-4-1 (Pango lineage B.1.1.7, WHO alpha) variants, indicating that our method can comprehensively reveal highly linked mutation sites of variants."
5,doi:10.3390/v14030454,B.1.617.2,"Among them, the frequency of H1-6-1 (Pango lineage B.1.617.2, WHO VOC Delta), which was first discovered in India, began to increase from May 2021, and gradually replaced the H1-4-1 to become the dominant prevalence haplotype subtype (Figure 3D and Figure S4, Table S5)."
6,doi:10.3390/v14030454,D.2,"Among them, the proportion of the H1-5-2 (Pango lineage D.2) haplotype subtype was the highest and accounted for 60.32% of the total population in Australia."
0,doi:10.1007/s00430-022-00728-7,B.1.1.529,"Edited by Matthias J. Reddehase..

On November 26, 2021, the World Health Organization classified B.1.1.529 as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VoC), named omicron."
1,doi:10.1007/s00430-022-00728-7,P.1,"Earlier VoCs were characterized either by an increased ability for transmission in the population [VoCs alpha (B.1.1.7) and delta (B.1.617.2)] or a partial immune escape with variable effects on neutralization by polyclonal serum antibodies [VoCs beta (B.1.351), gamma (P.1/B.1.1.28) and delta] [2–7]."
2,doi:10.1007/s00430-022-00728-7,B.1.1.7,"Earlier VoCs were characterized either by an increased ability for transmission in the population [VoCs alpha (B.1.1.7) and delta (B.1.617.2)] or a partial immune escape with variable effects on neutralization by polyclonal serum antibodies [VoCs beta (B.1.351), gamma (P.1/B.1.1.28) and delta] [2–7]."
3,doi:10.1007/s00430-022-00728-7,B.1.1.28,"Earlier VoCs were characterized either by an increased ability for transmission in the population [VoCs alpha (B.1.1.7) and delta (B.1.617.2)] or a partial immune escape with variable effects on neutralization by polyclonal serum antibodies [VoCs beta (B.1.351), gamma (P.1/B.1.1.28) and delta] [2–7]."
4,doi:10.1007/s00430-022-00728-7,B.1.617.2,"Earlier VoCs were characterized either by an increased ability for transmission in the population [VoCs alpha (B.1.1.7) and delta (B.1.617.2)] or a partial immune escape with variable effects on neutralization by polyclonal serum antibodies [VoCs beta (B.1.351), gamma (P.1/B.1.1.28) and delta] [2–7]."
5,doi:10.1007/s00430-022-00728-7,B.1.351,"Earlier VoCs were characterized either by an increased ability for transmission in the population [VoCs alpha (B.1.1.7) and delta (B.1.617.2)] or a partial immune escape with variable effects on neutralization by polyclonal serum antibodies [VoCs beta (B.1.351), gamma (P.1/B.1.1.28) and delta] [2–7]."
0,doi:10.1038/s41586-021-03732-8,B.1.351,"The Ad26.COV2.S vaccine expresses a stabilized spike protein from the WA1/2020 strain of SARS-CoV-2, and has recently demonstrated protective efficacy against symptomatic COVID-19 in humans in several geographical regions—including in South Africa, where 95% of sequenced viruses in cases of COVID-19 were the B.1.351 variant3."
1,doi:10.1038/s41586-021-03732-8,P.1,"Ad26.COV2.S induced lower binding and neutralizing antibodies against B.1.351 as compared to WA1/2020, but elicited comparable CD8 and CD4 T cell responses against the WA1/2020, B.1.351, B.1.1.7, P.1 and CAL.20C variants."
2,doi:10.1038/s41586-021-03732-8,B.1.1.7,"Ad26.COV2.S induced lower binding and neutralizing antibodies against B.1.351 as compared to WA1/2020, but elicited comparable CD8 and CD4 T cell responses against the WA1/2020, B.1.351, B.1.1.7, P.1 and CAL.20C variants."
3,doi:10.1038/s41586-021-03732-8,P.2,"Robust protection was observed in all geographical regions, with similar levels of protection against severe COVID-19 disease regardless of variant, including in the USA, in Brazil (where 69% of cases with sequence data were the P.2 variant) and in South Africa (where 95% of cases with sequence data were the B.1.351 variant)."
0,doi:10.3389/fpubh.2021.784300,P.1,"Two variants of concern (VOCs), Alpha (B.1.1.7) and Gamma (P.1), were first detected in December 2020."
1,doi:10.3389/fpubh.2021.784300,B.1.1.7,"Two variants of concern (VOCs), Alpha (B.1.1.7) and Gamma (P.1), were first detected in December 2020."
2,doi:10.3389/fpubh.2021.784300,B.1.375,"Although other variants, like B.1.375, also carry this deletion, in a scenario of B.1.1.7 expansion, SGTF represents B.1.1.7 infections and is used as a trusted proxy for it (5)..

As the ThermoFisher COVID-19 TaqMan assay is currently adopted in many UK laboratories, epidemiological data from B.1.1.7 are much more abundant than from the other two VOCs, which were initially recognized and investigated by RNA sequencing, a cumbersome and expensive method that provides a lower throughput."
3,doi:10.3389/fpubh.2021.784300,B.1.351,"P.1 also carries N501Y and shares with B.1.351, the receptor-binding domain (RBD) E484K mutation, associated with immune evasion, which is one of the explanations for the explosion of cases in the region previously reported to present, at that time, probably, the highest seroprevalence in the world, of about 66% (11)."
4,doi:10.3389/fpubh.2021.784300,P.2,"It was inevitable to conclude that P.1 clearly prevailed over B.1.1.7 and P.2, which was the major lineage in December 2020 all over the country (20)."
5,doi:10.3389/fpubh.2021.784300,B.1.617,"India experienced a similar situation, where B.1.1.7 was the dominant VOC until the emergence of B.1.617, which, since July 2021, has been responsible for the overwhelming majority of new cases worldwide1.."
6,doi:10.3389/fpubh.2021.784300,B.1.617.2,"Thus, it is inadvisable to compare the replacement of B.1.1.7 by B.1.617.2 in India, where B.1.1.7 represented 26% of the new cases in early March and <1% in early June1, since B.1.1.7 never surpassed the 5% frequency in Brazil.."
0,doi:10.3390/diagnostics11122216,B.1.351,The neutralization antibody titer against the wild type lineage A SARS-CoV-2 and against the beta variant (B.1.351) was determined using a conventional live virus neutralization test.
1,doi:10.3390/diagnostics11122216,P.1,"The World Health Organization has classified the alpha (B.1.1.7), beta (B.1.351), gamma (P.1), and delta (B.1.617.2) variants as VOCs [9]."
2,doi:10.3390/diagnostics11122216,B.1.1.7,"The World Health Organization has classified the alpha (B.1.1.7), beta (B.1.351), gamma (P.1), and delta (B.1.617.2) variants as VOCs [9]."
3,doi:10.3390/diagnostics11122216,B.1.617.2,"The World Health Organization has classified the alpha (B.1.1.7), beta (B.1.351), gamma (P.1), and delta (B.1.617.2) variants as VOCs [9]."
0,doi:10.3390/diagnostics11101818,B.1.617,"The objective of this study was to create an adaptable and comprehensive toolset for multiplexed Spike-gene SNP detection, which was applied to screen for SARS-CoV-2 B.1.617 lineage variants."
1,doi:10.3390/diagnostics11101818,B.1.617.2,We show 100% concordance with whole genome sequencing for a B.1.617.2 screening assay on the cobas6800 high-throughput system..
2,doi:10.3390/diagnostics11101818,P.1,"These include current variants of concern (VOC) B.1.1.7 (alpha variant) [1], B.1.351 (beta variant) [2], P.1 (gamma) [3], and B.1.617.2 (delta) variant [4], which has recently replaced the alpha-variant as the predominant lineage worldwide."
3,doi:10.3390/diagnostics11101818,B.1.1.7,"These include current variants of concern (VOC) B.1.1.7 (alpha variant) [1], B.1.351 (beta variant) [2], P.1 (gamma) [3], and B.1.617.2 (delta) variant [4], which has recently replaced the alpha-variant as the predominant lineage worldwide."
4,doi:10.3390/diagnostics11101818,B.1.351,"These include current variants of concern (VOC) B.1.1.7 (alpha variant) [1], B.1.351 (beta variant) [2], P.1 (gamma) [3], and B.1.617.2 (delta) variant [4], which has recently replaced the alpha-variant as the predominant lineage worldwide."
5,doi:10.3390/diagnostics11101818,B.1.617.1,"In light of the recent emergence of the B.1.617.1/2/3 lineages and classification as VOC [22], a multiplex assay (SCOV2-617VOC-UCT) was compiled from the existing assay list (Supplementary Table S1) to create a discriminatory high-throughput screening tool on the cobas6800 system (Table 1)."
0,doi:10.3346/jkms.2021.36.e341,B.1.617.2,"Since severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) B.1.617.2 (delta) variant was first detected in December 2020, it has become the dominant variant in the coronavirus disease 2019 (COVID-19) global pandemic.1 South Korea (Republic of Korea) was no exception to this global trend; the detection rate of the delta variant was only 1.4% in April 2021 but has since increased sharply to 90% in August 2021.23 Regarding the delta variants’ high transmissibility,4 this increased prevalence of the delta variant is thought to be contributing to the new nationwide COVID-19 outbreak of South Korea (the so-called ‘fourth wave’) that began in July 2021.."
0,doi:10.1016/j.eclinm.2021.101036,P.1,"We assessed whether there was an impact of vaccinations on the mortality of elderly individuals in a context of wide transmission of the SARS-CoV-2 gamma (P.1) variant..

Methods: By May 15, 2021, 238,414 COVID-19 deaths had been reported to the Brazilian Mortality Information System."
0,doi:10.15585/mmwr.mm7109e1,B.1.1.529,"The B.1.1.529 (Omicron) variant, first detected in November 2021, was responsible for a surge in U.S. infections with SARS-CoV-2, the virus that causes COVID-19, during December 2021–January 2022 (1)."
0,doi:10.1128/spectrum.01352-21,B.1.1.7,In vitro mutagenesis assays show that mutant residues found in the emerging new lineage B.1.1.7 of SARS-CoV-2 do not affect nCoV617 binding to the S-RBD.
1,doi:10.1128/spectrum.01352-21,P.1,"In addition to the B.1.1.7 variant, notable variants include B.1.351 (501Y.V2) (32, 33), B.1.1.28 (34, 35) (P.1 or 501Y.V3) (https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585), and B.1.617 (https://www.cnbc.com/2021/05/10/who-classifies-triple-mutant-covid-variant-from-india-as-global-health-risk-.html)."
2,doi:10.1128/spectrum.01352-21,B.1.1.28,"In addition to the B.1.1.7 variant, notable variants include B.1.351 (501Y.V2) (32, 33), B.1.1.28 (34, 35) (P.1 or 501Y.V3) (https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585), and B.1.617 (https://www.cnbc.com/2021/05/10/who-classifies-triple-mutant-covid-variant-from-india-as-global-health-risk-.html)."
3,doi:10.1128/spectrum.01352-21,B.1.617,"In addition to the B.1.1.7 variant, notable variants include B.1.351 (501Y.V2) (32, 33), B.1.1.28 (34, 35) (P.1 or 501Y.V3) (https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585), and B.1.617 (https://www.cnbc.com/2021/05/10/who-classifies-triple-mutant-covid-variant-from-india-as-global-health-risk-.html)."
4,doi:10.1128/spectrum.01352-21,B.1.351,"In addition to the B.1.1.7 variant, notable variants include B.1.351 (501Y.V2) (32, 33), B.1.1.28 (34, 35) (P.1 or 501Y.V3) (https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585), and B.1.617 (https://www.cnbc.com/2021/05/10/who-classifies-triple-mutant-covid-variant-from-india-as-global-health-risk-.html)."
5,doi:10.1128/spectrum.01352-21,B.1.617.2,"Our results have revealed the neutralizing mechanism of the NAb nCoV617, which may benefit both prophylactic and therapeutic interventions for the newly emerging SARS-CoV-2 lineage B.1.1.7 and provide effective options for comprehensive antibody therapy, but for the lineages B.1.351, B.1.1.28, B.1.617, and B.1.617.2, the effect of nCoV617 may be greatly reduced."
0,doi:10.1001/jamanetworkopen.2021.22240,B.1.1.7,"Results from subgroup analyses were similar to those reported in a previous systematic review and meta-analysis; however, the SAR was higher to contacts with comorbidities (3 studies; 50.0% [95% CI, 41.4%-58.6%]) compared with previous findings, and the estimated household SAR for the B.1.1.7 (α) variant was 24.5% (3 studies; 95% CI, 10.9%-46.2%).."
1,doi:10.1001/jamanetworkopen.2021.22240,B.1.617.2,"For the B.1.1.7 (α) variant, SARs ranged from 9.0% to 42.0%35,40,96,102,103 and were reported to be higher compared with SARs for wild-type variants102 or non-VOCs104 in Ontario, Canada, and compared with SARs for other lineages in the Netherlands88 and Oslo, Norway,103 but lower compared with SARs for the B.1.617.2 (δ) variant in England.96 These findings are consistent with those reported in a modeling study105 that estimated that the transmissibility of the B.1.1.7 (α) variant was 43% to 90% higher than that of preexisting variants.."
2,doi:10.1001/jamanetworkopen.2021.22240,P.1,"Regarding variants that were examined in fewer than 3 studies for which we did not perform meta-analyses, SARs were also higher for the B.1.351 (β) or P.1 (γ) variant (27.2%) and non-VOC variants (23.3%) compared with wild-type variants in Ontario, Canada.102Household SARs were higher for contacts with the B.1.427 and B.1.429 (ε) variants (35.6%) compared with contacts without these variants in San Francisco, California,18 whereas no major differences in household SARs were found between individuals with the B.1.526 (ι) variant and non-VOCs in New York, New York.106."
3,doi:10.1001/jamanetworkopen.2021.22240,B.1.526,"Regarding variants that were examined in fewer than 3 studies for which we did not perform meta-analyses, SARs were also higher for the B.1.351 (β) or P.1 (γ) variant (27.2%) and non-VOC variants (23.3%) compared with wild-type variants in Ontario, Canada.102Household SARs were higher for contacts with the B.1.427 and B.1.429 (ε) variants (35.6%) compared with contacts without these variants in San Francisco, California,18 whereas no major differences in household SARs were found between individuals with the B.1.526 (ι) variant and non-VOCs in New York, New York.106."
4,doi:10.1001/jamanetworkopen.2021.22240,B.1.429,"Regarding variants that were examined in fewer than 3 studies for which we did not perform meta-analyses, SARs were also higher for the B.1.351 (β) or P.1 (γ) variant (27.2%) and non-VOC variants (23.3%) compared with wild-type variants in Ontario, Canada.102Household SARs were higher for contacts with the B.1.427 and B.1.429 (ε) variants (35.6%) compared with contacts without these variants in San Francisco, California,18 whereas no major differences in household SARs were found between individuals with the B.1.526 (ι) variant and non-VOCs in New York, New York.106."
5,doi:10.1001/jamanetworkopen.2021.22240,B.1.427,"Regarding variants that were examined in fewer than 3 studies for which we did not perform meta-analyses, SARs were also higher for the B.1.351 (β) or P.1 (γ) variant (27.2%) and non-VOC variants (23.3%) compared with wild-type variants in Ontario, Canada.102Household SARs were higher for contacts with the B.1.427 and B.1.429 (ε) variants (35.6%) compared with contacts without these variants in San Francisco, California,18 whereas no major differences in household SARs were found between individuals with the B.1.526 (ι) variant and non-VOCs in New York, New York.106."
6,doi:10.1001/jamanetworkopen.2021.22240,B.1.351,"Regarding variants that were examined in fewer than 3 studies for which we did not perform meta-analyses, SARs were also higher for the B.1.351 (β) or P.1 (γ) variant (27.2%) and non-VOC variants (23.3%) compared with wild-type variants in Ontario, Canada.102Household SARs were higher for contacts with the B.1.427 and B.1.429 (ε) variants (35.6%) compared with contacts without these variants in San Francisco, California,18 whereas no major differences in household SARs were found between individuals with the B.1.526 (ι) variant and non-VOCs in New York, New York.106."
0,doi:10.1128/spectrum.00890-21,B.1.1.7,"In addition, we measured the relative antibody binding toward antigens from the CoV2 virus variants strains B.1.1.7 (Alpha) and B.1.351 (Beta)."
1,doi:10.1128/spectrum.00890-21,B.1.351,"In addition, we measured the relative antibody binding toward antigens from the CoV2 virus variants strains B.1.1.7 (Alpha) and B.1.351 (Beta)."
0,doi:10.1128/spectrum.01511-21,P.1,"The SARS-CoV-2 P.1 lineage emerged in Amazonas (AM), North Brazil and its evolution has been dynamically reported associated with increased transmissibility and/or immune evasion."
1,doi:10.1128/spectrum.01511-21,B.1.1.28,"Noteworthy, there was a high incidence of P.1 lineage in RS in February 2021, which coincided with a significant increase in hospitalizations (9)..

A phylogenetic analysis indicated that the VOC P.1 descended from the B.1.1.28 lineage (4), which together with the B.1.1.33 lineage were the first dominant lineages in Brazil in 2020 (5)."
2,doi:10.1128/spectrum.01511-21,B.1.1.33,"Noteworthy, there was a high incidence of P.1 lineage in RS in February 2021, which coincided with a significant increase in hospitalizations (9)..

A phylogenetic analysis indicated that the VOC P.1 descended from the B.1.1.28 lineage (4), which together with the B.1.1.33 lineage were the first dominant lineages in Brazil in 2020 (5)."
3,doi:10.1128/spectrum.01511-21,P.2,"These lineages were gradually replaced by the P.2 Variant of Interest (VOI), which was later replaced by the P.1 lineage (4)."
4,doi:10.1128/spectrum.01511-21,P.1.8,"Recently, new sublineages (P.1.2 to P.1.8) that have emerged from P.1 have been reported in Brazil (11, 12), which indicates a continuous evolution of the virus and the community spread in the country.."
5,doi:10.1128/spectrum.01511-21,P.1.2,"Recently, new sublineages (P.1.2 to P.1.8) that have emerged from P.1 have been reported in Brazil (11, 12), which indicates a continuous evolution of the virus and the community spread in the country.."
6,doi:10.1128/spectrum.01511-21,B.1.91,"Of the 74 specimens from 2020, most of them were classified into five SARS-CoV-2 lineages: B.1.1.28 (n = 25; 34%), B.1.1.161 (n = 25; 34%), B.1.1 (n = 6; 26%), B.1.1.33 (n = 4; 5%), and B.1.91 (n = 4; 5%) (Table S1)."
7,doi:10.1128/spectrum.01511-21,B.1.1,"Of the 74 specimens from 2020, most of them were classified into five SARS-CoV-2 lineages: B.1.1.28 (n = 25; 34%), B.1.1.161 (n = 25; 34%), B.1.1 (n = 6; 26%), B.1.1.33 (n = 4; 5%), and B.1.91 (n = 4; 5%) (Table S1)."
8,doi:10.1128/spectrum.01511-21,B.1.1.161,"Of the 74 specimens from 2020, most of them were classified into five SARS-CoV-2 lineages: B.1.1.28 (n = 25; 34%), B.1.1.161 (n = 25; 34%), B.1.1 (n = 6; 26%), B.1.1.33 (n = 4; 5%), and B.1.91 (n = 4; 5%) (Table S1)."
9,doi:10.1128/spectrum.01511-21,P.1.1,"Of the 126 specimens sequenced from 2021, most of them were classified as P.1 (n = 97; 77%), followed by P.2 (n = 12; 9.5%), P.1.2 (n = 6; 4.7%), B.1.1.28 (n = 6; 4.7%), and P.1.1 (n = 2, 1.5%) (Table S1; Fig."
0,doi:10.1186/s12985-021-01642-9,P.1,"These lineages include B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526 and B.1.617.1."
1,doi:10.1186/s12985-021-01642-9,B.1.1.7,"These lineages include B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526 and B.1.617.1."
2,doi:10.1186/s12985-021-01642-9,P.3,"These lineages include B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526 and B.1.617.1."
3,doi:10.1186/s12985-021-01642-9,B.1.526,"These lineages include B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526 and B.1.617.1."
4,doi:10.1186/s12985-021-01642-9,B.1.525,"These lineages include B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526 and B.1.617.1."
5,doi:10.1186/s12985-021-01642-9,B.1.617.2,"These lineages include B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526 and B.1.617.1."
6,doi:10.1186/s12985-021-01642-9,P.2,"These lineages include B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526 and B.1.617.1."
7,doi:10.1186/s12985-021-01642-9,B.1.427,"These lineages include B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526 and B.1.617.1."
8,doi:10.1186/s12985-021-01642-9,B.1.351,"These lineages include B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526 and B.1.617.1."
9,doi:10.1186/s12985-021-01642-9,B.1.429,B.1.427/B.1.429 variant was first identified in California.
10,doi:10.1186/s12985-021-01642-9,B.1.617,"Recently in India, SARS-CoV-2 variants were reported that belongs to the B.1.617 lineage: B.1.617.1 and B.1.617.2 (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/)."
11,doi:10.1186/s12985-021-01642-9,B.1.617.1,"Recently in India, SARS-CoV-2 variants were reported that belongs to the B.1.617 lineage: B.1.617.1 and B.1.617.2 (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/)."
0,doi:10.1093/infdis/jiab368,B.1.617,The SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020.
1,doi:10.1093/infdis/jiab368,B.1.429,L452R was observed in the epsilon variant B.1.429 and is associated with increase in viral load and around 20% increased transmissibility [3].
2,doi:10.1093/infdis/jiab368,P.1,"Little is known about E484Q, although E484K is a defining feature of 2 variants of concern (VOCs), B.1.351 and P.1, and is found alongside K417N/T as well as N501Y in these VOC."
3,doi:10.1093/infdis/jiab368,B.1.351,"Little is known about E484Q, although E484K is a defining feature of 2 variants of concern (VOCs), B.1.351 and P.1, and is found alongside K417N/T as well as N501Y in these VOC."
4,doi:10.1093/infdis/jiab368,B.1.1.7,"E484K has also emerged in the background of B.1.1.7 [6]..

All sequences excluding low-quality sequences (>5% N regions) with the L452R mutation were downloaded from GISAID database (https://gisaid.org) on 4 May 2021 and manually aligned to reference strain MN908947.3 with mafft v4.475 using the --keeplength --addfragments option."
5,doi:10.1093/infdis/jiab368,B.1.617.2,"B.1.617.1 has 3 key spike mutations, L452R, E484Q, and P681R, whereas B.1.617.2 is characterized by L452R, T478K, and P681R (cleavage site region)."
6,doi:10.1093/infdis/jiab368,B.1.617.3,"There was likely loss of E484Q in B.1.617.2 given that B.1.617.3 also bears E484Q (Figure 1A), indicating E484Q was present in the ancestral virus."
7,doi:10.1093/infdis/jiab368,B.1.617.1,"The number of sequenced isolates of B.1.617.1 and B.1.617.2 has been steadily increasing in India (Figure 1B), although with the caveat of very low sequencing of prevalent cases and heterogeneous sampling across the country.."
0,doi:10.1101/2021.10.18.21264623,B.1,"In the early spring of 2020, all detected variants were of the B.1 and closely related lineages."
1,doi:10.1101/2021.10.18.21264623,B.1.1.7,"A mixture of lineages followed, notably including B.1.243 followed by B.1.1.7 (alpha), with other lineages present at lower levels."
2,doi:10.1101/2021.10.18.21264623,B.1.243,"A mixture of lineages followed, notably including B.1.243 followed by B.1.1.7 (alpha), with other lineages present at lower levels."
3,doi:10.1101/2021.10.18.21264623,B.1.617.2,Later isolations were dominated by B.1.617.2 (delta) and other delta lineages; delta was the exclusive variant present by the last time sampled.
4,doi:10.1101/2021.10.18.21264623,P.1,"More recently, variants first identified in the UK (B.1.1.7 or alpha) (30, 31), South Africa (B.1.351 or beta), Brazil (P.1 or gamma), California (B.1.427 and B.1.429 or epsilon), New York (B.1.526 or iota) (32), and India (B.1.617.2 or delta) (8) have been suggested to be spreading at the expense of pre-existing viral types."
5,doi:10.1101/2021.10.18.21264623,B.1.526,"More recently, variants first identified in the UK (B.1.1.7 or alpha) (30, 31), South Africa (B.1.351 or beta), Brazil (P.1 or gamma), California (B.1.427 and B.1.429 or epsilon), New York (B.1.526 or iota) (32), and India (B.1.617.2 or delta) (8) have been suggested to be spreading at the expense of pre-existing viral types."
6,doi:10.1101/2021.10.18.21264623,B.1.429,"More recently, variants first identified in the UK (B.1.1.7 or alpha) (30, 31), South Africa (B.1.351 or beta), Brazil (P.1 or gamma), California (B.1.427 and B.1.429 or epsilon), New York (B.1.526 or iota) (32), and India (B.1.617.2 or delta) (8) have been suggested to be spreading at the expense of pre-existing viral types."
7,doi:10.1101/2021.10.18.21264623,B.1.427,"More recently, variants first identified in the UK (B.1.1.7 or alpha) (30, 31), South Africa (B.1.351 or beta), Brazil (P.1 or gamma), California (B.1.427 and B.1.429 or epsilon), New York (B.1.526 or iota) (32), and India (B.1.617.2 or delta) (8) have been suggested to be spreading at the expense of pre-existing viral types."
8,doi:10.1101/2021.10.18.21264623,B.1.351,"More recently, variants first identified in the UK (B.1.1.7 or alpha) (30, 31), South Africa (B.1.351 or beta), Brazil (P.1 or gamma), California (B.1.427 and B.1.429 or epsilon), New York (B.1.526 or iota) (32), and India (B.1.617.2 or delta) (8) have been suggested to be spreading at the expense of pre-existing viral types."
9,doi:10.1101/2021.10.18.21264623,B.1.2,"Numbers varied both as surveillance sequencing efforts accelerated and as the availability of samples varied..

Members of the B.1 lineage predominated March 2020 until fall 2020, at which time B.1.2 and B.1.243 became predominant."
10,doi:10.1101/2021.10.18.21264623,B.1.1.434,"From this view, it is evident that several further lineages waxed and waned notably over the sampling period, including B.1.1.434 and B.1.526..

As a control, we assessed the variants associated with spike (S) gene target failure samples (Figures 2C and 4 and Table S3), where an amplicon overlapping the 69–70 deletion in spike failed selectively."
11,doi:10.1101/2021.10.18.21264623,B.1.375,"Rarely, other lineages were seen that share the spike deletion with B.1.1.7 (B.1.375 and B.1.525) or were likely stochastic failures of S amplification or genomes with novel combinations of mutations..

As expected, we found that the B.1.1.7 lineage was estimated to be highly enriched in the S gene target failure set over what would be expected from its frequency in the surveillance lineage counts (Figure 4) (odds ratio of 120; 95% credible interval 38–470)."
12,doi:10.1101/2021.10.18.21264623,B.1.525,"Rarely, other lineages were seen that share the spike deletion with B.1.1.7 (B.1.375 and B.1.525) or were likely stochastic failures of S amplification or genomes with novel combinations of mutations..

As expected, we found that the B.1.1.7 lineage was estimated to be highly enriched in the S gene target failure set over what would be expected from its frequency in the surveillance lineage counts (Figure 4) (odds ratio of 120; 95% credible interval 38–470)."
0,doi:10.1172/jci157416,B.1.1.529,"However, the emergence of the highly mutated omicron (B.1.1.529) variant heightens the importance of finding effective anti–SARS-CoV-2 nAb therapeutics despite rapid viral evolution.."
1,doi:10.1172/jci157416,B.1.1.7,"These changes include many substitutions previously reported in the alpha (B.1.1.7), beta (B.1.351), and delta (B.1.617.2) VOCs as well as a host of changes not previously seen (6)."
2,doi:10.1172/jci157416,B.1.617.2,"These changes include many substitutions previously reported in the alpha (B.1.1.7), beta (B.1.351), and delta (B.1.617.2) VOCs as well as a host of changes not previously seen (6)."
3,doi:10.1172/jci157416,B.1.351,"These changes include many substitutions previously reported in the alpha (B.1.1.7), beta (B.1.351), and delta (B.1.617.2) VOCs as well as a host of changes not previously seen (6)."
0,doi:10.3390/microorganisms9081738,B.1.1.7,"Moreover, concordance was observed between NPS and saliva in the detection of viral mutations, and both N501Y and 69/70del (associated with the B.1.1.7 variant) were detected in the majority 6/8 (75%) of subjects, while the K417T mutation (associated with the P.1-type variants) was detected in 2/8 (25%) individuals."
1,doi:10.3390/microorganisms9081738,N.7,"Specifically, the specimen from individual n.7 at T2 resulted as positive using direct analysis, showing a Ct value of 39.91 for the N2 target gene."
0,doi:10.3390/v13091801,P.6,"We identified that the most prevalent viral variant during the first epidemic wave in Uruguay (December 2020–February 2021) was a B.1.1.28 sublineage carrying Spike mutations Q675H + Q677H, now designated as P.6, followed by lineages P.2 and P.7."
1,doi:10.3390/v13091801,B.1.1.28,"We identified that the most prevalent viral variant during the first epidemic wave in Uruguay (December 2020–February 2021) was a B.1.1.28 sublineage carrying Spike mutations Q675H + Q677H, now designated as P.6, followed by lineages P.2 and P.7."
2,doi:10.3390/v13091801,P.2,"We identified that the most prevalent viral variant during the first epidemic wave in Uruguay (December 2020–February 2021) was a B.1.1.28 sublineage carrying Spike mutations Q675H + Q677H, now designated as P.6, followed by lineages P.2 and P.7."
3,doi:10.3390/v13091801,P.7,The more efficient dissemination of lineage P.6 with respect to P.2 and P.7 and the presence of mutations (Q675H and Q677H) in the proximity of the key cleavage site at the S1/S2 boundary suggest that P.6 may be more transmissible than other lineages co-circulating in Uruguay.
4,doi:10.3390/v13091801,P.1,"Although P.6 was replaced by the variant of concern (VOC) P.1 as the predominant lineage in Uruguay since April 2021, the monitoring of the concurrent emergence of Q675H + Q677H in VOCs should be of worldwide interest..

By the end of 2020 and the beginning of 2021, several studies reported the emergence of novel SARS-CoV-2 variants of interest (VOIs) and concern (VOCs) with different missense mutations and deletions in the Spike (S) protein that impact viral transmissibility and escape from previous host’s immune responses, among other features [1,2]."
5,doi:10.3390/v13091801,B.1.1.33,"In Brazil, the SARS-CoV-2 lineages B.1.1.28 and B.1.1.33 dominated the first epidemic wave [3,4], but were replaced by VOC P.1 (WHO name: Gamma) and P.2 (former VOI Zeta), both descendants of lineage B.1.1.28, by the end of 2020 and beginning of 2021 [5]."
6,doi:10.3390/v13091801,P.4,"The lineages P.2, P.4, and P.5, carrying the concerning amino acid changes S:E484K, S:L452R, and S:E484Q/N501T, respectively, were also initially detected in samples from Brazil [10,11,12,13,14,15]."
7,doi:10.3390/v13091801,P.5,"The lineages P.2, P.4, and P.5, carrying the concerning amino acid changes S:E484K, S:L452R, and S:E484Q/N501T, respectively, were also initially detected in samples from Brazil [10,11,12,13,14,15]."
8,doi:10.3390/v13091801,P.3,"The lineage P.3 (former VOI Theta) emerged in the Philippines, and it includes substitutions S:E484K/N501Y/P681H among the lineage-defining mutations; the first sample was collected on 8 January 2021, and later it further spread to the USA, Germany, and Malaysia, among other countries [16]."
9,doi:10.3390/v13091801,B.31,"At the beginning, viral diversity was high, with cocirculation of strains A.2, A.5, B.1, B.1.195, and B.31, introduced mostly through Montevideo, Uruguay’s capital city and connection hub through its international airport and harbor [21]."
10,doi:10.3390/v13091801,B.1,"At the beginning, viral diversity was high, with cocirculation of strains A.2, A.5, B.1, B.1.195, and B.31, introduced mostly through Montevideo, Uruguay’s capital city and connection hub through its international airport and harbor [21]."
11,doi:10.3390/v13091801,A.5,"At the beginning, viral diversity was high, with cocirculation of strains A.2, A.5, B.1, B.1.195, and B.31, introduced mostly through Montevideo, Uruguay’s capital city and connection hub through its international airport and harbor [21]."
12,doi:10.3390/v13091801,A.2,"At the beginning, viral diversity was high, with cocirculation of strains A.2, A.5, B.1, B.1.195, and B.31, introduced mostly through Montevideo, Uruguay’s capital city and connection hub through its international airport and harbor [21]."
13,doi:10.3390/v13091801,B.1.195,"At the beginning, viral diversity was high, with cocirculation of strains A.2, A.5, B.1, B.1.195, and B.31, introduced mostly through Montevideo, Uruguay’s capital city and connection hub through its international airport and harbor [21]."
14,doi:10.3390/v13091801,B.1.1.1,"The “Others” category included B.1, B.1.1, B.1.1.1, B.1.1.34, B.1.177, B.1.177.12, and B.1.238."
15,doi:10.3390/v13091801,B.1.1.34,"The “Others” category included B.1, B.1.1, B.1.1.1, B.1.1.34, B.1.177, B.1.177.12, and B.1.238."
16,doi:10.3390/v13091801,B.1.177,"The “Others” category included B.1, B.1.1, B.1.1.1, B.1.1.34, B.1.177, B.1.177.12, and B.1.238."
17,doi:10.3390/v13091801,B.1.1,"The “Others” category included B.1, B.1.1, B.1.1.1, B.1.1.34, B.1.177, B.1.177.12, and B.1.238."
18,doi:10.3390/v13091801,B.1.177.12,"The “Others” category included B.1, B.1.1, B.1.1.1, B.1.1.34, B.1.177, B.1.177.12, and B.1.238."
19,doi:10.3390/v13091801,B.1.36,"Overall, the pair S:Q675H + Q677H appeared to be distributed in 12 different countries (in decreasing frequency order: Uruguay, England, USA, Belgium, India, Australia, Switzerland, Spain, Netherlands, Japan, Germany, and France) and in 13 different Pango lineages (in decreasing frequency order: P.6, B.1.36, B.1.2, C.36, B.1.538, B.1.1.316, B.1.526 (VOI Iota), B.1.525 (VOI Eta), B.1.243, B.1.1.70, B.1.1.7 (VOC Alpha), B.1.1.63, and B.1) (Figure S5).."
20,doi:10.3390/v13091801,C.36,"Overall, the pair S:Q675H + Q677H appeared to be distributed in 12 different countries (in decreasing frequency order: Uruguay, England, USA, Belgium, India, Australia, Switzerland, Spain, Netherlands, Japan, Germany, and France) and in 13 different Pango lineages (in decreasing frequency order: P.6, B.1.36, B.1.2, C.36, B.1.538, B.1.1.316, B.1.526 (VOI Iota), B.1.525 (VOI Eta), B.1.243, B.1.1.70, B.1.1.7 (VOC Alpha), B.1.1.63, and B.1) (Figure S5).."
21,doi:10.3390/v13091801,B.1.243,"Overall, the pair S:Q675H + Q677H appeared to be distributed in 12 different countries (in decreasing frequency order: Uruguay, England, USA, Belgium, India, Australia, Switzerland, Spain, Netherlands, Japan, Germany, and France) and in 13 different Pango lineages (in decreasing frequency order: P.6, B.1.36, B.1.2, C.36, B.1.538, B.1.1.316, B.1.526 (VOI Iota), B.1.525 (VOI Eta), B.1.243, B.1.1.70, B.1.1.7 (VOC Alpha), B.1.1.63, and B.1) (Figure S5).."
22,doi:10.3390/v13091801,B.1.1.7,"Overall, the pair S:Q675H + Q677H appeared to be distributed in 12 different countries (in decreasing frequency order: Uruguay, England, USA, Belgium, India, Australia, Switzerland, Spain, Netherlands, Japan, Germany, and France) and in 13 different Pango lineages (in decreasing frequency order: P.6, B.1.36, B.1.2, C.36, B.1.538, B.1.1.316, B.1.526 (VOI Iota), B.1.525 (VOI Eta), B.1.243, B.1.1.70, B.1.1.7 (VOC Alpha), B.1.1.63, and B.1) (Figure S5).."
23,doi:10.3390/v13091801,B.1.1.63,"Overall, the pair S:Q675H + Q677H appeared to be distributed in 12 different countries (in decreasing frequency order: Uruguay, England, USA, Belgium, India, Australia, Switzerland, Spain, Netherlands, Japan, Germany, and France) and in 13 different Pango lineages (in decreasing frequency order: P.6, B.1.36, B.1.2, C.36, B.1.538, B.1.1.316, B.1.526 (VOI Iota), B.1.525 (VOI Eta), B.1.243, B.1.1.70, B.1.1.7 (VOC Alpha), B.1.1.63, and B.1) (Figure S5).."
24,doi:10.3390/v13091801,B.1.2,"Overall, the pair S:Q675H + Q677H appeared to be distributed in 12 different countries (in decreasing frequency order: Uruguay, England, USA, Belgium, India, Australia, Switzerland, Spain, Netherlands, Japan, Germany, and France) and in 13 different Pango lineages (in decreasing frequency order: P.6, B.1.36, B.1.2, C.36, B.1.538, B.1.1.316, B.1.526 (VOI Iota), B.1.525 (VOI Eta), B.1.243, B.1.1.70, B.1.1.7 (VOC Alpha), B.1.1.63, and B.1) (Figure S5).."
25,doi:10.3390/v13091801,B.1.526,"Overall, the pair S:Q675H + Q677H appeared to be distributed in 12 different countries (in decreasing frequency order: Uruguay, England, USA, Belgium, India, Australia, Switzerland, Spain, Netherlands, Japan, Germany, and France) and in 13 different Pango lineages (in decreasing frequency order: P.6, B.1.36, B.1.2, C.36, B.1.538, B.1.1.316, B.1.526 (VOI Iota), B.1.525 (VOI Eta), B.1.243, B.1.1.70, B.1.1.7 (VOC Alpha), B.1.1.63, and B.1) (Figure S5).."
26,doi:10.3390/v13091801,B.1.538,"Overall, the pair S:Q675H + Q677H appeared to be distributed in 12 different countries (in decreasing frequency order: Uruguay, England, USA, Belgium, India, Australia, Switzerland, Spain, Netherlands, Japan, Germany, and France) and in 13 different Pango lineages (in decreasing frequency order: P.6, B.1.36, B.1.2, C.36, B.1.538, B.1.1.316, B.1.526 (VOI Iota), B.1.525 (VOI Eta), B.1.243, B.1.1.70, B.1.1.7 (VOC Alpha), B.1.1.63, and B.1) (Figure S5).."
27,doi:10.3390/v13091801,B.1.525,"Overall, the pair S:Q675H + Q677H appeared to be distributed in 12 different countries (in decreasing frequency order: Uruguay, England, USA, Belgium, India, Australia, Switzerland, Spain, Netherlands, Japan, Germany, and France) and in 13 different Pango lineages (in decreasing frequency order: P.6, B.1.36, B.1.2, C.36, B.1.538, B.1.1.316, B.1.526 (VOI Iota), B.1.525 (VOI Eta), B.1.243, B.1.1.70, B.1.1.7 (VOC Alpha), B.1.1.63, and B.1) (Figure S5).."
28,doi:10.3390/v13091801,B.1.1.316,"Overall, the pair S:Q675H + Q677H appeared to be distributed in 12 different countries (in decreasing frequency order: Uruguay, England, USA, Belgium, India, Australia, Switzerland, Spain, Netherlands, Japan, Germany, and France) and in 13 different Pango lineages (in decreasing frequency order: P.6, B.1.36, B.1.2, C.36, B.1.538, B.1.1.316, B.1.526 (VOI Iota), B.1.525 (VOI Eta), B.1.243, B.1.1.70, B.1.1.7 (VOC Alpha), B.1.1.63, and B.1) (Figure S5).."
29,doi:10.3390/v13091801,B.1.1.70,"Overall, the pair S:Q675H + Q677H appeared to be distributed in 12 different countries (in decreasing frequency order: Uruguay, England, USA, Belgium, India, Australia, Switzerland, Spain, Netherlands, Japan, Germany, and France) and in 13 different Pango lineages (in decreasing frequency order: P.6, B.1.36, B.1.2, C.36, B.1.538, B.1.1.316, B.1.526 (VOI Iota), B.1.525 (VOI Eta), B.1.243, B.1.1.70, B.1.1.7 (VOC Alpha), B.1.1.63, and B.1) (Figure S5).."
0,doi:10.1101/2021.01.28.21250486,B.1.1.7,"It was found that the B.1.1.7 (also 501Y.V1) variant first detected in the UK4,5 could be serendipitously detected by the ThermoFisher TaqPath COVID-19 PCR assay because a key deletion in these viruses, spike Δ69-70, would cause a “spike gene target failure” (SGTF) result."
1,doi:10.1101/2021.01.28.21250486,P.1,"However, a SGTF result is not definitive for B.1.1.7, and this assay cannot detect other variants of concern that lack spike Δ69-70, such as B.1.351 (also 501Y.V2) detected in South Africa6 and P.1 (also 501Y.V3) recently detected in Brazil7."
2,doi:10.1101/2021.01.28.21250486,B.1.351,"However, a SGTF result is not definitive for B.1.1.7, and this assay cannot detect other variants of concern that lack spike Δ69-70, such as B.1.351 (also 501Y.V2) detected in South Africa6 and P.1 (also 501Y.V3) recently detected in Brazil7."
3,doi:10.1101/2021.01.28.21250486,B.1.375,"1, Supplementary Table 1), most notably Pango lineages B.1.258 detected throughout Europe and B.1.375 detected primarily in the US12,13, meaning that SGTF results are not definitive for B.1.1.7."
4,doi:10.1101/2021.01.28.21250486,B.1.258,"1, Supplementary Table 1), most notably Pango lineages B.1.258 detected throughout Europe and B.1.375 detected primarily in the US12,13, meaning that SGTF results are not definitive for B.1.1.7."
5,doi:10.1101/2021.01.28.21250486,P.2,"Of the samples without both deletions (expected outcome = detection with all three primer/probe sets), 2.9% (6/210) were P.2 (variant of interest [VOI]) and 97.1% (204/210) were other lineages not of current interest (Fig."
6,doi:10.1101/2021.01.28.21250486,B.1.525,"Of the samples with both ORF1a Δ3675-3677 and spike Δ69-70 deletions (expected outcome = target failure with both the ORF1a and spike sets), 97.1% (67/69) were B.1.1.7 (VOC) and 2.9% (2/69) were B.1.525 (VOI; Fig."
7,doi:10.1101/2021.01.28.21250486,B.1.526,"Of the samples with ORF1a Δ3675-367, 47.1 % (24/51) were B.1.351 (VOC), 31.4% (16/51) were P.1 (VOC), 7.8% (4/51) were B.1.526 (VOI), and 13.7% (7/51) were other lineages not of current interest (Fig."
0,doi:10.1016/j.epidem.2021.100480,B.1.1.7,"This study aims to estimate the transmission fitness advantage and the effective reproductive number of B.1.1.7 through time based on data from Switzerland..

We generated whole genome sequences from 11.8 % of all confirmed SARS-CoV-2 cases in Switzerland between 14 December 2020 and 11 March 2021."
1,doi:10.1016/j.epidem.2021.100480,A.7,"All sequences are available on GISAID (Elbe and Buckland-Merrett, 2017) (section A.7)..

We analyze three different datasets."
2,doi:10.1016/j.epidem.2021.100480,A.3,The mathematical derivations are described in the supplementary materials in the sections A.3 and A.4.
3,doi:10.1016/j.epidem.2021.100480,A.5,"As discussed above, we believe these discrepancies are a result of regional differences in the reproductive number (see also the supplementary materials, section A.5)."
0,doi:10.1016/j.watres.2021.117104,B.1.1.298,"New SARS-CoV-2 mutations are constantly emerging, raising concerns of increased transmissibility, virulence or escape from host immune response..

We describe a nested RT-PCR assay (∼1500 bps) to detect multiple nucleotide changes resulting in key spike protein mutations distinctive of the major known circulating SARS-CoV-2 variants, including the three Variants of Concern (VOCs) 20I/501Y.V1 (United Kingdom), 20H/501Y.V2 (South Africa), and 20J/501Y.V3 (Brazil), as well as the 20E.EU1 variant (Spain), the CAL.20C recently identified in California, and the mink-associated variant (GR, lineage B.1.1.298)."
1,doi:10.1016/j.watres.2021.117104,B.1.177,"In all, six countries (Denmark, the Netherlands, Spain, Sweden, Italy and the United States) reported cases of farmed mink infected with SARS-CoV-2 to the World Organisation for Animal Health (OIE) (WHO, 2020b)..

An additional novel variant - clade GV, lineage B.1.177 (GISAID) or 20E.EU1 (Nexstrain) - emerged in early summer of 2020 in Spain, and subsequently spread to multiple locations in Europe, possibly introduced into other countries by summer tourists (Hodcroft et al., 2020)..

On 14 December 2020, British authorities announced that a new SARS-CoV-2 variant had been identified through viral genomic sequencing (WHO, 2020c)."
2,doi:10.1016/j.watres.2021.117104,B.1.1.7,"The new variant belongs to clade GR, lineage B.1.1.7 (GISAID), or clade 20I/501Y.V1 (Nextstrain) and was discovered following an unforeseen rise in COVID-19 cases in South East England, between October and December 2020 (WHO, 2020d)."
3,doi:10.1016/j.watres.2021.117104,B.1.351,"As for antigenic response, to date, it is considered unlikely that 20I/501Y.V1 may hinder vaccine-induced immunity (Conti et al., 2021)..

On 18 December 2020, national authorities in South Africa announced the detection of a new variant of SARS-CoV-2, belonging to clade GH, lineage B.1.351 (GISAID) or 20H/501Y.V2 (Nextstrain)."
4,doi:10.1016/j.watres.2021.117104,P.1,"In January, another variant, clade GR lineage P.1 (GISAID) or 20J/501Y.V3 (Nextrain) was identified in Japan in four travellers who had arrived from Brazil (NIID, 2021; Galloway et al., 2021)."
5,doi:10.1016/j.watres.2021.117104,B.1.429,"To date, the P.1 variant has been identified either in Brazil, or in travellers from Brazil (mostly from the State of Amazonas), including one returning to Italy from Brazil (Maggi et al., 2021)..

Lastly, on 17 January 2021, public health officials announced that the SARS-CoV-2 GH, lineage B.1.429 (GISAID) – also termed CAL.20C – has become increasingly common in multiple Californian counties and has been responsible for several large COVID-19 outbreaks in that state..

All of these variants have characteristic mutations, the most significant of which are located in the gene encoding the spike (S) protein (Li et al., 2020; Pillay et al., 2020).."
6,doi:10.1016/j.watres.2021.117104,B.1,"The geographic and temporal occurrence of the mutations detected in the field samples, obtained using the GISAID CoVsurver: Mutation Analysis tool, is summarized in Supplementary Materials.Table 3Variant analysis of clinical samples obtained using PCR ID 980 and different bioinformatics toolsTable 3:SampleIdentification based on WGSMutation map 1GISAID blastNextcladeswab_1-A222VGV_B.1.17720E (EU1)swab_2-S477NGH_B.1.16020Aswab_3-S477NGH_B.1.16020Aswab_4-A222VGV_ B.1.17720E (EU1)swab_5-A222VGV_ B.1.17720E (EU1)swab_6-A222VGV_ B.1.17720E (EU1)swab_7-A222VGV_ B.1.17720E (EU1)swab_8-A222VGV_ B.1.17720E (EU1)swab_9-A222VGV_ B.1.17720E (EU1)swab_10-A222VGV_ B.1.17720E (EU1)swab_11-A222VGV_ B.1.17720E (EU1)swab_12-A222VGV_ B.1.17720E (EU1)swab_13-S477NGH_B.1.16020Aswab_14--Not assignable 220Aswab_15--Not assignable 320Aswab_16-S477NGH_B.1.16020Aswab_17-A222VGV_ B.1.17720E (EU1)swab_18-A222V, A262S, P272LGV_ B.1.177 420E (EU1)swab_19-S98FG_B.1.22120Aswab_20-A222VGV_ B.1.17720E (EU1)swab_21-n.d.n.d.n.d.swab_22-n.d.n.d.n.d.swab_23-S477NGH_B.1.16020Aswab_24-A222V, A411SGV_B.1.17720E (EU1)swab_25G B.1 / 20A-Not assignable 519Aswab_26G B.1 / 20AD215HNot assignable 619Aswab_27GR B.1.1.316 / 20B-Not assignable 519Aswab_28GR B.1.1.229 / 20B-Not assignable 519Aswab_29GV B.1.177 / 20E EU1A222VGV_ B.1.17720E (EU1)swab_30GV B.1.177 / 20E EU1A222VGV_ B.1.17720E (EU1)swab_31GR B.1.1.7 / 20I/501Y.V1H69del, V70del, Y144del, N501Y, A570DGR/501Y.V1 (B.1.1.7)20B1Analysis with GISAID CoVsurver: Mutation Analysis (https://www.gisaid.org/epiflu-applications/covsurver-mutations-app/)2G_B.1.241; G_B.1.78; G_B.1.416; GR_B.1.1.216; G_B.1; GR_B.1.1.297; GRB.1.1.8_GR_B.1.1.105; GH_B.1.23100% identity with GH_B.1.2; G_B.1; GR_B.1.1.37; GR_B.1.1.3064100% identity with GV_B.1.177 or GV_B.1.177.25100% identity with sequences assigned to the following clades: GR_B.1.1.222; GR_B.1.1.70; GR_B.1.1.119; GR_B.1.1.28; GR_B.1.1.316; GR_B.1.1.33; GR_B.1.1.103; GH_B.1.2; GH_B.1.425; G_B.1; G_B.1.91; GH_B.1.47036100% identity with sequences assigned to the following clades: G_B.1; GH_B.1.2; GR_B.1.1.47; GR_B.1.1.304; GR_B.1.1.127; GR_B.1.1.284; GR_B.1.1.119; O_B-13, n.d. not done due to absence of PCR amplification."
7,doi:10.1016/j.watres.2021.117104,B.1.1.316,"The geographic and temporal occurrence of the mutations detected in the field samples, obtained using the GISAID CoVsurver: Mutation Analysis tool, is summarized in Supplementary Materials.Table 3Variant analysis of clinical samples obtained using PCR ID 980 and different bioinformatics toolsTable 3:SampleIdentification based on WGSMutation map 1GISAID blastNextcladeswab_1-A222VGV_B.1.17720E (EU1)swab_2-S477NGH_B.1.16020Aswab_3-S477NGH_B.1.16020Aswab_4-A222VGV_ B.1.17720E (EU1)swab_5-A222VGV_ B.1.17720E (EU1)swab_6-A222VGV_ B.1.17720E (EU1)swab_7-A222VGV_ B.1.17720E (EU1)swab_8-A222VGV_ B.1.17720E (EU1)swab_9-A222VGV_ B.1.17720E (EU1)swab_10-A222VGV_ B.1.17720E (EU1)swab_11-A222VGV_ B.1.17720E (EU1)swab_12-A222VGV_ B.1.17720E (EU1)swab_13-S477NGH_B.1.16020Aswab_14--Not assignable 220Aswab_15--Not assignable 320Aswab_16-S477NGH_B.1.16020Aswab_17-A222VGV_ B.1.17720E (EU1)swab_18-A222V, A262S, P272LGV_ B.1.177 420E (EU1)swab_19-S98FG_B.1.22120Aswab_20-A222VGV_ B.1.17720E (EU1)swab_21-n.d.n.d.n.d.swab_22-n.d.n.d.n.d.swab_23-S477NGH_B.1.16020Aswab_24-A222V, A411SGV_B.1.17720E (EU1)swab_25G B.1 / 20A-Not assignable 519Aswab_26G B.1 / 20AD215HNot assignable 619Aswab_27GR B.1.1.316 / 20B-Not assignable 519Aswab_28GR B.1.1.229 / 20B-Not assignable 519Aswab_29GV B.1.177 / 20E EU1A222VGV_ B.1.17720E (EU1)swab_30GV B.1.177 / 20E EU1A222VGV_ B.1.17720E (EU1)swab_31GR B.1.1.7 / 20I/501Y.V1H69del, V70del, Y144del, N501Y, A570DGR/501Y.V1 (B.1.1.7)20B1Analysis with GISAID CoVsurver: Mutation Analysis (https://www.gisaid.org/epiflu-applications/covsurver-mutations-app/)2G_B.1.241; G_B.1.78; G_B.1.416; GR_B.1.1.216; G_B.1; GR_B.1.1.297; GRB.1.1.8_GR_B.1.1.105; GH_B.1.23100% identity with GH_B.1.2; G_B.1; GR_B.1.1.37; GR_B.1.1.3064100% identity with GV_B.1.177 or GV_B.1.177.25100% identity with sequences assigned to the following clades: GR_B.1.1.222; GR_B.1.1.70; GR_B.1.1.119; GR_B.1.1.28; GR_B.1.1.316; GR_B.1.1.33; GR_B.1.1.103; GH_B.1.2; GH_B.1.425; G_B.1; G_B.1.91; GH_B.1.47036100% identity with sequences assigned to the following clades: G_B.1; GH_B.1.2; GR_B.1.1.47; GR_B.1.1.304; GR_B.1.1.127; GR_B.1.1.284; GR_B.1.1.119; O_B-13, n.d. not done due to absence of PCR amplification."
8,doi:10.1016/j.watres.2021.117104,B.1.36,"Nevertheless, the recently described variants from Nigeria (G, B.1.525), and from India (GH, B.1.36), also have key mutations in the region targeted by the described assays (A67V, H69del, H70del, Y144del, E484K for G, B.1.525, and N440K for GH, B.1.36) (data not shown), confirming that this is a hot spot region for mutations..

To our knowledge, this is the first evidence of the presence of sequences harboring key mutations of 20I/501Y.V1 and 20J/501Y.V3, as well as of the Spanish variant in urban wastewaters, highlighting the potential contribution of wastewater surveillance to explore SARS-CoV-2 diversity."
9,doi:10.1016/j.watres.2021.117104,B.1.525,"Nevertheless, the recently described variants from Nigeria (G, B.1.525), and from India (GH, B.1.36), also have key mutations in the region targeted by the described assays (A67V, H69del, H70del, Y144del, E484K for G, B.1.525, and N440K for GH, B.1.36) (data not shown), confirming that this is a hot spot region for mutations..

To our knowledge, this is the first evidence of the presence of sequences harboring key mutations of 20I/501Y.V1 and 20J/501Y.V3, as well as of the Spanish variant in urban wastewaters, highlighting the potential contribution of wastewater surveillance to explore SARS-CoV-2 diversity."
0,doi:10.1016/j.meegid.2021.104884,B.1.36,"The Bangladeshi genomes belonged to phylogenetic lineages A, B, B.1, B.1.1, B.1.1.23, B.1.1.25, B.1.113, and B.1.36, among which 50.0% sequences owned by the pangolin lineage B.1.1.25."
1,doi:10.1016/j.meegid.2021.104884,B.1.1.25,"The Bangladeshi genomes belonged to phylogenetic lineages A, B, B.1, B.1.1, B.1.1.23, B.1.1.25, B.1.113, and B.1.36, among which 50.0% sequences owned by the pangolin lineage B.1.1.25."
2,doi:10.1016/j.meegid.2021.104884,B.1,"The Bangladeshi genomes belonged to phylogenetic lineages A, B, B.1, B.1.1, B.1.1.23, B.1.1.25, B.1.113, and B.1.36, among which 50.0% sequences owned by the pangolin lineage B.1.1.25."
3,doi:10.1016/j.meegid.2021.104884,B.1.113,"The Bangladeshi genomes belonged to phylogenetic lineages A, B, B.1, B.1.1, B.1.1.23, B.1.1.25, B.1.113, and B.1.36, among which 50.0% sequences owned by the pangolin lineage B.1.1.25."
4,doi:10.1016/j.meegid.2021.104884,B.1.1,"The Bangladeshi genomes belonged to phylogenetic lineages A, B, B.1, B.1.1, B.1.1.23, B.1.1.25, B.1.113, and B.1.36, among which 50.0% sequences owned by the pangolin lineage B.1.1.25."
0,doi:10.1056/nejmoa2116597,B.1.617.2,"Before the emergence of the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccination reduced transmission of SARS-CoV-2 from vaccinated persons who became infected, potentially by reducing viral loads."
1,doi:10.1056/nejmoa2116597,B.1.1.7,We used multivariable Poisson regression to investigate associations between transmission and the vaccination status of index patients and contacts and to determine how these associations varied with the B.1.1.7 (alpha) and delta variants and time since the second vaccination..
0,doi:10.1016/j.vaccine.2022.02.047,R.1,"Vaccine efficacy against the R.1 lineage, which contains the E484K mutation but not the N501Y mutation, is uncertain."
0,doi:10.3201/eid2703.210038,B.1.1.7,"In December 2020, research surveillance detected the B.1.1.7 lineage of severe acute respiratory syndrome coronavirus 2 in São Paulo, Brazil."
1,doi:10.3201/eid2703.210038,B.1.1,"As outgroups, we included 2 B.1.1 sequences from the United Kingdom that were closely related to the lineage of interest and sequence WH04 from Wuhan, China (GISAID identification no."
0,doi:10.3390/tropicalmed6030151,P.1,The SARS-CoV-2 P.1 variant of concern (VOC) was first identified in Brazil and is now spreading in European countries.
1,doi:10.3390/tropicalmed6030151,B.1.1.7,"In December 2020, the European Center for Disease Control and Prevention (ECDC) first reported the spread of a new SARS-CoV-2 variant of concern (VOC) characterized by multiple spike protein mutations and mutations in other genomic regions, called VOC 202012/01—lineage B.1.1.7, in the UK, and labeled Alpha variant by the World Health Organization [1,2]."
2,doi:10.3390/tropicalmed6030151,B.1.617.2,"In May 2021, the SARS-CoV-2 B.1.617.2 Delta variant emerged in India and has spread all over the world [4]."
3,doi:10.3390/tropicalmed6030151,B.1.351,"In Europe, infections of the P.1 variant, as well as the B.1.1.7, B.1.351, and B.1.617.2 VOCs, have been associated with a higher risk of hospitalization and intensive care unit admission [4,12]."
0,doi:10.3390/s20185181,C.1,A total of 62.3% of C.1 and 34.8% of C.2 declared their understanding of telemedical services.
1,doi:10.3390/s20185181,C.2,A total of 62.3% of C.1 and 34.8% of C.2 declared their understanding of telemedical services.
0,doi:10.21203/rs.3.rs-155394/v1,B.1.1.7,Recent emergence of new SARS-CoV-2 variants B.1.1.7 in the UK12 and B.1.351 in South Africa13 is of concern because of their purported ease of transmission and extensive mutations in the spike protein.
1,doi:10.21203/rs.3.rs-155394/v1,B.1.351,Recent emergence of new SARS-CoV-2 variants B.1.1.7 in the UK12 and B.1.351 in South Africa13 is of concern because of their purported ease of transmission and extensive mutations in the spike protein.
2,doi:10.21203/rs.3.rs-155394/v1,B.1.1.28,"It is of equal concern that another variant, B.1.1.28 or 501Y.V3, is increasing rapidly in Brazil and spreading far beyond14,15."
0,doi:10.1038/s42003-021-02640-x,B.1.1.7,We found that the Alpha variant (B.1.1.7) increased competitive fitness over earlier parental D614G lineages in in-vitro and in-vivo systems.
1,doi:10.1038/s42003-021-02640-x,B.1.351,"Interestingly, two other VOCs, P1 and B.1.351, also contain the N501Y mutation14,15.."
0,doi:10.1056/nejmoa2117608,P.1,"Efficacy in the United States, primarily against the reference strain (B.1.D614G) and the B.1.1.7 (alpha) variant, was 69.7% (95% CI, 60.7 to 76.9); efficacy was reduced elsewhere against the P.1 (gamma), C.37 (lambda), and B.1.621 (mu) variants."
1,doi:10.1056/nejmoa2117608,B.1.621,"Efficacy in the United States, primarily against the reference strain (B.1.D614G) and the B.1.1.7 (alpha) variant, was 69.7% (95% CI, 60.7 to 76.9); efficacy was reduced elsewhere against the P.1 (gamma), C.37 (lambda), and B.1.621 (mu) variants."
2,doi:10.1056/nejmoa2117608,B.1.1.7,"Efficacy in the United States, primarily against the reference strain (B.1.D614G) and the B.1.1.7 (alpha) variant, was 69.7% (95% CI, 60.7 to 76.9); efficacy was reduced elsewhere against the P.1 (gamma), C.37 (lambda), and B.1.621 (mu) variants."
3,doi:10.1056/nejmoa2117608,C.37,"Efficacy in the United States, primarily against the reference strain (B.1.D614G) and the B.1.1.7 (alpha) variant, was 69.7% (95% CI, 60.7 to 76.9); efficacy was reduced elsewhere against the P.1 (gamma), C.37 (lambda), and B.1.621 (mu) variants."
4,doi:10.1056/nejmoa2117608,B.1.617.2,"Efficacy was 74.6% (95% CI, 64.7 to 82.1) against severe–critical Covid-19 (with only 4 severe–critical cases caused by the B.1.617.2 [delta] variant), 75.6% (95% CI, 54.3 to 88.0) against Covid-19 leading to medical intervention (including hospitalization), and 82.8% (95% CI, 40.5 to 96.8) against Covid-19–related death, with protection lasting 6 months or longer."
5,doi:10.1056/nejmoa2117608,B.1.351,"Because efficacy results for the primary end point were similar at 14 or more days and at 28 or more days after administration, only the latter results are shown for secondary and exploratory end points..

New viral lineages emerged and became dominant in most countries in the trial during the analysis period, with some variants occurring predominately in one country (e.g., B.1.351 [beta] in South Africa, C.37 [lambda] in Peru, and B.1.621 [mu] in Colombia) (Figure 1)."
6,doi:10.1056/nejmoa2117608,C.36.3,"None of the cases were caused by the eta, kappa, theta, or C.36.3 variant."
0,doi:10.15585/mmwr.mm7102e1,B.1.617.2,"The effectiveness of 2 doses of Pfizer-BioNTech vaccine received ≥28 days before hospital admission in preventing MIS-C was assessed using a test-negative case-control design¶ among hospitalized patients aged 12–18 years at 24 pediatric hospitals in 20 states** during July 1–December 9, 2021, the period when most MIS-C patients could be temporally linked to SARS-CoV-2 B.1.617.2 (Delta) variant predominance."
1,doi:10.15585/mmwr.mm7102e1,B.1.1.529,"Second, VE against MIS-C attributed to the B.1.1.529 (Omicron) variant could not be assessed, given the timing of hospital admission of included patients relative to emergence of this variant in the United States."
0,doi:10.1093/cid/ciab421,B.1.1.7,"We used multivariable logistic regression to investigate relationships between polymerase chain reaction (PCR)-confirmed infection in contacts of community-diagnosed cases and index case viral load, S gene target failure (proxy for B.1.1.7 infection), demographics, SARS-CoV-2 incidence, social deprivation, and contact event type."
0,doi:10.1126/science.abj9932,B.1.1.7,"During April 2021, the city became overwhelmed by COVID-19 cases and fatalities, as a new variant B.1.617.2 (Delta) replaced B.1.1.7 (Alpha)."
1,doi:10.1126/science.abj9932,B.1.617.2,"During April 2021, the city became overwhelmed by COVID-19 cases and fatalities, as a new variant B.1.617.2 (Delta) replaced B.1.1.7 (Alpha)."
2,doi:10.1126/science.abj9932,B.1.617.1,"Comparing April 2021 with November 2020, high viral load samples (Ct<20) doubled in clinical samples (p<0.001), and nearly doubled in campus surveillance testing data, where most positives were from recently infected individuals (15% (n=297) vs 9% (n=358), p=0.02)..

Genome analysis trends, in representative samples drawn from the general population over the same period, showed seeding and expansion of B.1.1.7 (Alpha), B.1.617.1 (Kappa) and B.1.617.2 (Delta) lineages in 2021, with Delta becoming the dominant lineage in Delhi during April (Fig 3B)."
0,doi:10.1038/s41467-021-25478-7,P.1,"We also show that these severe structural changes upon electric-field application also occur in the mutant RBDs corresponding to the variants of concern (VOC) B.1.1.7 (UK), B.1.351 (South Africa) and P.1 (Brazil)."
1,doi:10.1038/s41467-021-25478-7,B.1.1.7,"We also show that these severe structural changes upon electric-field application also occur in the mutant RBDs corresponding to the variants of concern (VOC) B.1.1.7 (UK), B.1.351 (South Africa) and P.1 (Brazil)."
2,doi:10.1038/s41467-021-25478-7,B.1.351,"We also show that these severe structural changes upon electric-field application also occur in the mutant RBDs corresponding to the variants of concern (VOC) B.1.1.7 (UK), B.1.351 (South Africa) and P.1 (Brazil)."
3,doi:10.1038/s41467-021-25478-7,B.1.617,"Other mutants not analysed here, such as the VOC B.1.617 (India), also involve charge substitutions that have been suggested to enhance electrostatic interaction of the RBD with the ACE2 receptor78."
4,doi:10.1038/s41467-021-25478-7,B.1.617.2,"The concrete case of the sub-variants B.1.617.1 (L452R changes from neutral to positive and E484Q from negative to neutral), B.1.617.2 (L452R changes from neutral to positive and T478K from neutral to positive) and B.1.617.3 (L454R changes from neutral to positive and E484Q from negative to neutral)79,80 clearly reflect this fact."
5,doi:10.1038/s41467-021-25478-7,B.1.617.3,"The concrete case of the sub-variants B.1.617.1 (L452R changes from neutral to positive and E484Q from negative to neutral), B.1.617.2 (L452R changes from neutral to positive and T478K from neutral to positive) and B.1.617.3 (L454R changes from neutral to positive and E484Q from negative to neutral)79,80 clearly reflect this fact."
6,doi:10.1038/s41467-021-25478-7,B.1.617.1,"The concrete case of the sub-variants B.1.617.1 (L452R changes from neutral to positive and E484Q from negative to neutral), B.1.617.2 (L452R changes from neutral to positive and T478K from neutral to positive) and B.1.617.3 (L454R changes from neutral to positive and E484Q from negative to neutral)79,80 clearly reflect this fact."
0,doi:10.1002/jmv.27066,B.1.1.7,SARS‐CoV‐2 B.1.1.7 reinfection after previous COVID‐19 in two immunocompetent Italian patients.
0,doi:10.1038/s41467-021-26055-8,B.1.620,"We here describe a SARS-CoV-2 lineage - designated B.1.620 - discovered in Lithuania and carrying many mutations and deletions in the spike protein shared with widespread variants of concern (VOCs), including E484K, S477N and deletions HV69Δ, Y144Δ, and LLA241/243Δ."
1,doi:10.1038/s41467-021-26055-8,P.1,"B.1.1.7, B.1.351, P.1 and B.1.617.2 according to the Pango SARS-CoV-2 lineage nomenclature4,5) have been universally categorised as variants of concern (VOCs), due to evidence of increased transmissibility, disease severity and/or possible reduced vaccine efficacy."
2,doi:10.1038/s41467-021-26055-8,B.1.617.2,"B.1.1.7, B.1.351, P.1 and B.1.617.2 according to the Pango SARS-CoV-2 lineage nomenclature4,5) have been universally categorised as variants of concern (VOCs), due to evidence of increased transmissibility, disease severity and/or possible reduced vaccine efficacy."
3,doi:10.1038/s41467-021-26055-8,B.1.351,"B.1.1.7, B.1.351, P.1 and B.1.617.2 according to the Pango SARS-CoV-2 lineage nomenclature4,5) have been universally categorised as variants of concern (VOCs), due to evidence of increased transmissibility, disease severity and/or possible reduced vaccine efficacy."
4,doi:10.1038/s41467-021-26055-8,B.1.177,"In some cases, a lineage may rise to high frequency in one location and seed others in its vicinity, such as lineage B.1.177 that became prevalent in Spain and was later spread across the rest of Europe2."
5,doi:10.1038/s41467-021-26055-8,A.23.1,"In others, reductions in human mobility, insufficient surveillance and passage of time allowed lineages to emerge and rise to high frequency in certain areas, as has happened with lineage A.23.1 in Uganda6, a pattern reminiscent of holdover H1N1 lineages discovered in West Africa years after the 2009 pandemic7."
6,doi:10.1038/s41467-021-26055-8,B.1.1.7,"The same sequencing programme was then perfectly positioned to observe a sweep where B.1.380 was replaced by lineage A.23.16, which was first detected in Uganda10, and to detect the country’s first cases of B.1.1.7 and B.1.351."
7,doi:10.1038/s41467-021-26055-8,B.1.380,"The same sequencing programme was then perfectly positioned to observe a sweep where B.1.380 was replaced by lineage A.23.16, which was first detected in Uganda10, and to detect the country’s first cases of B.1.1.7 and B.1.351."
8,doi:10.1038/s41467-021-26055-8,B.1.1.318,"During initial B.1.620 circulation in Lithuania the only other E484K-bearing lineages in Lithuania had been B.1.351 (one isolated case in Kaunas county, and 12 cases from a transmission chain centred in Vilnius county) and B.1.1.318 (one isolated case in Alytus county), none of which had been found in Utena county despite a high epidemic sequencing coverage in Lithuania (Supplementary Fig."
9,doi:10.1038/s41467-021-26055-8,B.1,"Finally, we provide a description of local transmission in Lithuania, France, Spain, Italy, and Germany through phylogenetic and phylogeographic analysis, and in Belgium through the collection of travel records..

Lineage B.1.620 attracted our attention due to large numbers of unique mutations in B.1.620 genomes from Lithuania in nextclade analyses (its genomes are 18 mutations away from nearest relatives and 26 from reference strain Wuhan-Hu-1), and those genomes initially being assigned to clade 20A, corresponding to B.1 in Pangolin nomenclature4,5."
10,doi:10.1038/s41467-021-26055-8,B.1.177.57,"Meanwhile, Pangolin (using the 2021-04-01 version of pangoLEARN) variously misclassified B.1.620 genomes as B.1.177 or B.1.177.57 and occasionally as correct but unhelpful B.1, prior to the official designation of B.1.620 by the Pango SARS-CoV-2 lineage nomenclature team."
11,doi:10.1038/s41467-021-26055-8,B.1.619,"Synonymous mutations at site 15324 and S:T1027I appear to be some of the earliest mutations that occurred in the evolution of lineage B.1.620, both of which are found in at least one other lineage associated with Cameroon (B.1.619), followed by S:E484K which also appears in genomes closest to lineage B.1.620."
12,doi:10.1038/s41467-021-26055-8,B.1.177.60,"We used default parameters for refinement with extended molecular dynamics (MD) simulation (steps for heating phase: 200, steps for 300K phase: 2500, steps for cooling phase: 1000)..

We combined 614 sequences belonging to lineage B.1.620 with sequences from lineages that have circulated in Lithuania at appreciable levels: B.1.1.7, B.1.1.280, B.1.177.60 and other VOCs that share mutations with lineage B.1.620: B.1.351, P.1 and B.1.526.2."
13,doi:10.1038/s41467-021-26055-8,B.1.1.280,"We used default parameters for refinement with extended molecular dynamics (MD) simulation (steps for heating phase: 200, steps for 300K phase: 2500, steps for cooling phase: 1000)..

We combined 614 sequences belonging to lineage B.1.620 with sequences from lineages that have circulated in Lithuania at appreciable levels: B.1.1.7, B.1.1.280, B.1.177.60 and other VOCs that share mutations with lineage B.1.620: B.1.351, P.1 and B.1.526.2."
0,doi:10.1101/2021.09.08.21263095,B.1.1.529,"Here, we compare the neutralization of variants of concern, including B.1.617.2 (Delta) and B.1.1.529 (Omicron) in sera from individuals exposed to variant infection, vaccination, or both."
1,doi:10.1101/2021.09.08.21263095,B.1.617.2,"Here, we compare the neutralization of variants of concern, including B.1.617.2 (Delta) and B.1.1.529 (Omicron) in sera from individuals exposed to variant infection, vaccination, or both."
2,doi:10.1101/2021.09.08.21263095,B.1.1.519,"To accomplish this, we collected serum from subjects with prior infections by variants B.1 (D614G mutation only), B.1.429 (Epsilon), P.2 (Zeta), B.1.1.519, and B.1.617.2 (Delta), which were identified by viral sequencing."
3,doi:10.1101/2021.09.08.21263095,B.1,"To accomplish this, we collected serum from subjects with prior infections by variants B.1 (D614G mutation only), B.1.429 (Epsilon), P.2 (Zeta), B.1.1.519, and B.1.617.2 (Delta), which were identified by viral sequencing."
4,doi:10.1101/2021.09.08.21263095,P.2,"To accomplish this, we collected serum from subjects with prior infections by variants B.1 (D614G mutation only), B.1.429 (Epsilon), P.2 (Zeta), B.1.1.519, and B.1.617.2 (Delta), which were identified by viral sequencing."
5,doi:10.1101/2021.09.08.21263095,B.1.429,"To accomplish this, we collected serum from subjects with prior infections by variants B.1 (D614G mutation only), B.1.429 (Epsilon), P.2 (Zeta), B.1.1.519, and B.1.617.2 (Delta), which were identified by viral sequencing."
6,doi:10.1101/2021.09.08.21263095,P.1,"We measured and compared the neutralization titer of each serum cohort against a panel of pseudoviruses representing each different exposure variant plus the variants of concern B.1.351 (Beta), P.1 (Gamma), B.1.617, B.1.617.2 (Delta), and B.1.1.529 (Omicron), which have one or more spike mutations of interest in common with one of the exposure variants."
7,doi:10.1101/2021.09.08.21263095,B.1.617,"We measured and compared the neutralization titer of each serum cohort against a panel of pseudoviruses representing each different exposure variant plus the variants of concern B.1.351 (Beta), P.1 (Gamma), B.1.617, B.1.617.2 (Delta), and B.1.1.529 (Omicron), which have one or more spike mutations of interest in common with one of the exposure variants."
8,doi:10.1101/2021.09.08.21263095,B.1.351,"We measured and compared the neutralization titer of each serum cohort against a panel of pseudoviruses representing each different exposure variant plus the variants of concern B.1.351 (Beta), P.1 (Gamma), B.1.617, B.1.617.2 (Delta), and B.1.1.529 (Omicron), which have one or more spike mutations of interest in common with one of the exposure variants."
9,doi:10.1101/2021.09.08.21263095,B.1.526,"All samples were sequenced using ARTIC Network V3 primers on an Illumina NovaSeq platform and consensus genomes generated from the resulting raw .fastq files using IDseq [8]..

Convalescent serum donors were selected based on sequence-confirmed infection with the following variants of interest: B.1 (D614G mutation only; n=10 donors), B.1.429 (Epsilon; n=15), B.1.1.519 (n=6), P.2 (Zeta; n=1), B.1.526 (Iota; n=1), B.1.617.2 (Delta; n=3), D614G infection with subsequent BNT162b2 vaccination (n=8), and B.1.429 infection with subsequent BNT162b2 vaccination (n=17)."
0,doi:10.1101/2020.10.18.344622,B.1.1.7,"Variant N501Y in the RBD, which has emerged in a rapidly spreading lineage (B.1.1.7) in England, enhances affinity for wild type ACE2 20-fold but remains tightly bound to engineered sACE22.v2.4."
0,doi:10.21203/rs.3.rs-448370/v1,B.1.1.7,"Here, using a panel of monoclonal antibodies (mAbs) corresponding to many in advanced clinical development by Vir Biotechnology, AbbVie, AstraZeneca, Regeneron, and Lilly we report the impact on protection in animals against authentic SARS-CoV-2 variants including WA1/2020 strains, a B.1.1.7 isolate, and chimeric strains with South African (B.1.351) or Brazilian (B.1.1.28) spike genes."
1,doi:10.21203/rs.3.rs-448370/v1,B.1.1.28,"Here, using a panel of monoclonal antibodies (mAbs) corresponding to many in advanced clinical development by Vir Biotechnology, AbbVie, AstraZeneca, Regeneron, and Lilly we report the impact on protection in animals against authentic SARS-CoV-2 variants including WA1/2020 strains, a B.1.1.7 isolate, and chimeric strains with South African (B.1.351) or Brazilian (B.1.1.28) spike genes."
2,doi:10.21203/rs.3.rs-448370/v1,B.1.351,"Here, using a panel of monoclonal antibodies (mAbs) corresponding to many in advanced clinical development by Vir Biotechnology, AbbVie, AstraZeneca, Regeneron, and Lilly we report the impact on protection in animals against authentic SARS-CoV-2 variants including WA1/2020 strains, a B.1.1.7 isolate, and chimeric strains with South African (B.1.351) or Brazilian (B.1.1.28) spike genes."
3,doi:10.21203/rs.3.rs-448370/v1,B.1.429,"A B.1.429 isolate from California contained the characteristic S13I, W152C, and L452R changes."
0,doi:10.1128/mra.00240-21,B.1.1.7,"Here, we report the near-complete genome sequence and the genetic variations of a clinical sample of SARS-CoV-2 harboring the N501Y mutation assigned to the B.1.1.7 lineage."
0,doi:10.3390/microorganisms10030612,B.1.258,"Of the 32 isolates, 4 (12.5%) carried a nonsynonymous nucleotide mutation leading to the N439K (3/4), lineage B.1.258 (∆H69/∆V70), and S477N (1/4) substitution."
1,doi:10.3390/microorganisms10030612,B.1,"The growth curves of the B.1, B.1.258 (∆H69/∆V70), B.1.617.2-AY.43, and B.1.1.529.BA1 variants did not show any significant differences."
2,doi:10.3390/microorganisms10030612,B.1.1.529,"A microneutralization assay was carried out using four different serum samples that were collected: (a) 6 months after the infection from a COVID-19 adult patient infected by the B.1 strain and recovered in May 2020; (b) 2 weeks after the administration of the second dose of Comirnaty (Pfizer-BioNTech) vaccine from a uninfected, vaccinated adult subject; (c) from a recently recovered (December 2021) patient (2 weeks after the infection with B.1.1.529) who became infected after receiving the third dose of the Comirnaty (Pfizer-BioNTech) vaccine; (d) from a SARS-CoV-2-seronegative subject."
3,doi:10.3390/microorganisms10030612,B.1.617.2,"In addition, the Delta-like (EPI_ISL_7698448) strain was compared to the reference SARS-CoV-2 genome isolate (Wuhan-Hu-1, NC_045512.2) (Table 5), and it was assigned to the lineage B.1.617.2 + AY.43 strain using the Pangolin tool [28] based on the presence of the nonsynonymous mutations or deletions A1306S, A1809V, P2046L, P2287S, V2930L, T3255I, T3646A, P4715L, G5063S, L5230I, P5401L, and A6319V in the ORF1ab gene; T19R, G142D, EFR156G (F157Δ, R158Δ), L452R, T478K, D614G, P681R, and D950N in the S gene; S26L in the ORF3a gene; I82T in the M gene; V82A and T120I in the ORF7a gene, T40I in the ORF7b gene; C37R, D119Δ, and F120Δ in the ORF8 gene; and Q9L, D63G, R203M, G215C, and D377Y in the N gene.."
4,doi:10.3390/microorganisms10030612,B.1.1.298,"Our results are in line with the published literature, indicating that the neutralizing activity of sera from the COVID-19 vaccinated subject decreased against the B.1.258 strain up to two-fold compared to the B.1 strain..

NGS also revealed the presence of the Δ69/70 mutation in the B.1.258 strain, a mutation that emerged independently in the other five strains (namely B.1.1.7, B.1.1.298, B.1.160, B.1.177, B.1.375), always after the acquisition of receptor binding motif replacements, such as N439, in several European countries in the beginning of August 2020."
5,doi:10.3390/microorganisms10030612,B.1.1.7,"Our results are in line with the published literature, indicating that the neutralizing activity of sera from the COVID-19 vaccinated subject decreased against the B.1.258 strain up to two-fold compared to the B.1 strain..

NGS also revealed the presence of the Δ69/70 mutation in the B.1.258 strain, a mutation that emerged independently in the other five strains (namely B.1.1.7, B.1.1.298, B.1.160, B.1.177, B.1.375), always after the acquisition of receptor binding motif replacements, such as N439, in several European countries in the beginning of August 2020."
6,doi:10.3390/microorganisms10030612,B.1.160,"Our results are in line with the published literature, indicating that the neutralizing activity of sera from the COVID-19 vaccinated subject decreased against the B.1.258 strain up to two-fold compared to the B.1 strain..

NGS also revealed the presence of the Δ69/70 mutation in the B.1.258 strain, a mutation that emerged independently in the other five strains (namely B.1.1.7, B.1.1.298, B.1.160, B.1.177, B.1.375), always after the acquisition of receptor binding motif replacements, such as N439, in several European countries in the beginning of August 2020."
7,doi:10.3390/microorganisms10030612,B.1.375,"Our results are in line with the published literature, indicating that the neutralizing activity of sera from the COVID-19 vaccinated subject decreased against the B.1.258 strain up to two-fold compared to the B.1 strain..

NGS also revealed the presence of the Δ69/70 mutation in the B.1.258 strain, a mutation that emerged independently in the other five strains (namely B.1.1.7, B.1.1.298, B.1.160, B.1.177, B.1.375), always after the acquisition of receptor binding motif replacements, such as N439, in several European countries in the beginning of August 2020."
8,doi:10.3390/microorganisms10030612,B.1.177,"Our results are in line with the published literature, indicating that the neutralizing activity of sera from the COVID-19 vaccinated subject decreased against the B.1.258 strain up to two-fold compared to the B.1 strain..

NGS also revealed the presence of the Δ69/70 mutation in the B.1.258 strain, a mutation that emerged independently in the other five strains (namely B.1.1.7, B.1.1.298, B.1.160, B.1.177, B.1.375), always after the acquisition of receptor binding motif replacements, such as N439, in several European countries in the beginning of August 2020."
0,doi:10.1016/s2665-9913(21)00333-7,B.1.617.2,"The primary outcomes were humoral immunity to the SARS-CoV-2 spike glycoprotein, defined as titres of total spike-specific IgG and of neutralising antibody to wild-type, alpha (B.1.1.7), and delta (B.1.617.2) SARS-CoV-2 variants, and cellular immunity defined as spike-specific T-cell responses (including numbers of cells producing interferon-γ, IL-2, IL-21).."
1,doi:10.1016/s2665-9913(21)00333-7,B.1.1.7,"The primary outcomes were humoral immunity to the SARS-CoV-2 spike glycoprotein, defined as titres of total spike-specific IgG and of neutralising antibody to wild-type, alpha (B.1.1.7), and delta (B.1.617.2) SARS-CoV-2 variants, and cellular immunity defined as spike-specific T-cell responses (including numbers of cells producing interferon-γ, IL-2, IL-21).."
0,doi:10.1371/journal.pone.0260958,B.1.1.7,"Furthermore, niclosamide remains its potency against the D614G, Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants."
1,doi:10.1371/journal.pone.0260958,B.1.617.2,"Furthermore, niclosamide remains its potency against the D614G, Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants."
2,doi:10.1371/journal.pone.0260958,B.1.351,"Furthermore, niclosamide remains its potency against the D614G, Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants."
0,doi:10.1016/j.meegid.2021.104910,P.1,"Twelve COVID-19 samples from Brazilian patients were evaluated for both WGS and Sanger sequencing: three P.2, two P.1, six B.1.1 and one B.1.1.117 lineage."
1,doi:10.1016/j.meegid.2021.104910,B.1.1,"Twelve COVID-19 samples from Brazilian patients were evaluated for both WGS and Sanger sequencing: three P.2, two P.1, six B.1.1 and one B.1.1.117 lineage."
2,doi:10.1016/j.meegid.2021.104910,B.1.1.117,"Twelve COVID-19 samples from Brazilian patients were evaluated for both WGS and Sanger sequencing: three P.2, two P.1, six B.1.1 and one B.1.1.117 lineage."
3,doi:10.1016/j.meegid.2021.104910,P.2,"Twelve COVID-19 samples from Brazilian patients were evaluated for both WGS and Sanger sequencing: three P.2, two P.1, six B.1.1 and one B.1.1.117 lineage."
4,doi:10.1016/j.meegid.2021.104910,B.1.1.7,"In summary, this approach allows a much broader network of laboratories to perform molecular surveillance of SARS-CoV-2 VOCs and report results within a shorter time frame, which is of utmost importance in the context of rapid public health decisions in a fast evolving worldwide pandemic..

As of December 2020, the United Kingdom reported a new SARS-CoV-2 variant, the B.1.1.7, a highly transmissible lineage, bringing deep concerns about the prospects of the COVID-19 pandemic (Leung et al., 2021)."
5,doi:10.1016/j.meegid.2021.104910,B.1.526,"Shortly after, other so-called “Variants Of Concern” (VOCs) were reported in South Africa (B.1.3.51), Brazil (P.1) and more recently, in the U.S.A (B.1.526) (Makoni, 2021; Faria et al., 2021; Annavajhala et al., 2021)."
0,doi:10.1093/jtm/taab131,C.36,"Of 29 cases, 28 were B.1.1.7, and one C.36 (first description of this lineage in Colombia)."
1,doi:10.1093/jtm/taab131,B.1.1.7,"Of 29 cases, 28 were B.1.1.7, and one C.36 (first description of this lineage in Colombia)."
0,doi:10.1080/22221751.2021.2004866,P.1,"Moreover, vaccinated HCWs developed a similar protective neutralizing antibodies response against the EU (B.1), Alpha (B.1.1.7), Gamma (P.1), and Eta (B.1.525) SARS-CoV-2 variants, while Beta (B.1.351) and Delta (B.1.617.2) strains displayed a consistent partial immune evasion."
1,doi:10.1080/22221751.2021.2004866,B.1.1.7,"Moreover, vaccinated HCWs developed a similar protective neutralizing antibodies response against the EU (B.1), Alpha (B.1.1.7), Gamma (P.1), and Eta (B.1.525) SARS-CoV-2 variants, while Beta (B.1.351) and Delta (B.1.617.2) strains displayed a consistent partial immune evasion."
2,doi:10.1080/22221751.2021.2004866,B.1,"Moreover, vaccinated HCWs developed a similar protective neutralizing antibodies response against the EU (B.1), Alpha (B.1.1.7), Gamma (P.1), and Eta (B.1.525) SARS-CoV-2 variants, while Beta (B.1.351) and Delta (B.1.617.2) strains displayed a consistent partial immune evasion."
3,doi:10.1080/22221751.2021.2004866,B.1.525,"Moreover, vaccinated HCWs developed a similar protective neutralizing antibodies response against the EU (B.1), Alpha (B.1.1.7), Gamma (P.1), and Eta (B.1.525) SARS-CoV-2 variants, while Beta (B.1.351) and Delta (B.1.617.2) strains displayed a consistent partial immune evasion."
4,doi:10.1080/22221751.2021.2004866,B.1.617.2,"Moreover, vaccinated HCWs developed a similar protective neutralizing antibodies response against the EU (B.1), Alpha (B.1.1.7), Gamma (P.1), and Eta (B.1.525) SARS-CoV-2 variants, while Beta (B.1.351) and Delta (B.1.617.2) strains displayed a consistent partial immune evasion."
5,doi:10.1080/22221751.2021.2004866,B.1.351,"Moreover, vaccinated HCWs developed a similar protective neutralizing antibodies response against the EU (B.1), Alpha (B.1.1.7), Gamma (P.1), and Eta (B.1.525) SARS-CoV-2 variants, while Beta (B.1.351) and Delta (B.1.617.2) strains displayed a consistent partial immune evasion."
0,doi:10.3390/v13112127,B.1.1.7,"These senior authors contributed equally to this work..

A SARS-CoV-2 B.1.1.7 variant of concern (VOC) has been associated with increased transmissibility, hospitalization, and mortality."
1,doi:10.3390/v13112127,P.1,"Plasma of CoronaVac-vaccinated persons after a single or two doses presented a lower neutralization capacity against P.1 isolates, another VOC that emerged and become the dominant lineage in Brazil [33]."
0,doi:10.7326/m21-3509,B.1.617.2,Real-world evidence on inactivated COVID-19 vaccines against the SARS-CoV-2 B.1.617.2 (Delta) variant is limited.
0,doi:10.3390/v14020294,B.1.1.529,"Omicron, the novel highly mutated SARS-CoV-2 Variant of Concern (VOC, Pango lineage B.1.1.529) was first collected in early November 2021 in South Africa."
1,doi:10.3390/v14020294,B.1.617.2,"In all these locations, Omicron outcompeted Delta VOC (lineage B.1.617.2), which in October 2021 accounted for more than 99% of genomes sequenced in Europe, North America, and Oceania, more than 90% in Asia and South America, and nearly 90% in Africa.."
0,doi:10.1101/2021.02.11.21251585,B.1.351,"Out of 45 mutations assessed, only one from the B.1.351 Spike overlapped with a low-prevalence CD8+ epitope, suggesting that virtually all anti-SARS-CoV-2 CD8+ T-cell responses should recognize these newly described variants..

Due to the proofreading ability of the coronavirus (CoV) RNA-dependent RNA polymerase, the evolution of the global SARS-CoV-2 viral population during the current pandemic has been relatively constrained as compared to other endemic RNA viruses that do not possess this ability[1]."
1,doi:10.1101/2021.02.11.21251585,B.1.1.7,"However, during late 2020, three distinct variants that each possessed a significantly increased amount of amino acid polymorphisms were identified in association with spikes in cases of COVID-19 in the United Kingdom (variant B.1.1.7), South Africa (variant B.1.351), and Brazil (variant B.1.1.248)[2–4].."
2,doi:10.1101/2021.02.11.21251585,B.1.1.248,"However, during late 2020, three distinct variants that each possessed a significantly increased amount of amino acid polymorphisms were identified in association with spikes in cases of COVID-19 in the United Kingdom (variant B.1.1.7), South Africa (variant B.1.351), and Brazil (variant B.1.1.248)[2–4].."
0,doi:10.1016/j.micinf.2022.104949,B.1.1.33,"Genomes recovered from two placentas belong to the B.1.1.28 and B.1.1.33 lineages and present nonsynonymous mutations associated with virus fitness and infectivity; other not frequently reported mutations (B.1.1.33: NSP3 V2090G, M A2S and ORF3ab S253P and Y264N; B.1.1.28: NSP3 E995D, NSP12 R240K, NSP14H1897Y and in ORF7b V21F) were found in proteins involved in viral replication, viral induction of apoptosis, viral interference on interferon and on NF-Κβ pathways."
1,doi:10.1016/j.micinf.2022.104949,B.1.1.28,"Genomes recovered from two placentas belong to the B.1.1.28 and B.1.1.33 lineages and present nonsynonymous mutations associated with virus fitness and infectivity; other not frequently reported mutations (B.1.1.33: NSP3 V2090G, M A2S and ORF3ab S253P and Y264N; B.1.1.28: NSP3 E995D, NSP12 R240K, NSP14H1897Y and in ORF7b V21F) were found in proteins involved in viral replication, viral induction of apoptosis, viral interference on interferon and on NF-Κβ pathways."
2,doi:10.1016/j.micinf.2022.104949,B.1.1,"These two genome sequences belong to lineages B.1.1.28 clade 1 and B.1.1.33 clade 2, respectively and share 99.84% and 99.76% amino acid (aa) identity, respectively, with reference sequence hCoV-19/Wuhan/WIV04/2019 and 99.9% aa similarity with other two SARS-CoV-2 sequences obtained from placenta in the same time period (USA/Connecticut-Yale-050 MT886396 from lineage B.1.1 and human/BRA/Rio-P1/2020 MT939654.1 from lineage B.1.1.33)."
0,doi:10.3390/vaccines9060592,B.1.1.7,"Given that the spread of the variant will depend on the number of B.1.1.7 variant infections, we first explore outcomes of our model given different initial conditions of I˜s and I˜m.."
1,doi:10.3390/vaccines9060592,B.1.1.28,"In particular, since December 2020, some VOCs have been reported by national public health authorities to the World Health Organization (WHO), including VOC-202012/01 (also known as lineage B.1.1.7, commonly referred to as the “B.1.1.7 variant” or the “British variant”), 20I/501Y.V2 (known as lineage B.1.351, commonly termed as the “South African variant”), and lineage B.1.1.28 (known as the “Brazilian variant”)."
2,doi:10.3390/vaccines9060592,B.1.351,"In particular, since December 2020, some VOCs have been reported by national public health authorities to the World Health Organization (WHO), including VOC-202012/01 (also known as lineage B.1.1.7, commonly referred to as the “B.1.1.7 variant” or the “British variant”), 20I/501Y.V2 (known as lineage B.1.351, commonly termed as the “South African variant”), and lineage B.1.1.28 (known as the “Brazilian variant”)."
3,doi:10.3390/vaccines9060592,P.1,"Other variants are under investigation and strict follow-up from international public health bodies, including the “Japanese variant” (variant P.1, lineage B.1.1.28) and the “USA variant” (L452R)."
0,doi:10.1073/pnas.2111400119,B.1.1.7,"While the authentic variants of concern (VOCs) B.1.1.7 (alpha) and B.1.351 (beta) differ in cell-free infectivity from wild type and from each other, these VOCs have similar cell-to-cell transmission capability and exhibit differential sensitivity to neutralization by vaccinee sera."
1,doi:10.1073/pnas.2111400119,B.1.351,"While the authentic variants of concern (VOCs) B.1.1.7 (alpha) and B.1.351 (beta) differ in cell-free infectivity from wild type and from each other, these VOCs have similar cell-to-cell transmission capability and exhibit differential sensitivity to neutralization by vaccinee sera."
2,doi:10.1073/pnas.2111400119,B.1.5,"As such, we examined the cell-to-cell transmission capability of authentic SARS-CoV-2 wild type (WT) (USA-WA1/2020), D614G variant (B.1.5), and two VOCs B.1.1.7 (501Y.V1) and B.1.351 (South African, 501Y.V2), in the presence or absence of pooled sera from mRNA vaccines (three from Moderna and three from Pfizer)."
0,doi:10.1101/2021.07.05.21259105,B.1.526,"The predominant virus variant was the alpha (B.1.1.7), however a significant association between lineage B.1.526 and amino acid change S: E484K with positives after vaccination was noted when genomes were compared to a large control cohort from a matched time frame."
1,doi:10.1101/2021.07.05.21259105,B.1.1.7,"The predominant virus variant was the alpha (B.1.1.7), however a significant association between lineage B.1.526 and amino acid change S: E484K with positives after vaccination was noted when genomes were compared to a large control cohort from a matched time frame."
2,doi:10.1101/2021.07.05.21259105,P.1,"Chi-square analysis was performed for lineages P.1, B.1.1.7, B.1.351, B.1.526, and B.1.526.1..

As a part of whole genome sequencing of SARS-CoV-2 for surveillance, we identified 133 positives after the completion of either Moderna or Pfizer vaccination regimes that were collected in the time frame of January 2021- May 2021 (Table 1 summarizes the clinical and metadata of this cohort)."
3,doi:10.1101/2021.07.05.21259105,B.1.351,"Chi-square analysis was performed for lineages P.1, B.1.1.7, B.1.351, B.1.526, and B.1.526.1..

As a part of whole genome sequencing of SARS-CoV-2 for surveillance, we identified 133 positives after the completion of either Moderna or Pfizer vaccination regimes that were collected in the time frame of January 2021- May 2021 (Table 1 summarizes the clinical and metadata of this cohort)."
4,doi:10.1101/2021.07.05.21259105,B.1.526.1,"Of the genomes that had more than 50% coverage and more than an average depth of 50 (a total of 88), the majority (61%) belonged to the B.1.1.7 (alpha variant) lineage (20I/501Y.V1 clade) followed by the 20C lineages (iota variants) B.1.526 (9%) and B.1.526.1 (4.5%) (Figure 1A and B)."
0,doi:10.3390/ijerph18157799,B.1.1.7,"However, a significant upsurge was observed in some districts after the discovery of the new COVID-19 variant B.1.1.7 (Alpha)."
0,doi:10.3201/eid2711.211198,P.1,"We report on a PCR method for SARS-CoV-2 VOCs, the surveillance workflow, and multiple independent introductions and community transmission of the SARS-CoV-2 P.1 VOC in Uruguay..

By late 2020, because of natural viral evolution, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genetic variants emerged, some of which show increased transmissibility and cause more severe coronavirus disease (COVID-19) (1)."
1,doi:10.3201/eid2711.211198,B.1.1.7,"By July 2021, a total of 4 variants of concern (VOCs) had been identified: B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617 (Delta) (2)."
2,doi:10.3201/eid2711.211198,B.1.617,"By July 2021, a total of 4 variants of concern (VOCs) had been identified: B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617 (Delta) (2)."
3,doi:10.3201/eid2711.211198,B.1.351,"By July 2021, a total of 4 variants of concern (VOCs) had been identified: B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617 (Delta) (2)."
0,doi:10.1002/jmv.27326,P.1,"According to the PANGO lineage nomenclature system, these VOCs belonged to B.1.1.7, B.1.351, P.1, and B.1.617.2."
1,doi:10.1002/jmv.27326,B.1.1.7,"According to the PANGO lineage nomenclature system, these VOCs belonged to B.1.1.7, B.1.351, P.1, and B.1.617.2."
2,doi:10.1002/jmv.27326,B.1.351,"According to the PANGO lineage nomenclature system, these VOCs belonged to B.1.1.7, B.1.351, P.1, and B.1.617.2."
3,doi:10.1002/jmv.27326,B.1.617.2,"1
, 
2
, 
3
 The SARS‐CoV‐2 B.1.617.2 virus has shown higher transmissibility than the other three VOCs and is becoming dominant variant worldwide."
4,doi:10.1002/jmv.27326,B.1.617.1,"Among them, 50 (36.8%) belonged to B.1.617.1 lineage, 77 (56.6%) belonged to B.1.617.2 lineage, and nine (6.6%) belonged to non‐B.1.617 lineage."
0,doi:10.3390/microorganisms9081744,B.1.1.7,"Our data suggest that the biological Anti-SARS-CoV-2 research reagents such as NIBSC 20/130 show lower neutralization against B.1.351 SA (South Africa) and B.1.1.7 UK (United Kingdom) VOC, whereas a commercially available monoclonal antibody MM43 retains activity against both these variants."
1,doi:10.3390/microorganisms9081744,B.1.351,"Our data suggest that the biological Anti-SARS-CoV-2 research reagents such as NIBSC 20/130 show lower neutralization against B.1.351 SA (South Africa) and B.1.1.7 UK (United Kingdom) VOC, whereas a commercially available monoclonal antibody MM43 retains activity against both these variants."
2,doi:10.3390/microorganisms9081744,B.1.617,"It remains to be further confirmed if the neutralization activity of Sino-40591-MM43 is retained against other variants of concern, such as the B.1.617 delta and kappa variants."
0,doi:10.1080/22221751.2021.2024455,B.1.617.1,"Here, we isolate 9 neutralizing mouse MAbs raised against the spike protein of a SARS-CoV-2 prototype strain and evaluate their neutralizing potency towards a panel of variants, including B.1.1.7, B.1.351, B.1.617.1, and B.1.617.2."
1,doi:10.1080/22221751.2021.2024455,B.1.1.7,"Here, we isolate 9 neutralizing mouse MAbs raised against the spike protein of a SARS-CoV-2 prototype strain and evaluate their neutralizing potency towards a panel of variants, including B.1.1.7, B.1.351, B.1.617.1, and B.1.617.2."
2,doi:10.1080/22221751.2021.2024455,B.1.351,"Here, we isolate 9 neutralizing mouse MAbs raised against the spike protein of a SARS-CoV-2 prototype strain and evaluate their neutralizing potency towards a panel of variants, including B.1.1.7, B.1.351, B.1.617.1, and B.1.617.2."
3,doi:10.1080/22221751.2021.2024455,B.1.617.2,"S5D2 binds the top lateral edge of the receptor-binding motif within the receptor-binding domain (RBD) with a binding footprint centred around the loop477–489, and efficiently neutralizes all variant pseudoviruses, but the potency against B.1.617.2 was observed to decrease significantly."
4,doi:10.1080/22221751.2021.2024455,B.1.1.28,"A number of SARS-CoV-2 variants of interest (VOI) and variants of concern (VOC) have emerged, such as B.1.1.7 lineage that arose in the United Kingdom, B.1.1.28 lineage (also called “P.1”) in Brazil, and B.1.351 lineage in South Africa [20,27]."
5,doi:10.1080/22221751.2021.2024455,B.1.617,"The B.1.617 lineage, emerged recently in India [33], includes three main subtypes, namely B.1.617.1, B.1.617.2 and B.1.617.3 [20,27]."
6,doi:10.1080/22221751.2021.2024455,B.1.617.3,"The B.1.617 lineage, emerged recently in India [33], includes three main subtypes, namely B.1.617.1, B.1.617.2 and B.1.617.3 [20,27]."
0,doi:10.5339/qmj.2021.49,B.1.617.2,"However, currently, the Delta variant (B.1.617.2) is the most dreaded one owing to its enhanced transmissibility and increased virulence."
1,doi:10.5339/qmj.2021.49,P.1,"The Alpha(B.1.1.7) variant was identified in United Kingdom in late December 2020, Beta(B.1.351) variant in South Africa in December 2020, and Gamma (P.1) variant in Brazil in early January 2021."
2,doi:10.5339/qmj.2021.49,B.1.1.7,"The Alpha(B.1.1.7) variant was identified in United Kingdom in late December 2020, Beta(B.1.351) variant in South Africa in December 2020, and Gamma (P.1) variant in Brazil in early January 2021."
3,doi:10.5339/qmj.2021.49,B.1.351,"The Alpha(B.1.1.7) variant was identified in United Kingdom in late December 2020, Beta(B.1.351) variant in South Africa in December 2020, and Gamma (P.1) variant in Brazil in early January 2021."
4,doi:10.5339/qmj.2021.49,B.1.526,"The current identified VIOs are as follows: Iota (B.1.526), Eta (B.1.525), Kappa (B.1.617.1), and Lambda (C.37).13
."
5,doi:10.5339/qmj.2021.49,B.1.525,"The current identified VIOs are as follows: Iota (B.1.526), Eta (B.1.525), Kappa (B.1.617.1), and Lambda (C.37).13
."
6,doi:10.5339/qmj.2021.49,B.1.617.1,"The current identified VIOs are as follows: Iota (B.1.526), Eta (B.1.525), Kappa (B.1.617.1), and Lambda (C.37).13
."
7,doi:10.5339/qmj.2021.49,C.37,"The current identified VIOs are as follows: Iota (B.1.526), Eta (B.1.525), Kappa (B.1.617.1), and Lambda (C.37).13
."
8,doi:10.5339/qmj.2021.49,B.14,"The major lineage labels of SARS-CoV-2 begin with a letter, and the current lineages represented are A and B.14 This system of categorization is proposed only for tracking currently circulating lineages."
0,doi:10.1038/s41541-022-00450-8,B.1.617.2,"In mice, NARUVAX-C19 vaccine administered intramuscularly twice at 21-day interval elicited balanced Th1/Th2 humoral and T-cell responses with high titers of neutralizing antibodies against wild-type (D614G) and delta (B.1.617.2) variants."
0,doi:10.15585/mmwr.mm7047e1,B.1.617.2,"Since the B.1.617.2 (Delta) variant of SARS-CoV-2 (the virus that causes COVID-19) became the predominant circulating variant,* there have been anecdotal reports of increasing rates of stillbirths in women with COVID-19.† CDC used the Premier Healthcare Database Special COVID-19 Release (PHD-SR), a large hospital-based administrative database,§ to assess whether a maternal COVID-19 diagnosis documented at delivery hospitalization was associated with stillbirth during March 2020–September 2021 as well as before and during the period of Delta variant predominance in the United States (March 2020–June 2021 and July–September 2021, respectively)."
0,doi:10.7705/biomedica.5834,B.1.5,"Finally, a complete genome sequence obtained by next-generation sequencing allowed classifying the isolate as B.1.5 lineage.."
0,doi:10.1101/2021.06.07.21258351,P.1,"Cross-neutralizing activity against major variants of concern (B.1.1.7, P.1 and B.1.351) has been observed following vaccination, albeit at a reduced potency, but whether vaccines based on the Spike glycoprotein of these viral variants will produce a superior cross-neutralizing antibody response has not been fully investigated."
1,doi:10.1101/2021.06.07.21258351,B.1.1.7,"Cross-neutralizing activity against major variants of concern (B.1.1.7, P.1 and B.1.351) has been observed following vaccination, albeit at a reduced potency, but whether vaccines based on the Spike glycoprotein of these viral variants will produce a superior cross-neutralizing antibody response has not been fully investigated."
2,doi:10.1101/2021.06.07.21258351,B.1.351,"Cross-neutralizing activity against major variants of concern (B.1.1.7, P.1 and B.1.351) has been observed following vaccination, albeit at a reduced potency, but whether vaccines based on the Spike glycoprotein of these viral variants will produce a superior cross-neutralizing antibody response has not been fully investigated."
0,doi:10.3389/fmicb.2021.676314,P.1,"In the past few months, the identification of new B.1.1.7 (United Kingdom), B.1.351 (South Africa), and P.1 (Brazil) variants of concern (VOC) has highlighted the importance of tracking the emergence of mutations in the SARS-CoV-2 genome that impact transmissibility, virulence, and immune and neutralizing antibody escape."
1,doi:10.3389/fmicb.2021.676314,B.1.1.7,"In the past few months, the identification of new B.1.1.7 (United Kingdom), B.1.351 (South Africa), and P.1 (Brazil) variants of concern (VOC) has highlighted the importance of tracking the emergence of mutations in the SARS-CoV-2 genome that impact transmissibility, virulence, and immune and neutralizing antibody escape."
2,doi:10.3389/fmicb.2021.676314,B.1.351,"In the past few months, the identification of new B.1.1.7 (United Kingdom), B.1.351 (South Africa), and P.1 (Brazil) variants of concern (VOC) has highlighted the importance of tracking the emergence of mutations in the SARS-CoV-2 genome that impact transmissibility, virulence, and immune and neutralizing antibody escape."
0,doi:10.1080/21645515.2022.2027160,B.1.1.7,The full-dose regimen of the Pfizer/BioNTech vaccine is the most effective against infections with the B.1.1.7 and B.1.351 variants.
1,doi:10.1080/21645515.2022.2027160,B.1.351,The full-dose regimen of the Pfizer/BioNTech vaccine is the most effective against infections with the B.1.1.7 and B.1.351 variants.
2,doi:10.1080/21645515.2022.2027160,P.2,"*** Data was obtained from the USA study cohort, where the dominant variant was (Wuhan-Hu-1), the South Africa study cohort, where the dominant variant was (B.1.351) and from the Brazil study cohort, where the dominant variants were (P.2) and (Wuhan-Hu-1).¶Includes fatal disease as well as severe or critical illness."
3,doi:10.1080/21645515.2022.2027160,P.1,"eThe nomenclature system established by WHO on May 31 for naming and tracking SARS-CoV-2 variants of concern are as follows: 1) Alpha (B.1.1.7) first documented in the UK in September 2020; 2) Beta (B.1.351) first documented in South Africa in May 2020; 3) Gamma (P.1) first documented in Brazil in November 2020; 4) Delta (B.1.617.2) firstly documented in India in October 2020.67 As a result of the emergence of the new variants, several research groups conducted studies to assess the efficacy of the approved vaccines against each variant."
4,doi:10.1080/21645515.2022.2027160,B.1.617.2,"eThe nomenclature system established by WHO on May 31 for naming and tracking SARS-CoV-2 variants of concern are as follows: 1) Alpha (B.1.1.7) first documented in the UK in September 2020; 2) Beta (B.1.351) first documented in South Africa in May 2020; 3) Gamma (P.1) first documented in Brazil in November 2020; 4) Delta (B.1.617.2) firstly documented in India in October 2020.67 As a result of the emergence of the new variants, several research groups conducted studies to assess the efficacy of the approved vaccines against each variant."
5,doi:10.1080/21645515.2022.2027160,B.1.1.1,Sequencing was available for 41 of the 42 participants and 39 (95.1%) of those were due to the B.1.351 variant and 2 (4.9%) were due to the B.1.1.1 and B.1.144 lineages.
6,doi:10.1080/21645515.2022.2027160,B.1.144,Sequencing was available for 41 of the 42 participants and 39 (95.1%) of those were due to the B.1.351 variant and 2 (4.9%) were due to the B.1.1.1 and B.1.144 lineages.
0,doi:10.1038/s41467-021-25985-7,A.23.1,"In particular, we report a shift in variant distribution towards the emerging sub-lineage A.23.1 that is currently dominating."
1,doi:10.1038/s41467-021-25985-7,B.1.1.7,"Furthermore, we report the detection of the first Rwandan cases of the B.1.1.7 and B.1.351 variants of concern among incoming travelers tested at Kigali International Airport."
2,doi:10.1038/s41467-021-25985-7,B.1.351,"Furthermore, we report the detection of the first Rwandan cases of the B.1.1.7 and B.1.351 variants of concern among incoming travelers tested at Kigali International Airport."
3,doi:10.1038/s41467-021-25985-7,B.1.380,"In this study, we reconstruct the introduction and subsequent dispersal of lineages A.23.1 and B.1.380 based on genomic analysis of isolates from the first and second waves of the epidemic in Rwanda."
4,doi:10.1038/s41467-021-25985-7,B.1,"Both of these subtrees consist of genetically distinct lineages, with the larger cluster belonging to lineage B.1.380 (and hence referred to as subtree B.1) and the smaller one to A.23.1 (referred to as subtree A)."
5,doi:10.1038/s41467-021-25985-7,A.23,"5), which contains sequences from lineages A.23 and A.23.1, we inferred a minimum number of 22 (HPD 95%: [16–29]) introduction events into Rwanda, with a minimum of respectively 13 and 4 of these events originating from Uganda and Kenya (Fig."
0,doi:10.7554/elife.72619,B.1.1.7,"Vaccine-elicited spike-specific T cells responded similarly to stimulation by spike epitopes from the ancestral, B.1.1.7 and B.1.351 variant strains, both in terms of cell numbers and phenotypes."
1,doi:10.7554/elife.72619,B.1.351,"Vaccine-elicited spike-specific T cells responded similarly to stimulation by spike epitopes from the ancestral, B.1.1.7 and B.1.351 variant strains, both in terms of cell numbers and phenotypes."
2,doi:10.7554/elife.72619,P.1,"More worrisome, however, was the emergence at the end of 2020 of rapidly spreading variants in multiple parts of the world, including B.1.1.7, B.1.351, P.1, and B.1.427/B.1.429 (originally identified in United Kingdom, South Africa, Brazil, and California, respectively) Plante et al., 2021, followed by additional highly transmissible variants in 2021 including the B.1.617.2 which was first detected in India Callaway, 2021."
3,doi:10.7554/elife.72619,B.1.617.2,"More worrisome, however, was the emergence at the end of 2020 of rapidly spreading variants in multiple parts of the world, including B.1.1.7, B.1.351, P.1, and B.1.427/B.1.429 (originally identified in United Kingdom, South Africa, Brazil, and California, respectively) Plante et al., 2021, followed by additional highly transmissible variants in 2021 including the B.1.617.2 which was first detected in India Callaway, 2021."
4,doi:10.7554/elife.72619,B.1.427,"More worrisome, however, was the emergence at the end of 2020 of rapidly spreading variants in multiple parts of the world, including B.1.1.7, B.1.351, P.1, and B.1.427/B.1.429 (originally identified in United Kingdom, South Africa, Brazil, and California, respectively) Plante et al., 2021, followed by additional highly transmissible variants in 2021 including the B.1.617.2 which was first detected in India Callaway, 2021."
0,doi:10.1016/j.jinf.2021.04.026,B.1.1.7,"The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has placed unprecedented strain on health-care services, leading to 134,125,854 cases and more than 2905,412 deaths worldwide, as of 09/04/21.1 Globally it has been observed that more transmissible variants develop.2 Since October, one such variant of concern (VOC) (SARS-CoV-2 20B/GR clade; VOC-202012/01; lineage B.1.1.7) has been described in the UK.3 B.1.1.7 appears to have substantially increased transmissibility compared to other variants and has quickly become the dominant variant in much of the UK.4 A report by the Office for National Statistics suggested that people infected with B.1.1.7 are more likely to have a cough, sore throat, fatigue, or myalgia than those infected with other variants.5 Furthermore, preliminary data indicate that infection with VOC B.1.1.7 is associated with an increased risk of death compared with other variants.4 At University Hospitals Birmingham (UHB) NHS Foundation Trust, we undertake whole genome sequencing on a substantial proportion of our SARS-CoV-2 positive samples."
1,doi:10.1016/j.jinf.2021.04.026,B.1.351,"Lineages were assigned with Pangolin.6 To understand the impact of the VOCs: VOC-202012/01 B.1.1.7 and B.1.351, clinical details for patients whose samples resulted in an assignment of lineage were collected."
2,doi:10.1016/j.jinf.2021.04.026,B.1.177,"During the study period, 52.3% of positive samples were the UK ‘Kent’ variant (B.1.1.7), 40.2% the ‘Spanish’ variant (B.1.177), and one South African variant (B.1.351) (Fig."
0,doi:10.1101/2021.04.27.441655,B.1.429,"Here, we demonstrate the neutralization of SARS-CoV, bat CoVs WIV-1 and RsSHC014, and SARS-CoV-2 variants D614G, B.1.1.7, B.1.429, B1.351 by a receptor-binding domain (RBD)-specific antibody DH1047."
1,doi:10.1101/2021.04.27.441655,B.1.1.7,"Here, we demonstrate the neutralization of SARS-CoV, bat CoVs WIV-1 and RsSHC014, and SARS-CoV-2 variants D614G, B.1.1.7, B.1.429, B1.351 by a receptor-binding domain (RBD)-specific antibody DH1047."
2,doi:10.1101/2021.04.27.441655,B.1.351,"Here, we demonstrate, using both pseudoviruses and live virus assays, that DH1047 neutralizes SARS-CoV, SARS-like bat viruses RsSHC014 and WIV-1, and SARS-CoV-2 D614G, B.1.1.7, B.1.429, B.1.351 variants."
0,doi:10.1038/s41598-021-99661-7,B.1.1.7,"The emergence of a novel SARS-CoV-2 B.1.1.7 variant sparked global alarm due to increased transmissibility, mortality, and uncertainty about vaccine efficacy, thus accelerating efforts to detect and track the variant."
1,doi:10.1038/s41598-021-99661-7,B.1.1.298,"Since other SARS-CoV-2 variants share the ΔH69/ΔV70 deletion (e.g., B.1.1.298, B.1.160, B.1.177, B.1.258, B.1.375, B.1.525), we designed a series of reverse primers to target the second, three base pair deletion (bp: 21,991–21,993; ΔY144) and utilized allele-specific PCR approaches14–16 and judicious placement of LNA-modified nucleotides to enhance the specificity of the assay (Supplementary Fig."
2,doi:10.1038/s41598-021-99661-7,B.1.258,"Since other SARS-CoV-2 variants share the ΔH69/ΔV70 deletion (e.g., B.1.1.298, B.1.160, B.1.177, B.1.258, B.1.375, B.1.525), we designed a series of reverse primers to target the second, three base pair deletion (bp: 21,991–21,993; ΔY144) and utilized allele-specific PCR approaches14–16 and judicious placement of LNA-modified nucleotides to enhance the specificity of the assay (Supplementary Fig."
3,doi:10.1038/s41598-021-99661-7,B.1.160,"Since other SARS-CoV-2 variants share the ΔH69/ΔV70 deletion (e.g., B.1.1.298, B.1.160, B.1.177, B.1.258, B.1.375, B.1.525), we designed a series of reverse primers to target the second, three base pair deletion (bp: 21,991–21,993; ΔY144) and utilized allele-specific PCR approaches14–16 and judicious placement of LNA-modified nucleotides to enhance the specificity of the assay (Supplementary Fig."
4,doi:10.1038/s41598-021-99661-7,B.1.375,"Since other SARS-CoV-2 variants share the ΔH69/ΔV70 deletion (e.g., B.1.1.298, B.1.160, B.1.177, B.1.258, B.1.375, B.1.525), we designed a series of reverse primers to target the second, three base pair deletion (bp: 21,991–21,993; ΔY144) and utilized allele-specific PCR approaches14–16 and judicious placement of LNA-modified nucleotides to enhance the specificity of the assay (Supplementary Fig."
5,doi:10.1038/s41598-021-99661-7,B.1.525,"Since other SARS-CoV-2 variants share the ΔH69/ΔV70 deletion (e.g., B.1.1.298, B.1.160, B.1.177, B.1.258, B.1.375, B.1.525), we designed a series of reverse primers to target the second, three base pair deletion (bp: 21,991–21,993; ΔY144) and utilized allele-specific PCR approaches14–16 and judicious placement of LNA-modified nucleotides to enhance the specificity of the assay (Supplementary Fig."
6,doi:10.1038/s41598-021-99661-7,B.1.177,"Since other SARS-CoV-2 variants share the ΔH69/ΔV70 deletion (e.g., B.1.1.298, B.1.160, B.1.177, B.1.258, B.1.375, B.1.525), we designed a series of reverse primers to target the second, three base pair deletion (bp: 21,991–21,993; ΔY144) and utilized allele-specific PCR approaches14–16 and judicious placement of LNA-modified nucleotides to enhance the specificity of the assay (Supplementary Fig."
7,doi:10.1038/s41598-021-99661-7,B.1.1,"It is important to note, however, that SGTPs are produced by other variants that contain the ΔH69/ΔV70 deletion, including the B.1.1, B1.258, B.1.525, and B.1.1.298 (the mink cluster V) lineages, as well7."
8,doi:10.1038/s41598-021-99661-7,B.1.1.76,"Although our observed data did not fit models of previously established replication numbers for lineage B.1.1.76,8, we attribute this discrepancy to region specific presence of other competing SARS-CoV-2 variants."
9,doi:10.1038/s41598-021-99661-7,P.1,"Although the assays described here can accurately detect and differentiate the B.1.1.7 variant, a limitation is that it does not detect other emerging variants of concern (VOCs) such as B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta)."
10,doi:10.1038/s41598-021-99661-7,B.1.617.2,"Although the assays described here can accurately detect and differentiate the B.1.1.7 variant, a limitation is that it does not detect other emerging variants of concern (VOCs) such as B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta)."
11,doi:10.1038/s41598-021-99661-7,B.1.351,"Although the assays described here can accurately detect and differentiate the B.1.1.7 variant, a limitation is that it does not detect other emerging variants of concern (VOCs) such as B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta)."
0,doi:10.3390/v13112177,B.1.160,"In France, most cases were due to spike D641G-harbouring viruses that descended initially from the Wuhan strain, then by the variant of B.1.160 lineage we called Marseille-4 since the summer of 2020, which was followed by the Alpha and Beta variants in early 2021, then the Delta variant currently."
1,doi:10.3390/v13112177,P.1,"The remaining questions are whether the antibodies generated after vaccination and after natural infection confer long-lasting immunity and whether rapidly evolving mutants, especially those with spike protein mutations, modify the vaccines’ effectiveness..

Four new variants that have rapidly become dominant in the mentioned countries have garnered concerns: the Alpha (PANGO Lineage: B.1.1.7) variant that was identified in the United Kingdom (UK), the Beta (PANGO lineage: B.1.351) variant that was first detected in South Africa, the Gamma (PANGO lineage: P.1) variant that first spread in Brazil, and the Delta (PANGO lineage: B.1.617.2) variant that was first identified in India."
2,doi:10.3390/v13112177,B.1.1.7,"The remaining questions are whether the antibodies generated after vaccination and after natural infection confer long-lasting immunity and whether rapidly evolving mutants, especially those with spike protein mutations, modify the vaccines’ effectiveness..

Four new variants that have rapidly become dominant in the mentioned countries have garnered concerns: the Alpha (PANGO Lineage: B.1.1.7) variant that was identified in the United Kingdom (UK), the Beta (PANGO lineage: B.1.351) variant that was first detected in South Africa, the Gamma (PANGO lineage: P.1) variant that first spread in Brazil, and the Delta (PANGO lineage: B.1.617.2) variant that was first identified in India."
3,doi:10.3390/v13112177,B.1.617.2,"The remaining questions are whether the antibodies generated after vaccination and after natural infection confer long-lasting immunity and whether rapidly evolving mutants, especially those with spike protein mutations, modify the vaccines’ effectiveness..

Four new variants that have rapidly become dominant in the mentioned countries have garnered concerns: the Alpha (PANGO Lineage: B.1.1.7) variant that was identified in the United Kingdom (UK), the Beta (PANGO lineage: B.1.351) variant that was first detected in South Africa, the Gamma (PANGO lineage: P.1) variant that first spread in Brazil, and the Delta (PANGO lineage: B.1.617.2) variant that was first identified in India."
4,doi:10.3390/v13112177,B.1.351,"The remaining questions are whether the antibodies generated after vaccination and after natural infection confer long-lasting immunity and whether rapidly evolving mutants, especially those with spike protein mutations, modify the vaccines’ effectiveness..

Four new variants that have rapidly become dominant in the mentioned countries have garnered concerns: the Alpha (PANGO Lineage: B.1.1.7) variant that was identified in the United Kingdom (UK), the Beta (PANGO lineage: B.1.351) variant that was first detected in South Africa, the Gamma (PANGO lineage: P.1) variant that first spread in Brazil, and the Delta (PANGO lineage: B.1.617.2) variant that was first identified in India."
5,doi:10.3390/v13112177,B.1.351.2,"Eleven patients were infected by spike D614G-harbouring B lineage strains that spread during the first wave of COVID-19 infections in France, 9 were infected by the Marseille-4/B.1.160 variant, 10 were infected by the Alpha variant, and 12 were infected by the Beta/B.1.351.2 variant."
6,doi:10.3390/v13112177,B.1.1,"By arbitrarily classifying the patients with high titres of antibodies (IgG titres > 100), we found that the prevalence of the high titres decreased among patients infected by the original/B.1.1 genotype (8/9, 89%), the Alpha genotype (3/10, 30%), the Marseille-4/B.1.160 genotype (1/9, 11%), and the Beta genotype (0/12, 0%)."
7,doi:10.3390/v13112177,A.27,"Without taking into account the sera of patients convalescing for the Beta variant that react nearly only to Beta and Gamma variants, at a 1/5 MSN titre, 14/30 (47%) of the samples reacted against the Original/B.1.1 genotype, 10/19 (53%) reacted against the Marseille-4/B.1.160 genotype, 13/20 (65%) reacted against the Alpha genotype, 20/30 (66%) reacted against the Marseille-501/A.27 variant, 18/30 (60%) reacted against the Gamma variant, 15/60 (50%) reacted against the Marseille-484K.V1/R.1 variant, 24/30 (80%) reacted against the B.1.214.2 variant that was first described in Belgium, and 12/60 (50%) reacted against the Delta variant."
8,doi:10.3390/v13112177,R.1,"Without taking into account the sera of patients convalescing for the Beta variant that react nearly only to Beta and Gamma variants, at a 1/5 MSN titre, 14/30 (47%) of the samples reacted against the Original/B.1.1 genotype, 10/19 (53%) reacted against the Marseille-4/B.1.160 genotype, 13/20 (65%) reacted against the Alpha genotype, 20/30 (66%) reacted against the Marseille-501/A.27 variant, 18/30 (60%) reacted against the Gamma variant, 15/60 (50%) reacted against the Marseille-484K.V1/R.1 variant, 24/30 (80%) reacted against the B.1.214.2 variant that was first described in Belgium, and 12/60 (50%) reacted against the Delta variant."
9,doi:10.3390/v13112177,B.1.214.2,"Without taking into account the sera of patients convalescing for the Beta variant that react nearly only to Beta and Gamma variants, at a 1/5 MSN titre, 14/30 (47%) of the samples reacted against the Original/B.1.1 genotype, 10/19 (53%) reacted against the Marseille-4/B.1.160 genotype, 13/20 (65%) reacted against the Alpha genotype, 20/30 (66%) reacted against the Marseille-501/A.27 variant, 18/30 (60%) reacted against the Gamma variant, 15/60 (50%) reacted against the Marseille-484K.V1/R.1 variant, 24/30 (80%) reacted against the B.1.214.2 variant that was first described in Belgium, and 12/60 (50%) reacted against the Delta variant."
0,doi:10.1016/j.jbc.2021.101151,B.1.1.7,"Interestingly, the RBD N501Y mutation, present in emerging variants of concern (VOCs) that are fueling the pandemic worldwide (including the B.1.1.7 (α) lineage), bypassed this requirement."
1,doi:10.1016/j.jbc.2021.101151,P.1,"Over the 2019 to 2020 period, no major sequence variations were observed except for the N501Y mutation (4.4%), which started to arise at the end of the year in at least three independent lineages of interest (B.1.1.7, B.1.351, P.1) (27, 28, 29)."
2,doi:10.1016/j.jbc.2021.101151,B.1.351,"Over the 2019 to 2020 period, no major sequence variations were observed except for the N501Y mutation (4.4%), which started to arise at the end of the year in at least three independent lineages of interest (B.1.1.7, B.1.351, P.1) (27, 28, 29)."
3,doi:10.1016/j.jbc.2021.101151,B.1.617.2,"The majority of them bound better to ACE2 at physiological temperature, notably for lineages harboring the N501Y mutation (B.1.1.7, B.1.351, and P.1) or the L452R mutation (B.1.617.2 and B.1.429)."
4,doi:10.1016/j.jbc.2021.101151,B.1.429,"The majority of them bound better to ACE2 at physiological temperature, notably for lineages harboring the N501Y mutation (B.1.1.7, B.1.351, and P.1) or the L452R mutation (B.1.617.2 and B.1.429)."
0,doi:10.1038/s41598-022-04952-2,P.1,"A total of 734 samples from COVID-19 confirmed cases in Hiroshima were screened for the notable SARS-CoV-2 variants (B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.1, C.37, B.1.1.529, etc.)."
1,doi:10.1038/s41598-022-04952-2,B.1.1.7,"A total of 734 samples from COVID-19 confirmed cases in Hiroshima were screened for the notable SARS-CoV-2 variants (B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.1, C.37, B.1.1.529, etc.)."
2,doi:10.1038/s41598-022-04952-2,B.1.1.529,"A total of 734 samples from COVID-19 confirmed cases in Hiroshima were screened for the notable SARS-CoV-2 variants (B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.1, C.37, B.1.1.529, etc.)."
3,doi:10.1038/s41598-022-04952-2,B.1.617.2,"A total of 734 samples from COVID-19 confirmed cases in Hiroshima were screened for the notable SARS-CoV-2 variants (B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.1, C.37, B.1.1.529, etc.)."
4,doi:10.1038/s41598-022-04952-2,B.1.617.1,"A total of 734 samples from COVID-19 confirmed cases in Hiroshima were screened for the notable SARS-CoV-2 variants (B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.1, C.37, B.1.1.529, etc.)."
5,doi:10.1038/s41598-022-04952-2,B.1.351,"A total of 734 samples from COVID-19 confirmed cases in Hiroshima were screened for the notable SARS-CoV-2 variants (B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.1, C.37, B.1.1.529, etc.)."
6,doi:10.1038/s41598-022-04952-2,C.37,"A total of 734 samples from COVID-19 confirmed cases in Hiroshima were screened for the notable SARS-CoV-2 variants (B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.1, C.37, B.1.1.529, etc.)."
7,doi:10.1038/s41598-022-04952-2,P.3,"Later, the B.1.429 (VOI Epsilon GH/452R.V1), B.1.617.2, AY.1 and AY.2 (VOC Delta G/478 K.V1) and B.1.617.1 (VOI Kappa G/452R.V3), B.1.525 (VOI Eta G/484 K.V3), P.3 (VOI Theta GR/1092 K.V1P.3) and C.37 (VOI Lambda GR/452Q.V1) were continuously emerged."
8,doi:10.1038/s41598-022-04952-2,B.1.525,"Later, the B.1.429 (VOI Epsilon GH/452R.V1), B.1.617.2, AY.1 and AY.2 (VOC Delta G/478 K.V1) and B.1.617.1 (VOI Kappa G/452R.V3), B.1.525 (VOI Eta G/484 K.V3), P.3 (VOI Theta GR/1092 K.V1P.3) and C.37 (VOI Lambda GR/452Q.V1) were continuously emerged."
9,doi:10.1038/s41598-022-04952-2,B.1.429,"Later, the B.1.429 (VOI Epsilon GH/452R.V1), B.1.617.2, AY.1 and AY.2 (VOC Delta G/478 K.V1) and B.1.617.1 (VOI Kappa G/452R.V3), B.1.525 (VOI Eta G/484 K.V3), P.3 (VOI Theta GR/1092 K.V1P.3) and C.37 (VOI Lambda GR/452Q.V1) were continuously emerged."
0,doi:10.1002/jmv.27389,C.37,"Introduction of SARS‐CoV‐2 C.37 (WHO VOI lambda) in the Sao Paulo State, Southeast Brazil."
1,doi:10.1002/jmv.27389,P.1,This high incidence (9515/100 000 inhabitants) has been linked to the circulation of several variants of concern (VOCs) and interest (VOIs) with an almost total predominance of the Gamma VOC (P.1/GR 5‐1Y.V3/20J).
2,doi:10.1002/jmv.27389,V.2,The normalized sample libraries were sequenced through the Illumina MiSeq platform using the MiSeq Reagent v.2 Kit (2 × 300 cycles) (Illumina).
3,doi:10.1002/jmv.27389,V.1,"19
 using the TreeTime v.1 software."
0,doi:10.1128/mbio.01229-21,P.1,"Additionally, there was a noticeable overlap between antigenic regions and known mutation locations in selected emerging SARS-CoV-2 variants of current clinical consequence (B.1.1.7, B1.351, P.1, CAL20.C, and B.1.526)."
1,doi:10.1128/mbio.01229-21,B.1.526,"Additionally, there was a noticeable overlap between antigenic regions and known mutation locations in selected emerging SARS-CoV-2 variants of current clinical consequence (B.1.1.7, B1.351, P.1, CAL20.C, and B.1.526)."
2,doi:10.1128/mbio.01229-21,B.1.1.7,"Additionally, there was a noticeable overlap between antigenic regions and known mutation locations in selected emerging SARS-CoV-2 variants of current clinical consequence (B.1.1.7, B1.351, P.1, CAL20.C, and B.1.526)."
3,doi:10.1128/mbio.01229-21,B.1.351,"Antigenic reactivity also differed significantly among the three groups within the N region spanning aa 201 to 300, which contains the S235F and T205I mutations found in the SARS-CoV-2 B.1.1.7 and B.1.351 variants, respectively."
0,doi:10.15585/mmwr.mm7107a4,B.1.1.529,"* On December 2, 2021, the Minnesota Department of Health reported the first case of community-acquired COVID-19 in the United States caused by the SARS-CoV-2 B.1.1.529 (Omicron) variant in a person who had attended the event (1)."
1,doi:10.15585/mmwr.mm7107a4,B.1.617.2,"Genomic sequencing of 20 specimens identified the SARS-CoV-2 B.1.617.2 (Delta) variant (AY.25 and AY.103 sublineages) in 15 (75%) cases, and the Omicron variant (BA.1 sublineage) in five (25%) cases."
0,doi:10.3390/vaccines10030437,B.1.1.529,"The loss of this protective effect in December is likely due to the emergence of the omicron (B.1.1.529) variant, better adapted to evade vaccine-induced humoral immunity."
1,doi:10.3390/vaccines10030437,B.1.617.2,This has mainly concerned the B.1.617.2 (delta) variant that was first identified in India in December 2020 and became dominant in the European Region by June/July 2021 [8].
0,doi:10.3390/v14010144,A.2.5,"Here, we assessed ACE2 binding and antigenicity of Mu (B.1.621) and A.2.5 Spikes."
1,doi:10.3390/v14010144,B.1.621,"Here, we assessed ACE2 binding and antigenicity of Mu (B.1.621) and A.2.5 Spikes."
2,doi:10.3390/v14010144,P.1,"Some of the pivotal mutations such as N501Y and E484K in the receptor-binding domain (RBD) detected in B.1.1.7 (Alpha), B.1.351 (Beta) and P.1 (Gamma) are now present within the Mu variant."
3,doi:10.3390/v14010144,B.1.1.7,"Some of the pivotal mutations such as N501Y and E484K in the receptor-binding domain (RBD) detected in B.1.1.7 (Alpha), B.1.351 (Beta) and P.1 (Gamma) are now present within the Mu variant."
4,doi:10.3390/v14010144,B.1.351,"Some of the pivotal mutations such as N501Y and E484K in the receptor-binding domain (RBD) detected in B.1.1.7 (Alpha), B.1.351 (Beta) and P.1 (Gamma) are now present within the Mu variant."
5,doi:10.3390/v14010144,B.1.617.2,"Similarly, the L452R mutation of B.1.617.2 (Delta) variant is present in A.2.5."
6,doi:10.3390/v14010144,B.1.617,"In late 2020, several VOCs emerged named B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) as well as the VOIs B.1.429 (Epsilon), B.1.526 (Iota), B.1.617.1 (Kappa) and B.1.617 [12,13,14,15,16,17,18]."
7,doi:10.3390/v14010144,B.1.526,"In late 2020, several VOCs emerged named B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) as well as the VOIs B.1.429 (Epsilon), B.1.526 (Iota), B.1.617.1 (Kappa) and B.1.617 [12,13,14,15,16,17,18]."
8,doi:10.3390/v14010144,B.1.617.1,"In late 2020, several VOCs emerged named B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) as well as the VOIs B.1.429 (Epsilon), B.1.526 (Iota), B.1.617.1 (Kappa) and B.1.617 [12,13,14,15,16,17,18]."
9,doi:10.3390/v14010144,B.1.429,"In late 2020, several VOCs emerged named B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) as well as the VOIs B.1.429 (Epsilon), B.1.526 (Iota), B.1.617.1 (Kappa) and B.1.617 [12,13,14,15,16,17,18]."
0,doi:10.1016/j.vaccine.2021.09.077,B.1.351,"Furthermore, ISA 720-adjuvanted AKS-452 was immunogenic in rabbits and non-human primates (NHPs) and protected from infection and clinical symptoms with live SARS-CoV-2 virus in NHPs (USA-WA1/2020 viral strain) and the K18 human ACE2-trangenic (K18-huACE2-Tg) mouse (South African B.1.351 viral variant)."
1,doi:10.1016/j.vaccine.2021.09.077,B.1.617.2,"It is clear that different variants of SARS-CoV-2 containing unique mutations are associated with increased infection rates in different parts of the world including the B.1.1.7 (N501Y), B.1.351 (K417N, E484K, N501Y), and B.1.617.2 (L452R, T478K) variants [30], [31], [32]."
2,doi:10.1016/j.vaccine.2021.09.077,B.1.1.7,"It is clear that different variants of SARS-CoV-2 containing unique mutations are associated with increased infection rates in different parts of the world including the B.1.1.7 (N501Y), B.1.351 (K417N, E484K, N501Y), and B.1.617.2 (L452R, T478K) variants [30], [31], [32]."
0,doi:10.1016/j.jiph.2021.11.011,P.3,"Subsequent genomic analysis showed that all four were infected with a relatively rare Variant of Interest (P.3, Theta) derived from a single origin."
1,doi:10.1016/j.jiph.2021.11.011,P.1,"Along with other Variants of Concern (VOCs) classified by PHE, including B.1.1.7 (Alpha), P.1 (Gamma), and B.1.351 (Beta), all P.3 viruses contain multiple concerning mutations in the spike protein, including E484K, N501Y, and P681H [7], which have been linked to increased transmissibility and immune escape [11,12]."
2,doi:10.1016/j.jiph.2021.11.011,B.1.1.7,"Along with other Variants of Concern (VOCs) classified by PHE, including B.1.1.7 (Alpha), P.1 (Gamma), and B.1.351 (Beta), all P.3 viruses contain multiple concerning mutations in the spike protein, including E484K, N501Y, and P681H [7], which have been linked to increased transmissibility and immune escape [11,12]."
3,doi:10.1016/j.jiph.2021.11.011,B.1.351,"Along with other Variants of Concern (VOCs) classified by PHE, including B.1.1.7 (Alpha), P.1 (Gamma), and B.1.351 (Beta), all P.3 viruses contain multiple concerning mutations in the spike protein, including E484K, N501Y, and P681H [7], which have been linked to increased transmissibility and immune escape [11,12]."
0,doi:10.1016/j.virusres.2021.198531,B.1.1.7,"Here it is shown that a very simple evolutionary model can fit the observed change in frequency of B.1.1.7 for several countries, regions of countries and the whole world with a single parameter, its relative fitness f, which is almost universal f ≈ 1.5."
0,doi:10.1038/s41423-021-00779-5,A.30,"Therefore, it is important to investigate whether emerging SARS-CoV-2 variants exhibit altered host cell interactions and resistance against antibody-mediated neutralization..

We investigated host cell entry and antibody-mediated neutralization of the variant A.30 (also termed A.VOI.V2), which was detected in several patients in Angola and Sweden in spring 2021 and likely originated in Tanzania [2]."
1,doi:10.1038/s41423-021-00779-5,B.1.525,"For comparison, we analyzed the Beta (B.1.351) and Eta (B.1.525) variants."
2,doi:10.1038/s41423-021-00779-5,B.1.351,"For comparison, we analyzed the Beta (B.1.351) and Eta (B.1.525) variants."
3,doi:10.1038/s41423-021-00779-5,B.1,"Compared to the S protein of SARS-CoV-2 B.1, which circulated in the early phase of the pandemic, the S protein of the A.30 variant contains 10 amino acid substitutions and five deletions (Fig."
4,doi:10.1038/s41423-021-00779-5,B.1.617.2,"Finally, all variants tested exhibited reduced and comparable evasion of antibodies induced by heterologous ChAdOx1 nCoV-19/BNT162b2 vaccination, in keeping with findings published for the Delta (B.1.617.2) variant [7].."
5,doi:10.1038/s41423-021-00779-5,B.1.1.7,"Neutralization resistance exceeded that of the Beta (B.1.351) variant, which is markedly neutralization resistant in cell culture and, in comparison with the Alpha (B.1.1.7) variant, is less well inhibited by the ChAdOx1 nCoV-19 vaccine [9]."
0,doi:10.1093/cid/ciab998,B.1.351,"Binding antibodies (Ab) to SARS-CoV-2 receptor binding domain (RBD), spike domains S1 and S2, RBD Ab avidity, and neutralizing Ab against SARS-CoV-2 wild type and B.1.351 were assessed at days 0, 21, 28, and 49..

SARS-CoV-2 naïve residents had lower Ab responses to BNT162b2 mRNA vaccination than naïve staff."
0,doi:10.1093/cid/ciab265,B.1.1.7,This study used state-of-the-art phylodynamic methods to ascertain that the rapid rise of B.1.1.7 “Variant of Concern” most likely occurred by global dispersal rather than convergent evolution from multiple sources..
0,doi:10.1128/mra.00100-21,B.1.1.7,"The genome was also compared with UK variant VOC-202012/01 (GISAID accession number EPI_ISL_601443), which indicated that Bangladeshi strain G039392 had all 23 mutations that were identified in UK variant B.1.1.7 (Table 1)."
0,doi:10.1016/j.str.2021.05.014,B.1.1.7,"Emerging SARS-CoV-2 strains, B.1.1.7 and B.1.351, from the UK and South Africa, respectively, show decreased neutralization by monoclonal antibodies and convalescent or vaccinee sera raised against the original wild-type virus, and are thus of clinical concern."
1,doi:10.1016/j.str.2021.05.014,B.1.351,"Emerging SARS-CoV-2 strains, B.1.1.7 and B.1.351, from the UK and South Africa, respectively, show decreased neutralization by monoclonal antibodies and convalescent or vaccinee sera raised against the original wild-type virus, and are thus of clinical concern."
2,doi:10.1016/j.str.2021.05.014,P.1,"The E484K mutation—detected in B.1.351 and recently emerging strains P.1 and P.2 (Faria et al., 2021)—impairs recognition of numerous antibodies (Wang et al., 2021a) and also weakly improves ACE2 binding affinity."
3,doi:10.1016/j.str.2021.05.014,P.2,"The E484K mutation—detected in B.1.351 and recently emerging strains P.1 and P.2 (Faria et al., 2021)—impairs recognition of numerous antibodies (Wang et al., 2021a) and also weakly improves ACE2 binding affinity."
4,doi:10.1016/j.str.2021.05.014,B.1.1.28,"Both antibody classes recognize predominantly the RBM, which is mutated convergently in many emerging viral lineages (e.g., K417T, E484K, and N501Y in both B.1.351 and B.1.1.28 [Brazil])."
5,doi:10.1016/j.str.2021.05.014,B.1.526,"This may explain the rapid spread of convergent RBD mutations in different emerging SARS-CoV-2 lineages (e.g., E484K mutation in Brazilian P.1, SA B.1.351, and US B.1.526 lineages) (Sabino et al., 2021; West et al., 2021)."
0,doi:10.1016/j.ijid.2021.05.010,P.1,"We report 3 cases of severe COVID-19 due to the SARS-CoV-2 P.1 lineage in a familial cluster detected in Salvador, Bahia–Brazil."
1,doi:10.1016/j.ijid.2021.05.010,B.1.1.7,"In addition, in late 2020, new SARS-CoV-2 Variants of Concern (VOC) were identified, including the 501Y.V1 (B.1.1.7 lineage) reported in the United Kingdom (Public Health England, 2020) and 501Y.V2 (B.1.351 lineage) first detected in South Africa (Tegally et al., 2021).."
2,doi:10.1016/j.ijid.2021.05.010,B.1.351,"In addition, in late 2020, new SARS-CoV-2 Variants of Concern (VOC) were identified, including the 501Y.V1 (B.1.1.7 lineage) reported in the United Kingdom (Public Health England, 2020) and 501Y.V2 (B.1.351 lineage) first detected in South Africa (Tegally et al., 2021).."
0,doi:10.1073/pnas.2106433118,B.1.351,Cross-neutralization activity against SARS-CoV-2 variant B.1.351 decreased only approximately twofold relative to WA1/2020.
1,doi:10.1073/pnas.2106433118,B.1.1.7,"Given concerns about increased resistance of circulating SARS-CoV-2 viral variants to currently available vaccines, we assessed serum from RFN-vaccinated macaques for neutralizing antibody responses against two VOCs, B.1.1.7 and B.1.351."
0,doi:10.1016/j.celrep.2021.109450,B.1.351,"Here, we show that a combination of two mAbs in clinical trials, C144 and C135, have potent antiviral effects against even when initiated 48 h after infection and have therapeutic efficacy in vivo against the B.1.351 variant of concern (VOC)."
0,doi:10.1128/jcm.00921-21,B.1.427,"The massive emergence of L452R variants was first linked to lineage B.1.427/B.1.429 (clade 21C) that has been spreading in California since November and December 2020, originally named CAL.20C and currently variant of interest epsilon."
1,doi:10.1128/jcm.00921-21,B.1.232,"By PCR amplification and Sanger sequencing of a 541-base fragment coding for amino acids 414 to 583 of the RBD from a collection of clinical specimens, we identified a separate L452R variant that also recently emerged in California but derives from the lineage B.1.232, clade 20A (named CAL.20A)."
2,doi:10.1128/jcm.00921-21,B.1.1.7,"Because of the important functional and antigenic properties of the RBD, structural changes in this domain deserve special attention and have already been highlighted by such notorious RBD mutations as E484K (e.g., found in B.1.1.28, also known as the “Brazil” variant or VOI zeta) and N501Y (found in B.1.1.7, also known as the “British” variant or VOC alpha, and in B.1.351, also known as the “South African” variant or VOC beta) (4)..

We evaluated the feasibility of determining mutational changes in the S1 region by PCR amplification of a 541-base fragment within and immediately downstream from the RBD coding region (see Materials and Methods)."
3,doi:10.1128/jcm.00921-21,B.1.1.28,"Because of the important functional and antigenic properties of the RBD, structural changes in this domain deserve special attention and have already been highlighted by such notorious RBD mutations as E484K (e.g., found in B.1.1.28, also known as the “Brazil” variant or VOI zeta) and N501Y (found in B.1.1.7, also known as the “British” variant or VOC alpha, and in B.1.351, also known as the “South African” variant or VOC beta) (4)..

We evaluated the feasibility of determining mutational changes in the S1 region by PCR amplification of a 541-base fragment within and immediately downstream from the RBD coding region (see Materials and Methods)."
4,doi:10.1128/jcm.00921-21,B.1.351,"Because of the important functional and antigenic properties of the RBD, structural changes in this domain deserve special attention and have already been highlighted by such notorious RBD mutations as E484K (e.g., found in B.1.1.28, also known as the “Brazil” variant or VOI zeta) and N501Y (found in B.1.1.7, also known as the “British” variant or VOC alpha, and in B.1.351, also known as the “South African” variant or VOC beta) (4)..

We evaluated the feasibility of determining mutational changes in the S1 region by PCR amplification of a 541-base fragment within and immediately downstream from the RBD coding region (see Materials and Methods)."
5,doi:10.1128/jcm.00921-21,C.36.3,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
6,doi:10.1128/jcm.00921-21,B.1.466,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
7,doi:10.1128/jcm.00921-21,A.2.5.2,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
8,doi:10.1128/jcm.00921-21,P.4,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
9,doi:10.1128/jcm.00921-21,B.1.617.2,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
10,doi:10.1128/jcm.00921-21,B.1.429,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
11,doi:10.1128/jcm.00921-21,C.36.1,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
12,doi:10.1128/jcm.00921-21,C.37,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
13,doi:10.1128/jcm.00921-21,B.1.36,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
14,doi:10.1128/jcm.00921-21,C.16,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
15,doi:10.1128/jcm.00921-21,A.2.5.1,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
16,doi:10.1128/jcm.00921-21,B.1.177.83,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
17,doi:10.1128/jcm.00921-21,A.27,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
18,doi:10.1128/jcm.00921-21,B.1.526.1,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
19,doi:10.1128/jcm.00921-21,B.1.1.263,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
20,doi:10.1128/jcm.00921-21,A.21,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
21,doi:10.1128/jcm.00921-21,B.1.617.3,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
22,doi:10.1128/jcm.00921-21,B.1.617.1,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
23,doi:10.1128/jcm.00921-21,B.1.1.459,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
0,doi:10.2807/1560-7917.es.2021.26.12.2100276,P.1,The emergence of SARS-CoV-2 P.1 lineage coincided with a surge in hospitalisations in the North region of Brazil.
1,doi:10.2807/1560-7917.es.2021.26.12.2100276,B.1.1.28,"In the other three specimens from February 2021, SARS-CoV-2 lineages B.1.1.28 (n = 2) and B.1.1.143 (n = 1) were found."
2,doi:10.2807/1560-7917.es.2021.26.12.2100276,B.1.1.143,"In the other three specimens from February 2021, SARS-CoV-2 lineages B.1.1.28 (n = 2) and B.1.1.143 (n = 1) were found."
3,doi:10.2807/1560-7917.es.2021.26.12.2100276,B.1,"COVID-19: coronavirus disease; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2..

March–June 2020: B.1 (n = 1 specimen), B.1.1.106 (n = 1), and B.1.1.161 (n = 8); July–December 2020: B.1 (n = 1), B.1.1.161 (n = 5), B.1.1.28 (n = 8), B.1.1.33 (n = 1) and P.2 (n = 1); January 2021: B.1 (n = 1), B.1.1.28 (n = 4), P.2 (n = 9) and P.1 (n = 1); February 2021: B.1.1.143 (n = 1), B.1.1.28 (n = 2) and P.1 (n = 24)..

We also obtained the Ct values of the two genes of the nucleocapsid protein, N1 and N2 [3] from all cases in our hospital during the time of our investigation (n = 3,868 specimens)."
4,doi:10.2807/1560-7917.es.2021.26.12.2100276,B.1.1.106,"COVID-19: coronavirus disease; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2..

March–June 2020: B.1 (n = 1 specimen), B.1.1.106 (n = 1), and B.1.1.161 (n = 8); July–December 2020: B.1 (n = 1), B.1.1.161 (n = 5), B.1.1.28 (n = 8), B.1.1.33 (n = 1) and P.2 (n = 1); January 2021: B.1 (n = 1), B.1.1.28 (n = 4), P.2 (n = 9) and P.1 (n = 1); February 2021: B.1.1.143 (n = 1), B.1.1.28 (n = 2) and P.1 (n = 24)..

We also obtained the Ct values of the two genes of the nucleocapsid protein, N1 and N2 [3] from all cases in our hospital during the time of our investigation (n = 3,868 specimens)."
5,doi:10.2807/1560-7917.es.2021.26.12.2100276,P.2,"COVID-19: coronavirus disease; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2..

March–June 2020: B.1 (n = 1 specimen), B.1.1.106 (n = 1), and B.1.1.161 (n = 8); July–December 2020: B.1 (n = 1), B.1.1.161 (n = 5), B.1.1.28 (n = 8), B.1.1.33 (n = 1) and P.2 (n = 1); January 2021: B.1 (n = 1), B.1.1.28 (n = 4), P.2 (n = 9) and P.1 (n = 1); February 2021: B.1.1.143 (n = 1), B.1.1.28 (n = 2) and P.1 (n = 24)..

We also obtained the Ct values of the two genes of the nucleocapsid protein, N1 and N2 [3] from all cases in our hospital during the time of our investigation (n = 3,868 specimens)."
6,doi:10.2807/1560-7917.es.2021.26.12.2100276,B.1.1.33,"COVID-19: coronavirus disease; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2..

March–June 2020: B.1 (n = 1 specimen), B.1.1.106 (n = 1), and B.1.1.161 (n = 8); July–December 2020: B.1 (n = 1), B.1.1.161 (n = 5), B.1.1.28 (n = 8), B.1.1.33 (n = 1) and P.2 (n = 1); January 2021: B.1 (n = 1), B.1.1.28 (n = 4), P.2 (n = 9) and P.1 (n = 1); February 2021: B.1.1.143 (n = 1), B.1.1.28 (n = 2) and P.1 (n = 24)..

We also obtained the Ct values of the two genes of the nucleocapsid protein, N1 and N2 [3] from all cases in our hospital during the time of our investigation (n = 3,868 specimens)."
7,doi:10.2807/1560-7917.es.2021.26.12.2100276,B.1.1.161,"COVID-19: coronavirus disease; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2..

March–June 2020: B.1 (n = 1 specimen), B.1.1.106 (n = 1), and B.1.1.161 (n = 8); July–December 2020: B.1 (n = 1), B.1.1.161 (n = 5), B.1.1.28 (n = 8), B.1.1.33 (n = 1) and P.2 (n = 1); January 2021: B.1 (n = 1), B.1.1.28 (n = 4), P.2 (n = 9) and P.1 (n = 1); February 2021: B.1.1.143 (n = 1), B.1.1.28 (n = 2) and P.1 (n = 24)..

We also obtained the Ct values of the two genes of the nucleocapsid protein, N1 and N2 [3] from all cases in our hospital during the time of our investigation (n = 3,868 specimens)."
8,doi:10.2807/1560-7917.es.2021.26.12.2100276,B.1.1.248,"A previous study conducted in the municipality of Esteio, RS, from May to October 2020 revealed that the most common lineages were B.1.1.33 and P.2 (initially called B.1.1.248) [5]."
9,doi:10.2807/1560-7917.es.2021.26.12.2100276,B.1.1.7,"P.1 has been termed VOC due to important mutations in the spike protein (K417T, E484K, and N501Y) some of which are found in B.1.351 (South Africa) and B.1.1.7 (United Kingdom) lineages."
10,doi:10.2807/1560-7917.es.2021.26.12.2100276,B.1.351,"P.1 has been termed VOC due to important mutations in the spike protein (K417T, E484K, and N501Y) some of which are found in B.1.351 (South Africa) and B.1.1.7 (United Kingdom) lineages."
0,doi:10.1016/j.immuni.2021.03.023,B.1.1.7,Mutations present in B.1.1.7 Spike frequently conferred neutralization resistance to NTD-specific antibodies.
1,doi:10.1016/j.immuni.2021.03.023,B.1.351,"RBD mAbs P003_017 (Group 3) and P054_027 (Group 1) showed the greatest reduction in neutralization with only very weak neutralization detected at 50 μg/mL..

An additional E484K mutation, which is of particular concern for neutralization resistance in the B.1.351 variant prevalent in South Africa (Wang et al., 2021; Wibmer et al., 2021), has been observed in combination with B.1.1.7 mutations and identified as a variant of concern in the UK (VOC 202102/02) (Collier et al., 2021; Wise, 2021)."
0,doi:10.1128/mra.01182-21,B.1.1.7,A sequence analysis identified that the B.1 SARS-CoV-2 lineage was most prevalent with the worrying emergence of B.1.1.7 in June 2021..
1,doi:10.1128/mra.01182-21,B.1,A sequence analysis identified that the B.1 SARS-CoV-2 lineage was most prevalent with the worrying emergence of B.1.1.7 in June 2021..
0,doi:10.3390/v13112161,B.1.1.519,"Additionally, by late February 2021, lineage B.1.1.519 represented more than 89% of all circulating lineages in the country.."
1,doi:10.3390/v13112161,B.1.1.222,"Tree visualization was performed in R using the packages ggtree and treeio [25,26]..

To analyze the evolution of B.1.1.519 lineage, all high-coverage complete genome sequences for B.1.1.222 and B.1.1.519 lineages were downloaded from GISAID."
2,doi:10.3390/v13112161,B.1,The high frequency observed for some of these mutations reflected their presence in viruses that circulated early after the pandemic started in the country—notably lineage B.1 and other lineages derived from it.
3,doi:10.3390/v13112161,B.1.243,"Regarding the variants most frequently identified in the country during the year of study, lineages B.1 (n = 530, 13.5%), B.1.1 (n = 204, 5.2%), B.1.1.222 (n = 424, 10.8%), B.1.1.519 (n = 1512, 38.6%), B.1.243 (n = 173, 4.4%) and B.1.609 (n = 158, 4.1%) were predominant."
4,doi:10.3390/v13112161,B.1.609,"Regarding the variants most frequently identified in the country during the year of study, lineages B.1 (n = 530, 13.5%), B.1.1 (n = 204, 5.2%), B.1.1.222 (n = 424, 10.8%), B.1.1.519 (n = 1512, 38.6%), B.1.243 (n = 173, 4.4%) and B.1.609 (n = 158, 4.1%) were predominant."
5,doi:10.3390/v13112161,B.1.1,"Regarding the variants most frequently identified in the country during the year of study, lineages B.1 (n = 530, 13.5%), B.1.1 (n = 204, 5.2%), B.1.1.222 (n = 424, 10.8%), B.1.1.519 (n = 1512, 38.6%), B.1.243 (n = 173, 4.4%) and B.1.609 (n = 158, 4.1%) were predominant."
6,doi:10.3390/v13112161,B.1.189,"In the first 3 months of the epidemic (March–May 2020), lineages B.1, B.1.1, B.1.609, and B.1.189 accounted for 75.4% of the genomic sequences."
7,doi:10.3390/v13112161,B.1.241,"The same could be observed for B.1.241 and B.1.243 lineages, but they reached their highest prevalence in the second trimester of the pandemic and then started declining..

Few sequences were detected for VOC, VOI, and VUM other than B.1.1.519 during the first year."
8,doi:10.3390/v13112161,P.1,"VOC B.1.1.7 (Alpha) and P.1 (Gamma), and VUM B.1.427, B.1.429, and P.2 were found in frequencies not higher than 2% (Table 1, Figure 4)."
9,doi:10.3390/v13112161,B.1.1.7,"VOC B.1.1.7 (Alpha) and P.1 (Gamma), and VUM B.1.427, B.1.429, and P.2 were found in frequencies not higher than 2% (Table 1, Figure 4)."
10,doi:10.3390/v13112161,P.2,"VOC B.1.1.7 (Alpha) and P.1 (Gamma), and VUM B.1.427, B.1.429, and P.2 were found in frequencies not higher than 2% (Table 1, Figure 4)."
11,doi:10.3390/v13112161,B.1.429,"VOC B.1.1.7 (Alpha) and P.1 (Gamma), and VUM B.1.427, B.1.429, and P.2 were found in frequencies not higher than 2% (Table 1, Figure 4)."
12,doi:10.3390/v13112161,B.1.427,"VOC B.1.1.7 (Alpha) and P.1 (Gamma), and VUM B.1.427, B.1.429, and P.2 were found in frequencies not higher than 2% (Table 1, Figure 4)."
13,doi:10.3390/v13112161,B.1.2,"Moreover, B.1.2 increased slowly, passing from less than 0.5% before December 2020 to more than 2% of all sequences in February 2021.."
14,doi:10.3390/v13112161,B.1.351,"Substitution S:P681H, shared with VOC B.1.1.7 and B.1.351, has also been identified as evolving under strong pervasive and episodic positive selection and overlaps with a CTL epitope [44]."
15,doi:10.3390/v13112161,B.1.561,"Furthermore, lineages B.1.241, B.2.243, B.1.2, and B.1.561 that circulated at different times in the NW were reported concomitantly in California."
0,doi:10.1371/journal.ppat.1009883,B.1.1.218,"The viral strains belonged to lineages B.1.1.218 and B.1.1.305, possessing the mink-specific S-Y453F substitution."
1,doi:10.1371/journal.ppat.1009883,B.1.1.305,"The viral strains belonged to lineages B.1.1.218 and B.1.1.305, possessing the mink-specific S-Y453F substitution."
0,doi:10.1016/j.ijregi.2022.01.002,B.1.631,"ELISA was used for detecting IgG, IgM, and neutralizing Ab against SARS-CoV-2 antigens..

Around 4.9% (15/304) of the participants were SARS-CoV-2 positive, with B.1.631 being the only variant identified."
0,doi:10.1093/cid/ciab687,B.1.1.7,SARS-CoV-2 lineage B.1.1.7 (Alpha) was the most common variant (67.9% of viruses with lineage determined).
0,doi:10.1128/mbio.02687-21,P.1,"An exponential emergence of S protein variants was observed since October 2020 when the four major variants of concern (VOCs), namely, alpha (α) (B.1.1.7), beta (β) (B.1.351), gamma (γ) (P.1), and delta (δ) (B.1.617), started to circulate in various communities."
1,doi:10.1128/mbio.02687-21,B.1.1.7,"An exponential emergence of S protein variants was observed since October 2020 when the four major variants of concern (VOCs), namely, alpha (α) (B.1.1.7), beta (β) (B.1.351), gamma (γ) (P.1), and delta (δ) (B.1.617), started to circulate in various communities."
2,doi:10.1128/mbio.02687-21,B.1.617,"An exponential emergence of S protein variants was observed since October 2020 when the four major variants of concern (VOCs), namely, alpha (α) (B.1.1.7), beta (β) (B.1.351), gamma (γ) (P.1), and delta (δ) (B.1.617), started to circulate in various communities."
3,doi:10.1128/mbio.02687-21,B.1.351,"An exponential emergence of S protein variants was observed since October 2020 when the four major variants of concern (VOCs), namely, alpha (α) (B.1.1.7), beta (β) (B.1.351), gamma (γ) (P.1), and delta (δ) (B.1.617), started to circulate in various communities."
4,doi:10.1128/mbio.02687-21,B.1.315,"(B to E) Dispersion of SARS-CoV-2 α (B.1.1.7), β (B.1.315), γ (P.1), and δ (B.1.617) variants worldwide, respectively."
5,doi:10.1128/mbio.02687-21,B.1.617.2,"A total of 74 δ (B.1.617) S protein variants revealed from the 1,818 complete genomes were clustered into three sublineages, designated B.1.617.1 (represented by E154K), B.1.617.2 (T19R, T478K), and B.1.617.3 (T19R, T478) (Fig."
6,doi:10.1128/mbio.02687-21,B.1.617.3,"A total of 74 δ (B.1.617) S protein variants revealed from the 1,818 complete genomes were clustered into three sublineages, designated B.1.617.1 (represented by E154K), B.1.617.2 (T19R, T478K), and B.1.617.3 (T19R, T478) (Fig."
7,doi:10.1128/mbio.02687-21,B.1.617.1,"A total of 74 δ (B.1.617) S protein variants revealed from the 1,818 complete genomes were clustered into three sublineages, designated B.1.617.1 (represented by E154K), B.1.617.2 (T19R, T478K), and B.1.617.3 (T19R, T478) (Fig."
8,doi:10.1128/mbio.02687-21,B.1.429,"L452R was highly specific to δ (B.1.617) but also found in other variant lineages (e.g., B.1.429)."
9,doi:10.1128/mbio.02687-21,R.1,"Interestingly, E484K was commonly observed in β (B.1.351), γ (P.1), P.2, and R.1, and E484Q in δ (B.1.617.1/3)."
10,doi:10.1128/mbio.02687-21,P.2,"Interestingly, E484K was commonly observed in β (B.1.351), γ (P.1), P.2, and R.1, and E484Q in δ (B.1.617.1/3)."
11,doi:10.1128/mbio.02687-21,C.9,"Similarly, changes at residues 501 (N501Y in α, β, and γ; N501T in C.9) and 681 (P681H in α, B.1.1.519; P681R in δ; P618L in B.1.494) under positive selection were also found in several distantly related lineages, suggesting that these mutations have an adaptive benefit in host-virus interaction, probably driven by convergent evolution."
12,doi:10.1128/mbio.02687-21,B.1.494,"Similarly, changes at residues 501 (N501Y in α, β, and γ; N501T in C.9) and 681 (P681H in α, B.1.1.519; P681R in δ; P618L in B.1.494) under positive selection were also found in several distantly related lineages, suggesting that these mutations have an adaptive benefit in host-virus interaction, probably driven by convergent evolution."
13,doi:10.1128/mbio.02687-21,B.1.177,"Overall, A222V had the highest ratio of nonsynonymous and synonymous site (dN/dS ratio) substitutions (FUBAR [fast, unconstrained Bayesian approximation] test, ω=37.06), with a GCT (A) to GTT (V) change at the second codon position commonly observed in B.1.177, followed by residues 5 (ω=28.91), 477 (ω=28.22), and 98 (ω=28.05).."
14,doi:10.1128/mbio.02687-21,B.1,"For B cell epitope probability, S proteins featured in groups 1, 2, and 3 scored higher, except for the B.1 variant lineage (EPI_ISL_984896, group 2), which scored similar or higher than the prototype and D614G mutant."
0,doi:10.1038/s41586-021-04117-7,B.1.1.7,"The B.1.351 (Beta) and B.1.1.248 (Gamma) variants escaped almost 70% of these antibodies, while a much smaller portion was impacted by the B.1.1.7 (Alpha) and B.1.617.2 (Delta) variants."
1,doi:10.1038/s41586-021-04117-7,B.1.1.248,"The B.1.351 (Beta) and B.1.1.248 (Gamma) variants escaped almost 70% of these antibodies, while a much smaller portion was impacted by the B.1.1.7 (Alpha) and B.1.617.2 (Delta) variants."
2,doi:10.1038/s41586-021-04117-7,B.1.617.2,"The B.1.351 (Beta) and B.1.1.248 (Gamma) variants escaped almost 70% of these antibodies, while a much smaller portion was impacted by the B.1.1.7 (Alpha) and B.1.617.2 (Delta) variants."
3,doi:10.1038/s41586-021-04117-7,B.1.351,"The B.1.351 (Beta) and B.1.1.248 (Gamma) variants escaped almost 70% of these antibodies, while a much smaller portion was impacted by the B.1.1.7 (Alpha) and B.1.617.2 (Delta) variants."
0,doi:10.1038/s41586-021-04342-0,B.1.1.7,Here we show that the spike protein (S) from Alpha (also known as B.1.1.7) and Beta (B.1.351) VOCs had a greater affinity towards the human angiotensin-converting enzyme 2 (ACE2) receptor than that of the progenitor variant S(D614G) in vitro.
1,doi:10.1038/s41586-021-04342-0,B.1.351,Here we show that the spike protein (S) from Alpha (also known as B.1.1.7) and Beta (B.1.351) VOCs had a greater affinity towards the human angiotensin-converting enzyme 2 (ACE2) receptor than that of the progenitor variant S(D614G) in vitro.
2,doi:10.1038/s41586-021-04342-0,B.1.160,"Contemporary clinical isolates from the B.1.160 (SD614G) (EPI_ISL_414019), Alpha (EPI_ISL_2131446, EPI_ISL_751799 (L4549)) and Beta (EPI_ISL_803957 (L4550)) were isolated and minimally passaged on Vero E6 cells."
0,doi:10.1016/j.jcv.2021.104969,B.1.1.7,The ID triplex assay identified 62.8% of them as VOCs: 61.8% B.1.1.7 and 0.9% B.1.351/P.1.
1,doi:10.1016/j.jcv.2021.104969,B.1.351,The ID triplex assay identified 62.8% of them as VOCs: 61.8% B.1.1.7 and 0.9% B.1.351/P.1.
2,doi:10.1016/j.jcv.2021.104969,P.1,"Only 10/20 B1.351/P.1 strains detected with the ID triplex assay were confirmed by sequencing..

We conclude that the SGTF/SGTL profiles identified using the TaqPath assay and ID triplex results are suitable for detecting the B.1.1.7 lineage."
3,doi:10.1016/j.jcv.2021.104969,B.1.525,"This is somewhat surprising as the association of the 69–70 deletion and N501Y mutations detected by the ID triplex assay is specific for B.1.1.7, while the 69–70 deletion detected by the TaqPath COVID-19 assay is shared by other variants, including the B.1.525, and B.1.620 variants."
4,doi:10.1016/j.jcv.2021.104969,B.1.620,"This is somewhat surprising as the association of the 69–70 deletion and N501Y mutations detected by the ID triplex assay is specific for B.1.1.7, while the 69–70 deletion detected by the TaqPath COVID-19 assay is shared by other variants, including the B.1.525, and B.1.620 variants."
0,doi:10.1101/2021.03.22.436468,B.1.1.7,"Here we examine virus entry by the B.1.1.7 lineage, commonly referred to as the UK/Kent variant."
1,doi:10.1101/2021.03.22.436468,P.1,"The lineages are commonly referred to by the country in which they were originally identified, however, we will primarily use the PANGO lineage nomenclature (14): B.1.1.7 originating from the United Kingdom, B.1.351 from South Africa, and P.1 from Brazil."
2,doi:10.1101/2021.03.22.436468,B.1.351,"The lineages are commonly referred to by the country in which they were originally identified, however, we will primarily use the PANGO lineage nomenclature (14): B.1.1.7 originating from the United Kingdom, B.1.351 from South Africa, and P.1 from Brazil."
0,doi:10.15252/embr.202153865,B.1.617.2,Both bipNbs bind all currently circulating VOCs with high affinities and are capable to neutralize cellular infection with VOC B.1.351 (Beta) and B.1.617.2 (Delta) in vitro.
1,doi:10.15252/embr.202153865,B.1.351,Both bipNbs bind all currently circulating VOCs with high affinities and are capable to neutralize cellular infection with VOC B.1.351 (Beta) and B.1.617.2 (Delta) in vitro.
2,doi:10.15252/embr.202153865,B.1,"To assess if the bipNbs NM1267 and NM1268 confer protection against SARS‐CoV‐2 infection in vivo, human ACE2 transgenic mice are treated intranasally before infection with a lethal dose of SARS‐CoV‐2 B.1, B.1.351 (Beta) or B.1.617.2 (Delta)."
3,doi:10.15252/embr.202153865,B.1.1.7,"Mutations on RBD of identified SARS‐CoV‐2 variants, including B.1.1.7 (Alpha), B.1.351 (Beta), P1 (Gamma), B.1.617.2 (Delta), B.1.429 (Epsilon), P3 (Theta), B.1.617.1 (Kappa), and A.23.1 are highlighted in dark gray or dark red and labeled, respectively.NM1268‐binding epitope on RBD derived from crystal structure of the RBD:Nb complex for NM1226 (orange, PDB 7NKT) and HDX‐MS analysis for NM1228 (purple) (Wagner et al, 2021)."
4,doi:10.15252/embr.202153865,B.1.617.1,"Mutations on RBD of identified SARS‐CoV‐2 variants, including B.1.1.7 (Alpha), B.1.351 (Beta), P1 (Gamma), B.1.617.2 (Delta), B.1.429 (Epsilon), P3 (Theta), B.1.617.1 (Kappa), and A.23.1 are highlighted in dark gray or dark red and labeled, respectively.NM1268‐binding epitope on RBD derived from crystal structure of the RBD:Nb complex for NM1226 (orange, PDB 7NKT) and HDX‐MS analysis for NM1228 (purple) (Wagner et al, 2021)."
5,doi:10.15252/embr.202153865,A.23.1,"Mutations on RBD of identified SARS‐CoV‐2 variants, including B.1.1.7 (Alpha), B.1.351 (Beta), P1 (Gamma), B.1.617.2 (Delta), B.1.429 (Epsilon), P3 (Theta), B.1.617.1 (Kappa), and A.23.1 are highlighted in dark gray or dark red and labeled, respectively.NM1268‐binding epitope on RBD derived from crystal structure of the RBD:Nb complex for NM1226 (orange, PDB 7NKT) and HDX‐MS analysis for NM1228 (purple) (Wagner et al, 2021)."
6,doi:10.15252/embr.202153865,B.1.429,"Mutations on RBD of identified SARS‐CoV‐2 variants, including B.1.1.7 (Alpha), B.1.351 (Beta), P1 (Gamma), B.1.617.2 (Delta), B.1.429 (Epsilon), P3 (Theta), B.1.617.1 (Kappa), and A.23.1 are highlighted in dark gray or dark red and labeled, respectively.NM1268‐binding epitope on RBD derived from crystal structure of the RBD:Nb complex for NM1226 (orange, PDB 7NKT) and HDX‐MS analysis for NM1228 (purple) (Wagner et al, 2021)."
0,doi:10.1128/mbio.03442-21,B.1,"Here, we examined longitudinal antibody responses and viral neutralizing capacity to the B.1 lineage virus (Wuhan related), to variants of concern (VOC; Alpha, Beta, Gamma, and Delta), and to a local variant of interest (VOI; Lambda) in volunteers receiving the Sputnik V vaccine in Argentina."
1,doi:10.1128/mbio.03442-21,P.1,"The VSV-based system encoded GFP and was pseudotyped with the spike protein corresponding to the original SARS-CoV-2 (Wuhan) and the Alpha (lineage B.1.1.7), Beta (lineage B.1.351), Gamma (lineage P.1), and Delta (lineage B.1.617.2) variants, which were initially identified in the United Kingdom, South Africa, Manaos, and India, respectively."
2,doi:10.1128/mbio.03442-21,B.1.1.7,"The VSV-based system encoded GFP and was pseudotyped with the spike protein corresponding to the original SARS-CoV-2 (Wuhan) and the Alpha (lineage B.1.1.7), Beta (lineage B.1.351), Gamma (lineage P.1), and Delta (lineage B.1.617.2) variants, which were initially identified in the United Kingdom, South Africa, Manaos, and India, respectively."
3,doi:10.1128/mbio.03442-21,B.1.617.2,"The VSV-based system encoded GFP and was pseudotyped with the spike protein corresponding to the original SARS-CoV-2 (Wuhan) and the Alpha (lineage B.1.1.7), Beta (lineage B.1.351), Gamma (lineage P.1), and Delta (lineage B.1.617.2) variants, which were initially identified in the United Kingdom, South Africa, Manaos, and India, respectively."
4,doi:10.1128/mbio.03442-21,B.1.351,"The VSV-based system encoded GFP and was pseudotyped with the spike protein corresponding to the original SARS-CoV-2 (Wuhan) and the Alpha (lineage B.1.1.7), Beta (lineage B.1.351), Gamma (lineage P.1), and Delta (lineage B.1.617.2) variants, which were initially identified in the United Kingdom, South Africa, Manaos, and India, respectively."
5,doi:10.1128/mbio.03442-21,C.37,"The Lambda variant was initially detected in late December 2020 in South America (Andina, lineage C.37) (16)."
6,doi:10.1128/mbio.03442-21,B.1.1.1,"This novel sublineage within B.1.1.1, with a convergent deletion in the ORF1a gene (Δ3675–3677) and a novel deletion in the spike gene (Δ246–252, G75V, T76I, L452Q, F490S, T859N), rapidly spread in the region, replacing the Alpha variant and reaching frequencies in Argentina as high as 48% (17)."
0,doi:10.1002/mco2.126,B.1.1.529,"Omicron (B.1.1.529), the latest variant of concern (VOC), has so far shown exceptional spread and infectivity and has established itself as the dominant variant in recent months."
1,doi:10.1002/mco2.126,P.1,"At the time this review was written, there were five VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529)."
2,doi:10.1002/mco2.126,B.1.1.7,"At the time this review was written, there were five VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529)."
3,doi:10.1002/mco2.126,B.1.617.2,"At the time this review was written, there were five VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529)."
4,doi:10.1002/mco2.126,B.1.351,"At the time this review was written, there were five VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529)."
5,doi:10.1002/mco2.126,B.1.526,"88
 In another study, the antiviral activity of 19 different mAbs against eight variants (Alpha, B.1.526, B.1.429, Delta, Gamma, Beta, Omicron, B.1.1.529 + R346K) of SARS‐CoV‐2 was evaluated by calculating the fold changes in IC50, compared with WT virus."
6,doi:10.1002/mco2.126,B.1.429,"88
 In another study, the antiviral activity of 19 different mAbs against eight variants (Alpha, B.1.526, B.1.429, Delta, Gamma, Beta, Omicron, B.1.1.529 + R346K) of SARS‐CoV‐2 was evaluated by calculating the fold changes in IC50, compared with WT virus."
0,doi:10.1016/j.ijheh.2022.113928,B.1.1.7,The second outbreak involved two childcare facilities experiencing infection activity with the variant of concern (VOC) B.1.1.7 (Alpha).
1,doi:10.1016/j.ijheh.2022.113928,B.1.617.2,"Especially in light of the rapidly spreading VOC B.1.617.2 (Delta), our data underline the notion that rigorous SARS-CoV-2 testing in combination with screening of contacts regardless of symptoms is an important measure to prevent SARS-CoV-2 infection of unvaccinated individuals in daycare centers and associated households..

During the first wave of the SARS-CoV-2 pandemic in Germany, ranging from March until May 2020 , childcare facilities were closed in most federal states."
2,doi:10.1016/j.ijheh.2022.113928,B.1.1,The generated phylogenetic tree recapitulates the association of samples from F1 with B.1.1 and F2 and F3 with the variant B.1.1.7 (Fig.
0,doi:10.1016/j.nmni.2021.100929,B.1.617.2,"Recently, a novel variant B.1.617.2 has been identified in India, which is rapidly transmitting to other countries, challenging current therapeutics, wide vaccination and future research in COIVD-19.."
1,doi:10.1016/j.nmni.2021.100929,P.1,"As of June 12, 2021, ∼175 million cases of COVID-19 have been reported, with ∼3.79 million total deaths and an increasing number of recovering cases of >94 million; perhaps, these numbers could be substantially underestimated..

Three different VOCs, namely B.1.1.7, B.1.351, and P.1 were initially prevalent within the United Kingdom (UK), South Africa, and Brazil, respectively, and subsequently worldwide [3]."
2,doi:10.1016/j.nmni.2021.100929,B.1.1.7,"As of June 12, 2021, ∼175 million cases of COVID-19 have been reported, with ∼3.79 million total deaths and an increasing number of recovering cases of >94 million; perhaps, these numbers could be substantially underestimated..

Three different VOCs, namely B.1.1.7, B.1.351, and P.1 were initially prevalent within the United Kingdom (UK), South Africa, and Brazil, respectively, and subsequently worldwide [3]."
3,doi:10.1016/j.nmni.2021.100929,B.1.351,"As of June 12, 2021, ∼175 million cases of COVID-19 have been reported, with ∼3.79 million total deaths and an increasing number of recovering cases of >94 million; perhaps, these numbers could be substantially underestimated..

Three different VOCs, namely B.1.1.7, B.1.351, and P.1 were initially prevalent within the United Kingdom (UK), South Africa, and Brazil, respectively, and subsequently worldwide [3]."
4,doi:10.1016/j.nmni.2021.100929,B.1.617,"In addition, VOIs such as B.1.617 and B.1.618 have emerged in India, and recently, B.1.617.2 (also known as the Delta variant), a sublineage of B.1.617, is continuously transmitting at a higher rate within the country and across the world [4]."
5,doi:10.1016/j.nmni.2021.100929,B.1.618,"In addition, VOIs such as B.1.617 and B.1.618 have emerged in India, and recently, B.1.617.2 (also known as the Delta variant), a sublineage of B.1.617, is continuously transmitting at a higher rate within the country and across the world [4]."
6,doi:10.1016/j.nmni.2021.100929,B.1.427,"The B.1.427/B.1.429 lineages have such VOC called L452R mutation (first identified in the USA), and this has been shown to be almost >20% higher transmissibility in comparison to pre-existing reported variants [8]."
7,doi:10.1016/j.nmni.2021.100929,B.1.429,"Currently, many lineages are circulating at this time in India and worldwide, and the rapid expansion of B.1.617.2 (Delta variant) over other lineages could possibly be due to natural selection and genetic displacement of the SARS-CoV-2 genome [19,23].Table 1Summary details on SARS-CoV-2 lineages, including pre-existing variants of concerns and recently identified variant B.1.617 from IndiaTable 1OriginFirst reportedLineage/sub-lineage/DesignationTotal mutationTotal amino acid changeMain mutations with amino acid changes in spikeCountries foundReferencesUnited Kingdom (Kent)December, 2020B.1.1.7 (VOC-20DEC-01)2317Δ69/70, Δ144, E484K, S494P, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H, K1191N∼114Rambaut et al., 2020Davies et al.,., 2021South Africa (Eastern Cape)October, 2020B.1.351 (VOC-20DEC-02)2317D80A, D215G, Δ241/242/243 K417N, E484K N501Y, D614G A701V45Tegally et al.,., 2020Japan/Brazil (Rio de Janeiro)January, 2021B.1.1.28 (VOC-21JAN-02)3517L18F, T20N P26S, D138Y R190S, K417T E484K, N501Y D614G, H655Y T1027I, K417N21Voloch et al.,., 2020United States (California)May, 2021B.1.427/B.1.429 (CAL.20C)115L452R, S13I, W152C30Zhang et al.,., 2021India (Maharashtra)February 2021B.1.617B.1.617.1>156D614G, L452Ra, E484Qa, P618Ra, Q1071H, E154K del681∼34Until May 8(outbreak.info, cdc.gov)VUI-21APR-01B.1.617.2>156D614G, L452Ra, T478Ka, P681Ra, D950N, T19R del157/158∼31Until May 8(outbreak.info, cdc.gov)VOC-21APR-02B.1.617.3>155D614G, L452Ra, E484Qa, P618Ra, T19R∼4Until May 8(outbreak.info, cdc.gov)VUI-21APR-03aShows functional important mutations probably involved in pathogenesis in India..

Summary details on SARS-CoV-2 lineages, including pre-existing variants of concerns and recently identified variant B.1.617 from India."
8,doi:10.1016/j.nmni.2021.100929,B.1.1.28,"Increased transmission of the virus at this stage is incredible, given the fact that what we have understood about the other spike mutations present in B.1.1.7, B.1.351, B.1.1.28 etc."
0,doi:10.1016/s2352-4642(21)00030-4,B.1.1.7,"Media reports of increases in admissions to hospital and more serious illness in children and young people have resulted in public confusion and implicated the B.1.1.7 variant as a more pathogenic infection within this group.1, 2 This uncertainty has necessitated a public statement from the Royal College of Paediatrics and Child Health.3
."
0,doi:10.1002/jmv.27261,C.37,"The results indicate a steep increase of the lambda lineage (C.37) until becoming predominant between January and April 2021, despite the cocirculation of other variants of concern or interest."
1,doi:10.1002/jmv.27261,P.1,"The alpha (B.1.1.7) variant was first reported in our country in December 2020,
4
 whereas in January 2021, the gamma (P.1) variant was identified in three regions of our country, most of all in the Amazonian regions."
2,doi:10.1002/jmv.27261,B.1.1.7,"The alpha (B.1.1.7) variant was first reported in our country in December 2020,
4
 whereas in January 2021, the gamma (P.1) variant was identified in three regions of our country, most of all in the Amazonian regions."
3,doi:10.1002/jmv.27261,B.1.526.1,"13
, 
14
 And most importantly, it has the T859N mutation in lambda, also present in variant B.1.526.1 (New York), which has been associated with a reduced neutralization by monoclonal antibodies, and by convalescent and postvaccination sera."
0,doi:10.15585/mmwr.mm7106a4,B.1.617.2,"The data in this report are a summary of findings of recent proportions of circulating variants that are updated weekly on CDC’s COVID Data Tracker website to enable timely public health action.† The SARS-CoV-2 Delta (B.1.617.2 and AY sublineages) variant rose from 1% to >50% of viral lineages circulating nationally during 8 weeks, from May 1–June 26, 2021."
1,doi:10.15585/mmwr.mm7106a4,B.1.1.529,"Delta-associated infections remained predominant until being rapidly overtaken by infections associated with the Omicron (B.1.1.529 and BA sublineages) variant in December 2021, when Omicron increased from 1% to >50% of circulating viral lineages during a 2-week period."
2,doi:10.15585/mmwr.mm7106a4,B.1.1.7,Alpha (B.1.1.7 and Q sublineages) continued to decline nationally.
3,doi:10.15585/mmwr.mm7106a4,P.1,"Gamma (P.1 and descendent lineages) peaked at 12.1% (95% CI = 9.8%–14.7%) during the week ending June 5, 2021, before declining; Mu (B.1.621) and Lambda (C.37) increased to their peaks of 4.5% (95% CI = 3.5%–5.6%) and 0.6% (95% CI = 0.3%–0.9%), respectively, for the week ending June 19, before declining as Delta (B.1.617.2 and AY sublineages) reached predominance (>50%)."
4,doi:10.15585/mmwr.mm7106a4,C.37,"Gamma (P.1 and descendent lineages) peaked at 12.1% (95% CI = 9.8%–14.7%) during the week ending June 5, 2021, before declining; Mu (B.1.621) and Lambda (C.37) increased to their peaks of 4.5% (95% CI = 3.5%–5.6%) and 0.6% (95% CI = 0.3%–0.9%), respectively, for the week ending June 19, before declining as Delta (B.1.617.2 and AY sublineages) reached predominance (>50%)."
5,doi:10.15585/mmwr.mm7106a4,B.1.621,"Gamma (P.1 and descendent lineages) peaked at 12.1% (95% CI = 9.8%–14.7%) during the week ending June 5, 2021, before declining; Mu (B.1.621) and Lambda (C.37) increased to their peaks of 4.5% (95% CI = 3.5%–5.6%) and 0.6% (95% CI = 0.3%–0.9%), respectively, for the week ending June 19, before declining as Delta (B.1.617.2 and AY sublineages) reached predominance (>50%)."
6,doi:10.15585/mmwr.mm7106a4,B.1.526,"Variant proportion estimation methods use a complex survey design and statistical weights to account for the probability that a specimen is sequenced..

† SARS-CoV-2 WHO variant label and PANGO lineage: Alpha (B.1.1.7); Beta (B.1.351); Gamma (P.1); Delta (B.1.617.2), Epsilon (B.1.427/B.1.429); Zeta (P.2); Eta (B.1.525); Iota (B.1.526); Kappa (B.1.617.1); Lambda (C.37); Mu (B.1.621); and Omicron (B.1.1.529)."
7,doi:10.15585/mmwr.mm7106a4,B.1.427,"Variant proportion estimation methods use a complex survey design and statistical weights to account for the probability that a specimen is sequenced..

† SARS-CoV-2 WHO variant label and PANGO lineage: Alpha (B.1.1.7); Beta (B.1.351); Gamma (P.1); Delta (B.1.617.2), Epsilon (B.1.427/B.1.429); Zeta (P.2); Eta (B.1.525); Iota (B.1.526); Kappa (B.1.617.1); Lambda (C.37); Mu (B.1.621); and Omicron (B.1.1.529)."
8,doi:10.15585/mmwr.mm7106a4,B.1.351,"Variant proportion estimation methods use a complex survey design and statistical weights to account for the probability that a specimen is sequenced..

† SARS-CoV-2 WHO variant label and PANGO lineage: Alpha (B.1.1.7); Beta (B.1.351); Gamma (P.1); Delta (B.1.617.2), Epsilon (B.1.427/B.1.429); Zeta (P.2); Eta (B.1.525); Iota (B.1.526); Kappa (B.1.617.1); Lambda (C.37); Mu (B.1.621); and Omicron (B.1.1.529)."
9,doi:10.15585/mmwr.mm7106a4,B.1.525,"Variant proportion estimation methods use a complex survey design and statistical weights to account for the probability that a specimen is sequenced..

† SARS-CoV-2 WHO variant label and PANGO lineage: Alpha (B.1.1.7); Beta (B.1.351); Gamma (P.1); Delta (B.1.617.2), Epsilon (B.1.427/B.1.429); Zeta (P.2); Eta (B.1.525); Iota (B.1.526); Kappa (B.1.617.1); Lambda (C.37); Mu (B.1.621); and Omicron (B.1.1.529)."
10,doi:10.15585/mmwr.mm7106a4,B.1.617.1,"Variant proportion estimation methods use a complex survey design and statistical weights to account for the probability that a specimen is sequenced..

† SARS-CoV-2 WHO variant label and PANGO lineage: Alpha (B.1.1.7); Beta (B.1.351); Gamma (P.1); Delta (B.1.617.2), Epsilon (B.1.427/B.1.429); Zeta (P.2); Eta (B.1.525); Iota (B.1.526); Kappa (B.1.617.1); Lambda (C.37); Mu (B.1.621); and Omicron (B.1.1.529)."
11,doi:10.15585/mmwr.mm7106a4,P.2,"Variant proportion estimation methods use a complex survey design and statistical weights to account for the probability that a specimen is sequenced..

† SARS-CoV-2 WHO variant label and PANGO lineage: Alpha (B.1.1.7); Beta (B.1.351); Gamma (P.1); Delta (B.1.617.2), Epsilon (B.1.427/B.1.429); Zeta (P.2); Eta (B.1.525); Iota (B.1.526); Kappa (B.1.617.1); Lambda (C.37); Mu (B.1.621); and Omicron (B.1.1.529)."
0,doi:10.7554/elife.70658,B.1.1.7,"For example, the B.1.1.7 lineage has a mutation (N501Y) in its Spike RBD that enhances binding to ACE2."
1,doi:10.7554/elife.70658,B.1.351,"We analysed the effects of individual RBD mutations and combinations found in new SARS-CoV-2 Alpha (B.1.1.7), Beta (B.1.351), and Gamma (P1) variants."
2,doi:10.7554/elife.70658,P.1,"Although the K417N/T mutations found in the South African (B.1.351) and Brazilian (P.1) variants both decreased the affinity, the affinity-enhancing N501Y and E484K mutations that are also present in both variants confer a net ~4-fold increase in the affinity of their RBDs for ACE2.."
3,doi:10.7554/elife.70658,B.1.1.318,"The E484K mutation is present in the Beta and Gamma variants and has appeared independently in many other lineages, including Zeta (P.2; 20B/S.484K), B.1.1.318, Eta (B.1.525; 20A/S:484 K), and Iota (B.1.526; 20 C/S.484K)."
4,doi:10.7554/elife.70658,B.1.526,"The S477N mutation became dominant for periods in Australia (clade 20 F) and parts of Europe (20A.EU2) and then appeared in New York in the Iota or B.1.526 lineage (Zhou et al., 2021a)."
0,doi:10.3390/v13112182,B.1.1.519,We reported the emergence of SARS-CoV-2 variant B.1.1.519 in Mexico City.
1,doi:10.3390/v13112182,B.1.1.222,We then calculated the percentage of samples for the variants of interest B.1.1.222 and B.1.1.519 and the percentage of samples that belonged to the ensemble of other variants.
2,doi:10.3390/v13112182,B.1.1.159,"The B.1.1.159 variant is characterized by 9 mutations (C203T, C222T, C3140T, C10954T, A11117G, C12789T, C21306T, C22995A, and C23604A), four ORF1a substitutions (P959S, T3255I, I3618V, and T4175I) and three spike substitutions (T478K, P681H, and T732A) (Figure 1C)."
3,doi:10.3390/v13112182,B.1.1.318,"These variants, such as P.2 [30], B.1.621 [31], and B.1.1.318 [32], show spike mutations in receptor binding and S1/S2 cleavage sites and have spread widely within countries."
4,doi:10.3390/v13112182,P.2,"These variants, such as P.2 [30], B.1.621 [31], and B.1.1.318 [32], show spike mutations in receptor binding and S1/S2 cleavage sites and have spread widely within countries."
5,doi:10.3390/v13112182,B.1.621,"These variants, such as P.2 [30], B.1.621 [31], and B.1.1.318 [32], show spike mutations in receptor binding and S1/S2 cleavage sites and have spread widely within countries."
6,doi:10.3390/v13112182,B.1.617.2,"Accordingly, the Delta variant (B.1.617.2) carries the S:T478K substitution."
7,doi:10.3390/v13112182,P.1,"The Alpha (B.1.1.7) and Gamma (P.1) variants (recognized by the WHO as VOCs) carry S:P681H [37,39]."
8,doi:10.3390/v13112182,B.1.1.7,"The Alpha (B.1.1.7) and Gamma (P.1) variants (recognized by the WHO as VOCs) carry S:P681H [37,39]."
0,doi:10.1093/nar/gkab574,B.1.1.7,"Two aptamers, named MSA1 (Kd = 1.8 nM) and MSA5 (Kd = 2.7 nM), were assessed for binding to the heat-treated S1 protein, untreated S1 protein spiked into 50% human saliva and the trimeric spike protein of both the wildtype and the B.1.1.7 variant, demonstrating comparable affinities in all cases."
0,doi:10.12688/wellcomeopenres.16661.1,B.1.1.7,"Using a combination of data from routine surveillance, genomic sequencing and international travel we track the international dispersal of lineages B.1.1.7 and B.1.351 (variant 501Y-V2)."
1,doi:10.12688/wellcomeopenres.16661.1,B.1.351,"Using a combination of data from routine surveillance, genomic sequencing and international travel we track the international dispersal of lineages B.1.1.7 and B.1.351 (variant 501Y-V2)."
0,doi:10.1007/s11033-021-06717-y,B.1.1.7,A new variant was recently reported in the UK as a VOC 202012/01 or B.1.1.7 lineage [2].
0,doi:10.3389/fimmu.2022.856072,B.1.1.529,Early assessment of the clinical severity of SARS-CoV-2 Omicron variant (B.1.1.529) in South Africa suggested lower odds of severe disease compared to the Delta variant (2).
0,doi:10.1038/s41586-021-03908-2,B.1.1.7,"Two signature spike mutations of concern are E484K, which has a crucial role in the loss of neutralizing activity of antibodies, and N501Y, a driver of rapid worldwide transmission of the B.1.1.7 lineage."
1,doi:10.1038/s41586-021-03908-2,B.1.526,"Here we report the emergence of the variant lineage B.1.526 (also known as the Iota variant5), which contains E484K, and its rise to dominance in New York City in early 2021."
2,doi:10.1038/s41586-021-03908-2,P.1,"Reinfections with P.1 and another related Brazilian variant P.2 harbouring E484K have been documented15,16."
3,doi:10.1038/s41586-021-03908-2,P.2,"Reinfections with P.1 and another related Brazilian variant P.2 harbouring E484K have been documented15,16."
4,doi:10.1038/s41586-021-03908-2,B.1.351,"A previous study on B.1.351 demonstrated that this variant is refractory to neutralization by a number of monoclonal antibodies directed to the top of the RBD, including several that have received emergency use authorization4."
5,doi:10.1038/s41586-021-03908-2,B.1.623,"Samples that harboured both N501Y and E484K were genotyped as P.1 (n = 6), B.1.351 (n = 1) and B.1.623 (n = 1)."
6,doi:10.1038/s41586-021-03908-2,B.1.526.2,"Phylogenetic examination showed that the B.1.526 lineage comprises two closely related sub-lineages harbouring either E484K (B.1.526-E484K; defined as Pangolin lineage B.1.526) or S477N (B.1.526-S477N; Pangolin lineage B.1.526.2), and the additional sub-lineage B.1.526.1, harbouring the L452R substitution (B.1.526-L452R)."
7,doi:10.1038/s41586-021-03908-2,B.1.526.1,"Phylogenetic examination showed that the B.1.526 lineage comprises two closely related sub-lineages harbouring either E484K (B.1.526-E484K; defined as Pangolin lineage B.1.526) or S477N (B.1.526-S477N; Pangolin lineage B.1.526.2), and the additional sub-lineage B.1.526.1, harbouring the L452R substitution (B.1.526-L452R)."
8,doi:10.1038/s41586-021-03908-2,B.1.617.2,"B.1.526, with its higher transmissibility, appeared suddenly and rose to dominance, only to wane as variants (B.1.1.7 and, more recently, B.1.617.2) with even higher fitness emerged."
0,doi:10.1371/journal.pone.0254920,P.1,"Canada has amongst the longest periods between vaccine doses worldwide, despite Vancouver having the highest P.1 variant rate outside Brazil..

With surveillance data since the pandemic began, we tracked laboratory-confirmed SARS-CoV-2 infections, positivity rates, and vaccine uptake in all 25,558 HCWs in Vancouver Coastal Health, by occupation and subsector, and compared to the general population."
1,doi:10.1371/journal.pone.0254920,B.1.1.7,"During this time period, there was a shift from a rate of <1% VOC in early February to a high rate of two variants of concern (VOC) the B1.1.7 and P.1 variants–representing >92% of all infections by study closure, approximately evenly split between B.1.1.7 and P.1."
0,doi:10.1038/s41467-021-25137-x,B.1,Lineage B.1 accounted for 74% of sequenced cases.
1,doi:10.1038/s41467-021-25137-x,B.4,"Lineages A, B and B.4 were detected in screened individuals at the Kenya-Tanzania border or returning travellers."
2,doi:10.1038/s41467-021-25137-x,A.1,"We identified a single lineage A.1 sample, which could be an indicator for transmission of this lineage in the region."
3,doi:10.1038/s41467-021-25137-x,B.1.1.33,"The detection of lineage (B.1.1.33) in a sample that was collected during targeted testing (11th May 2020) in Mombasa city could be indicative of cryptic transmission within the region in spite of the intervention, but also could be failure to detect this lineage at the port of entry due to sampling limitations."
4,doi:10.1038/s41467-021-25137-x,B.1.1.1,"Genomic analysis of SARS-CoV-2 cases in Uganda detected lineages similar to those reported in our study (i.e., A, B, B.1, B.1.1, B.1.1.1 and B.4)9."
5,doi:10.1038/s41467-021-25137-x,B.1.1,"Genomic analysis of SARS-CoV-2 cases in Uganda detected lineages similar to those reported in our study (i.e., A, B, B.1, B.1.1, B.1.1.1 and B.4)9."
6,doi:10.1038/s41467-021-25137-x,V.1,"RT-PCR was undertaken using primer/probes from the four protocols; (i) the Berlin (Charité)targeting E i.e., envelope gene, N i.e., nucleocapsid gene or RdRp i.e., RNA-dependent RNA-polymerase gene), (ii) European Virus Archive—GLOBAL (EVA-g) (targeting E or RdRp genes), (iii) Da An Gene Co. detection Kit (targeting N or ORF1ab) and Beijing Genomic Institute (BGI) RT-PCR kit (targeting ORF1ab)..

At the beginning of the epidemic all SAR-CoV-2 positive samples were processed for whole genome sequencing using the ARTIC nCoV-2019 sequencing V.1 protocol19."
0,doi:10.15585/mmwr.mm7034e2,B.1.617.2,Whole genome sequencing of 454 case-patient specimens found that 242 (53.3%) belonged to the B.1.1.7 (Alpha) lineage and 74 (16.3%) to the B.1.617.2 (Delta) lineage.
1,doi:10.15585/mmwr.mm7034e2,B.1.1.7,Whole genome sequencing of 454 case-patient specimens found that 242 (53.3%) belonged to the B.1.1.7 (Alpha) lineage and 74 (16.3%) to the B.1.617.2 (Delta) lineage.
0,doi:10.1016/j.eclinm.2021.100948,B.1.1.7,None of four and 7/15 (47%) sequenced strains in rounds 1 and 2 were the highly transmissible SARS-CoV-2 B.1.1.7 variant.
0,doi:10.1007/s00705-021-05295-5,P.1,"Variants designated G, alpha (B.1.1.7), beta (B.1.351), gamma (P.1), and delta (B.1.617.2) are important lineages that emerged sequentially and are considered variants of concern."
1,doi:10.1007/s00705-021-05295-5,B.1.1.7,"Variants designated G, alpha (B.1.1.7), beta (B.1.351), gamma (P.1), and delta (B.1.617.2) are important lineages that emerged sequentially and are considered variants of concern."
2,doi:10.1007/s00705-021-05295-5,B.1.617.2,"Variants designated G, alpha (B.1.1.7), beta (B.1.351), gamma (P.1), and delta (B.1.617.2) are important lineages that emerged sequentially and are considered variants of concern."
3,doi:10.1007/s00705-021-05295-5,B.1.351,"Variants designated G, alpha (B.1.1.7), beta (B.1.351), gamma (P.1), and delta (B.1.617.2) are important lineages that emerged sequentially and are considered variants of concern."
0,doi:10.15585/mmwr.mm7032e2,B.1.617.2,"On May 5, 2021, the Colorado Department of Public Health and Environment (CDPHE) identified the first five COVID-19 cases caused by the SARS-CoV-2 B.1.617.2 (Delta) variant in Mesa County in western Colorado (population 154,933, <3% of the state population)."
1,doi:10.15585/mmwr.mm7032e2,B.1.1.7,"Whole genome sequencing is performed in the CDPHE laboratory on specimens submitted as part of sentinel surveillance (38 sites across Colorado, including one acute care hospital in Mesa County), as well as for cluster and outbreak response and on suspected variants (reverse transcription–polymerase chain reaction [RT-PCR]–positive specimens with S-gene target failure associated with the B.1.1.7 lineage) (1)."
0,doi:10.1101/2021.06.11.448134,B.1.1.7,"In this study, African green monkeys were infected intranasally with either a contemporary D614G or the UK B.1.1.7 variant."
0,doi:10.1136/bmjresp-2021-001029,B.1.1.7,SARS-CoV-2 lineage B.1.1.7 has been associated with an increased rate of transmission and disease severity among subjects testing positive in the community.
0,doi:10.1016/j.cell.2021.03.052,B.1.1.7,"The highly transmissible B.1.1.7 variant of SARS-CoV-2, first identified in the United Kingdom, has gained a foothold across the world."
1,doi:10.1016/j.cell.2021.03.052,P.1,"The N501Y mutation is also shared with other VOCs first identified in South Africa (501Y.V2; B.1.351) (Tegally et al., 2020) and Brazil (501Y.V3; P.1) (Faria et al., 2021), but B.1.1.7 has several additional “signature” mutations in the SARS-CoV-2 Spike protein, including deletions at 69-70 and 144, as well as mutations A570D, P681H, T716I, S982A, and D1118H (Rambaut et al., 2020a)."
2,doi:10.1016/j.cell.2021.03.052,B.1.351,"The N501Y mutation is also shared with other VOCs first identified in South Africa (501Y.V2; B.1.351) (Tegally et al., 2020) and Brazil (501Y.V3; P.1) (Faria et al., 2021), but B.1.1.7 has several additional “signature” mutations in the SARS-CoV-2 Spike protein, including deletions at 69-70 and 144, as well as mutations A570D, P681H, T716I, S982A, and D1118H (Rambaut et al., 2020a)."
3,doi:10.1016/j.cell.2021.03.052,B.1.1,"In addition, even though more than half of our tested samples are from the remaining 47 US states, obtaining accurate estimates of the country-wide prevalence of B.1.1.7 is complicated by the historically uneven sampling of SARS-CoV-2 genomes across the US..


REAGENT or RESOURCESOURCEIDENTIFIERCritical commercial assaysHelix ® COVID-19 TestHelixEUA201636TaqPath COVID-19 Combo KitThermo FisherCat#A47814Illumina CovidSeq TestIllumina1000000128490 v01MagMAX Viral/Pathogen II Nucleic Acid Isolation KitThermo FisherCat#A48383Omega BioTek MagBind Viral DNA/RNA KitOmega BiotekCat#M6246-03Nextera XTIlluminaCat#FC-131-1096Illumina NextSeq with 500/550 Mid Output Kit v2.5IlluminaCat#20024908Illumina NovaSeq 6000 with SP Reagent Kit v1.5IlluminaCat#20028400Nanopore MinION KAPA HyperPrep kitRocheCat#07962363001End-repair and Ligation Sequencing KitOxford NanoporeCat#SQK-LSK109Quick-DNA/RNA Viral MagBead kitZymo ResearchCat#R2141Illumina NovaSeq 6000 S4 flow cell & Reagent Kit v1.5IlluminaCat#20044417Illumina NovaSeq Xp 4-lane Kit v1.5IlluminaCat#20042337Omega BioTex MagBind Viral DNA/RNA KitOmega BiotekCat#M6246-03KindFisher Flex Purification SystemThermo FisherCat#5400630Protoscript First Strand cDNA Synthesis KitNEBCat#E6560LQ5 Hot Start High-Fidelity DNA Polymerase KitNEBCat #0493LNEBNext Ultra II DNA Library Kit for IlluminaNEBCat#E7645LMiSeq Reagent Kit V2IlluminaCat#MS-102-2002Deposited dataSARS-CoV-2 reference genomeNCBINCBI: NC_045512.2B.1.1.7 first identified sequenceGISAIDGISAID: EPI_ISL_601443B.1.1.7 outgroupNCBINCBI: NC_045512BEAST XML and log filesThis paperhttps://github.com/andersen-lab/paper_2021_early-b117-usaNon-US B.1.1.7 and additional B.1.1 lineage sequencesGISAIDData S2US B.1.1.7 sequencesThis paper; GISAIDData S2SGTF and B117 ongoing Summary Level DataThis paperData S2; https://github.com/myhelix/helix-covid19dbOligonucleotidesSARS-CoV-2 primersQuick et al., 2017N/ANEBNext Multiplex Oligos for IlluminaNEBCat#E6440LARTIC Network n-CoV-19 V3 primersARTIC Networkhttps://github.com/artic-network/artic-ncov2019/tree/master/primer_schemes/nCoV-2019/V3Software and algorithmsDRAGEN COVIDSeq Test Pipeline v.1.3.0.28IlluminaN/APangolin v2.0O’Toole et al., 2021bhttps://github.com/cov-lineages/pangolinNextClade v0.12.0Hadfield et al., 2018https://github.com/nextstrain/nextcladeIqtree2Minh et al., 2020https://github.com/iqtree/iqtree2BEASTv1.10.5preSuchard et al., 2018https://github.com/beast-dev/beast-mcmc/tree/v1.10.5pre_thorney_v0.1.0BEAGLEAyres et al., 2019https://faculty.washington.edu/browning/beagle/beagle.html#downloadbaltichttps://github.com/evogytis/balticChiu lab genome assembly & variant callingDeng et al., 2020N/AAndersen Lab consensus calling for nanopore datahttps://github.com/artic-network/artic-ncov2019SnakemakeKöster and Rahmann, 2012https://snakemake.readthedocs.io/en/stable/bwa-memLi, 2013https://github.com/lh3/bwaiVar v1.2.2Grubaugh et al., 2019bhttps://github.com/andersen-lab/ivar/releases/tag/v1.2.2Transmissibility estimationVolz et al., 2021N/AConditional reference prior for overall clock rateFerreira and Suchard, 2008N/A
."
0,doi:10.12659/ajcr.935329,P.1,This is a report of a 48-year-old female resident of southern Florida with confirmed reinfection with P.1 variant 9 months following the initial infection.
0,doi:10.1128/jvi.02186-21,B.1.617.2,"IMPORTANCE Recently emerging SARS-CoV-2 variants B.1.1.7 (alpha variant), B.1.617.2 (delta variant), and B.1.1.529 (omicron variant) harbor spike mutations and have been linked to increased virus pathogenesis."
1,doi:10.1128/jvi.02186-21,B.1.1.529,"IMPORTANCE Recently emerging SARS-CoV-2 variants B.1.1.7 (alpha variant), B.1.617.2 (delta variant), and B.1.1.529 (omicron variant) harbor spike mutations and have been linked to increased virus pathogenesis."
2,doi:10.1128/jvi.02186-21,B.1.1.7,"IMPORTANCE Recently emerging SARS-CoV-2 variants B.1.1.7 (alpha variant), B.1.617.2 (delta variant), and B.1.1.529 (omicron variant) harbor spike mutations and have been linked to increased virus pathogenesis."
0,doi:10.1007/s12602-021-09879-0,B.1.351,"Thus, the present study aims to compute the binding energies between a wide range of bacteriocins with receptor-binding domain (RBD) on spike proteins of wild type (WT) and beta variant (lineage B.1.351)."
0,doi:10.1128/mra.00093-21,B.1.5,"Phylogenetic analysis showed that this virus, named hCoV-19/Cameroon/1958-CMR-YAO/2020, belongs to lineage B.1.5 and is closely related to an isolate from France..

We describe the coding-complete genome sequence of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain obtained in Cameroon from a 58-year-old French patient who arrived from France on 24 February 2020."
1,doi:10.1128/mra.00093-21,B.1.1.5,"1) shows that hCoV-19/Cameroon/1958-CMR-YAO/2020 clusters with B.1.1.5 SARS-CoV-2 lineage sequences isolated in France in March 2020..

Phylogenetic analysis of the Cameroon SARS-CoV-2 complete genome sequence generated in this study (indicated with a red circle), with complete sequences from different countries available in the GISAID database as of 30 December 2020."
0,doi:10.1016/j.envres.2022.112816,B.1.1.529,"After Alpha, Beta, Gamma, and Delta variants, the most recently emerged variant of concern (VOC) is the Omicron (B.1.1.529) that has evolved due to the accumulation of high numbers of mutations especially in the spike protein, raising concerns for its ability to evade from pre-existing immunity acquired through vaccination or natural infection as well as overpowering antibodies-based therapies."
1,doi:10.1016/j.envres.2022.112816,B.1.429,"While N501Y is associated with increased transmissibility, other mutations also enhance the affinity of spike towards ACE2 like in the B.1.429 lineage, the L452R showed higher ACE2 interaction (Gong et al., 2021)."
2,doi:10.1016/j.envres.2022.112816,P.1,"(2021) developed a TaqMan SARS-CoV-2 mutation panel molecular genotyping assay that was able to differentiate variants B.1.617.2 (Delta), B.1.1.7 (Alpha), B.1.526 (Iota), B.1.351 (Beta), P.1 (Gamma), P.2 (Zeta), B.1.617.1 (Kappa) and B.1.427/B.1.429 (Epsilon)."
3,doi:10.1016/j.envres.2022.112816,B.1.1.7,"(2021) developed a TaqMan SARS-CoV-2 mutation panel molecular genotyping assay that was able to differentiate variants B.1.617.2 (Delta), B.1.1.7 (Alpha), B.1.526 (Iota), B.1.351 (Beta), P.1 (Gamma), P.2 (Zeta), B.1.617.1 (Kappa) and B.1.427/B.1.429 (Epsilon)."
4,doi:10.1016/j.envres.2022.112816,B.1.526,"(2021) developed a TaqMan SARS-CoV-2 mutation panel molecular genotyping assay that was able to differentiate variants B.1.617.2 (Delta), B.1.1.7 (Alpha), B.1.526 (Iota), B.1.351 (Beta), P.1 (Gamma), P.2 (Zeta), B.1.617.1 (Kappa) and B.1.427/B.1.429 (Epsilon)."
5,doi:10.1016/j.envres.2022.112816,B.1.617.2,"(2021) developed a TaqMan SARS-CoV-2 mutation panel molecular genotyping assay that was able to differentiate variants B.1.617.2 (Delta), B.1.1.7 (Alpha), B.1.526 (Iota), B.1.351 (Beta), P.1 (Gamma), P.2 (Zeta), B.1.617.1 (Kappa) and B.1.427/B.1.429 (Epsilon)."
6,doi:10.1016/j.envres.2022.112816,P.2,"(2021) developed a TaqMan SARS-CoV-2 mutation panel molecular genotyping assay that was able to differentiate variants B.1.617.2 (Delta), B.1.1.7 (Alpha), B.1.526 (Iota), B.1.351 (Beta), P.1 (Gamma), P.2 (Zeta), B.1.617.1 (Kappa) and B.1.427/B.1.429 (Epsilon)."
7,doi:10.1016/j.envres.2022.112816,B.1.617.1,"(2021) developed a TaqMan SARS-CoV-2 mutation panel molecular genotyping assay that was able to differentiate variants B.1.617.2 (Delta), B.1.1.7 (Alpha), B.1.526 (Iota), B.1.351 (Beta), P.1 (Gamma), P.2 (Zeta), B.1.617.1 (Kappa) and B.1.427/B.1.429 (Epsilon)."
8,doi:10.1016/j.envres.2022.112816,B.1.427,"(2021) developed a TaqMan SARS-CoV-2 mutation panel molecular genotyping assay that was able to differentiate variants B.1.617.2 (Delta), B.1.1.7 (Alpha), B.1.526 (Iota), B.1.351 (Beta), P.1 (Gamma), P.2 (Zeta), B.1.617.1 (Kappa) and B.1.427/B.1.429 (Epsilon)."
9,doi:10.1016/j.envres.2022.112816,B.1.351,"(2021) developed a TaqMan SARS-CoV-2 mutation panel molecular genotyping assay that was able to differentiate variants B.1.617.2 (Delta), B.1.1.7 (Alpha), B.1.526 (Iota), B.1.351 (Beta), P.1 (Gamma), P.2 (Zeta), B.1.617.1 (Kappa) and B.1.427/B.1.429 (Epsilon)."
